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ABSTRACT 
Post-translational modifications are decisive in providing functional maturation and 
diversity of many proteins. Leukocyte-specific protein 1 (LSP1) plays an important role in the 
regulation of endothelial permeability, leukocyte chemotaxis and transendothelial migration 
during inflammation. Unlike leukocyte-expressed LSP1 which is predominantly a cytosolic 
protein, endothelial cell-expressed LSP1 is mainly localized in the nucleus. It’s translocation to 
extranuclear compartments is promoted by tumor necrosis factor-α (TNF-α). There is a 
discrepancy between the predicted molecular weight of LSP1 (37 kDa) and its actual appearance 
in SDS-PAGE (˃ 50 kDa). All of these discrepancies indicate possible post-translational 
modifications. In spite of its important role in acute inflammation and these apparent indications, 
very little is known about post-translational modifications of endothelial cell-expressed LSP1. To 
address this, we investigated whether endothelial cell-expressed LSP1 activation is linked to its 
phosphorylation by p38 mitogen activated protein kinase (p38 MAPK) and protein kinase C (PKC) 
upon chemokine treatment of endothelial cells and whether it requires additional signaling such as 
leukocyte-endothelial cell interaction. The present study also addresses how post-translational 
modifications help maintain the functions of endothelial cell-expressed LSP1.  
Using in vitro adhesion assay and immunoblotting, we showed that endothelial cell-
expressed LSP1 was phosphorylated only in the presence of adherent neutrophils or engagement 
of endothelial intercellular cell adhesion moelecule-1 (ICAM-1), but not cytokine or chemokine 
alone. Pharmacological inhibition of p38 MAPK by SB 203580, a selective MAPK inhibitor, 
significantly blunted the phosphorylation of endothelial LSP1. In endothelial cells, ICAM-1 
engagement, in vitro, also caused a novel interaction between LSP1 and moesin which was 
mediated by p38 MAPK and Rho kinase. Absence of either LSP1 or moesin blunted the ICAM-1 
engagement-induced endothelial permeability changes.  
Using scratched wound healing and in vitro transmigration assay, we found that silencing 
of LSP1 reduced migratory behavior of endothelial cells. Selective deficiency of endothelial cell-
expressed LSP1 also resulted in a marked reduction of neutrophil transendothelial migration and 
a subtle reduction in endothelial cell proliferation and neutrophil adhesion. The study demonstrates 
that LSP1-deficiency resulted in GATA-2-mediated selective reduction of endothelial cell-
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expressed platelet endothelial cell adhesion molecule-1 (PECAM-1) that altered the endothelial 
cell functions. 
Using murine primary endothelial cells and recombinant LSP1 expressed in mouse 
endothelial cell line (SVEC4-10EE2) cells and human embryonic kidney (HEK293T) cells, we 
demonstrate that LSP1 is post-translationally modified by small ubiquitin-like modifier 1 
(SUMO1). Single lysine-to-alanine mutation at K270 and K318 of murine LSP1 prevented the 
SUMOylation of recombinant LSP1 in HEK293T cells. DeSUMOylation resulted in marked 
reduction in steady-state LSP1 levels. It is shown that reduced steady-state level of SUMOylation-
deficient LSP1 was due to enhanced ubiquitination and subsequent rapid proteasomal degradation 
and that deSUMOylation of LSP1 impaired its translocation from nucleus to extranuclear 
compartments in endothelial cells in response to TNF-α stimulation. 
This study confirms that adhesion-mediated phosphorylation is required for endothelial 
cell-expressed LSP1 functions whereas SUMOylation helps to maintain its functions by protecting 
LSP1 from proteasomal degradation and facilitating its translocation from nucleus to cytoskeleton 
in endothelial cells. 
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1.0  INTRODUCTION 
This thesis presents my studies on how endothelial cell-expressed leukocyte-specific 
protein 1 (LSP1) becomes phosphorylated and regulates endothelial cell functions, whether LSP1 
is post-translationally modified by SUMOylation and whether this modification affects endothelial 
cell-expressed LSP1. Endothelial functions investigated include endothelial permeability, 
neutrophil adhesion, transendothelial migration and endothelial cell migration.  Major mechanisms 
explored include LSP1-mediated transcriptional regulation of endothelial cell-expressed platelet-
endothelial cell adhesion molecule-1 (PECAM-1) and LSP1-moesin interaction. Therefore, the 
introduction will begin with short discussions on features of acute inflammation such as 
endothelial permeability, the leukocyte recruitment cascade, adhesion molecules and ligands 
involved in different steps of leukocyte recruitment and the role of some these adhesion molecule-
ligand interactions in the recruitment process. Post-translational modifications (PTMs) of proteins 
will be discussed briefly with an emphasis on phosphorylation and SUMOylation. Following brief 
background discussions on transcriptional regulation of protein expression, protein-protein 
interactions, LSP1 and ezrin/radixin/moesin (ERM) proteins, rationale and objectives of this set of 
studies will be highlighted. 
1.1 Inflammation 
Efficient removal of foreign invaders and harmful stimuli such as infectious pathogens, 
toxic chemicals and damaged tissues is central to survival of a living organism. The complex set 
of response to these invaders and stimuli through which an organism performs these functions is 
known as inflammation. This is the body’s protective response against the infection and tissue 
damage that clears, dilutes, or walls-off the invaded pathogens and the injured tissues. It also 
initiates the healing and repair of the injury sites. Therefore, inflammation is crucial because in its 
absence wounds will never heal and infections will always go unchecked [1, 2]. 
However, components of this response that destroy and/or eliminate noxious stimuli has 
the ability to destroy or damage normal host tissues. Initial injurious stimulation is usually 
accompanied by normal beneficial reactions if the inflammatory response is finely balanced. 
However, the reaction can easily turn into a pathologic one if it is inappropriate such as when it is 
directed against self-antigens as in auto-immunity, harmless environmental antigens as in 
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hypersensitivity, too strong as in severe infection or prolonged when the causative agent resists 
the eradication [3].   
Depending on its onset and duration, inflammation can be divided into either acute or 
chronic inflammation. Acute inflammation develops very quickly and is characterized by marked 
vasodilation, increased vascular permeability and neutrophil infiltration. On the other hand, 
chronic inflammation is the presence of an active inflammation for a prolonged duration (weeks 
to years) in which tissue destruction and repair take place simultaneously. In a chronic 
inflammatory site, the majority of the infiltrated leukocytes are mononuclear cells such as 
lymphocytes, macrophages, and plasma cells [3].   
1.1.1 Vascular permeability 
When acute inflammation sets in, volume of blood flow increases at the site of 
inflammation due to arteriolar vasodilation resulting in increased intravascular hydrostatic 
pressure. Plasma-rich fluid firstly moves from capillaries to the surrounding tissues due to this 
rising pressure. Very soon, rise in vascular permeability leads to loss of protein-rich fluid into the 
surrounding tissues increasing the osmotic pressure of the interstitium. Water and electrolytes keep 
moving into the surroundings in an attempt to balancing the intra- and extravascular osmotic 
pressure. The resulting fluid accumulation in the extravascular tissues is known as edema. 
Increased vascular permeability in acute inflammation, however, can be attributed to any one or a 
combination of the following mechanisms:  
1. Formation of intercellular gaps in postcapillary venules due to endothelial cell 
contraction  this is a rapid and reversible response usually elicited by histamine, 
bradykinin, leukotrienes, and many other chemical mediators. Cytokine-induced 
endothelial cell retraction is a prolonged but slower process resulting from cytoskeletal 
rearrangement [4, 5]. Although all of these mediators disrupt endothelial barrier 
function by cytoskeletal rearrangement of the endothelial cells, the underlying 
mechanisms are completely different. For example, histamine regulates cell contraction 
by modulating endothelial calcium signaling, myosin light chain kinase and 
phosphorylation of junctional proteins whereas bradykinin’s effect is mediated by 
endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) 
[4].  
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2. Direct injury to vascular endothelium by burns, certain infections or other severe 
injuries may result in immediate or sometimes delayed vascular leakage usually by 
causing endothelial cell detachment and necrosis.  
3. Activated leukocytes may also damage the endothelium during adhesion and 
transmigration by secreting toxic mediators. Leukocyte-mediated endothelial cell 
injury often results in increased endothelial permeability by causing endothelial 
detachment [3, 6]. Leukocyte-endothelial cell interactions may also induce endothelial 
hypermeability by contracting endothelial cells in a Ca2+-dependent manner [7].  
4. Healing and repair of injured tissue requires the formation of new blood vessels, a 
process commonly known as angiogenesis. These vessel labyrinths remain leaky until 
the migrated, vessel forming endothelial cells form intercellular junctions via 
remodeling and maturation. Endothelial cells of these newly forming vessels express 
high level of receptors for angiogenic and vasoactive mediators, hence, are very leaky 
[3, 8].  
1.1.2 Leukocyte recruitment 
Leukocyte recruitment and vascular hypermeability are the hallmark signs of acute 
inflammation which occurs within minutes to hours [1]. During acute inflammation, leukocyte 
recruitment takes place in postcapillary venules where the hemodynamic shear forces is quite low. 
This is a tightly regulated multistep process of trafficking leukocytes from the flowing blood 
stream at the vasculature to the inflamed tissue which is fairly similar for different subsets of 
leukocytes in various inflammatory conditions [9]. 
Leukocyte recruitment is the result of sequential and often overlapping steps mediated by 
the interactions of adhesion molecules expressed on leukocytes and their ligands expressed on the 
surface of endothelial cells [10]. However, based on in vivo observations, it was first described as 
a two-step model consisting of leukocyte rolling followed by firm adhesion [11]. With the advent 
of science and modern technologies, the leukocyte recruitment paradigm has so far been updated 
dramatically (Figure 1.1). Although most of the recent investigations are based on neutrophil 
recruitment, other leukocytes also usually follow a similar multi-step cascade with some 
variations. According to the updated paradigm, recruitment starts with the capture of the free-
flowing leukocytes to the surface of the endothelium commonly known as tethering which is 
followed by slow rolling along the endothelium. Following firm adhesion, leukocytes crawl along 
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the endothelium in search of suitable places for transendotheial migration. Then they migrate 
across the endothelium either transcellularly or paracellularly, and finally they migrate toward the 
site of infection or injury in the tissue.  
1.1.2.1 Endothelial activation, leukocyte tethering and rolling  
Endothelial cell activation is the prerequisite for leukocyte recruitment. Endothelium can 
be activated by the pattern recognition receptor (PRR)-mediated endothelial cell-pathogen 
interactions or by the inflammatory mediators (e.g., cytokines, leukotrienes and histamine) 
released from tissue resident cells or sentinel leukocytes when these cells come in contact with 
pathogens. This activation upregulates endothelial adhesion molecules [12, 13].  
 
Figure 1.1: Sequential steps of neutrophil recruitment at post-capillary venule. Activated 
endothelium upregulates adhesion molecules on the luminal surface and drives neutrophil 
margination. Selectins are the first group of adhesion molecules that get upregulated during 
inflammation. The initial steps of neutrophil recruitment (tethering and rolling) are mostly selectin-
dependent. Interaction of chemokines lining the luminal part of endothelium with their receptors 
on neutrophils induces conformational changes (active conformation) of neutrophil surface 
integrins via inside-out signaling. Therefore, the later steps (firm adhesion, crawling and 
transmigration) depend primarily on the interactions of integrin and their ligands. Crawling 
neutrophils follow the chemokine gradient along endothelium, which guides them to the 
preferential sites of transmigration (adapted from [14]). 
 
In response to the inflammatory or infectious stimuli, endothelial cells upregulate selectins 
and then immunoglobulin-like cell adhesion molecules (CAMs such as ICAM-1 (intercellular cell 
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adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1)) on their surface. Weibel-
Palade bodies contain stored P-selectins in endothelial cells. Upon activation, P-selectins are 
exocytosed from Weibel-Palade bodies to the surface of endothelial cells within minutes and P-
selectins can be synthesized by the transcriptional and translational regulations and expressed on 
the endothelial cell surface within hours. However, E-selectin upregulation requires synthesis of 
new E-selectin molecules hence requires at least a few hours [9, 15]. Integrins are a family of 
adhesion molecules constitutively expressed on the surface of leukocytes. Upon leukocyte 
activation, integrins become activated via conformational changes and may also become 
upregulated in the number of expressed molecules. Integrins are transmembrane heterodimers 
consisting of an -subunit and a -subunit [16, 17]. In mammals, 24 different integrin heterodimers 
have been described which are formed by combining 18 different α and 8 different β subunits [18, 
19]. Most notable integrins involved in leukocyte recruitment are: 4 integrins (CD49d) such as 
41 (CD49d/CD29, also known as VLA-4–very late antigen-4) and 47 (LPAM–lymphocyte 
Peyer’s patch adhesion molecule) and the 2 integrins, namely L2 (LFA-1–lymphocyte function-
associated antigen-1 also known as CD11a/CD18), M2 (Mac-1–macrophage antigen-1 also 
known as CD11b/CD18), D2 (CD11d/CD18) and x2 (CD11c/CD18). Selectins on the surface 
of endothelium and their ligands specifically 4 integrins and PSGL-1 (P-selectin glycoprotein 
ligand-1) on leukocytes mediate initial contact (tethering) between free-flowing leukocytes and 
endothelium in vivo. Subsequently, tethered leukocytes roll along the vessel wall before being 
arrested (Figure 1.1) [12, 20, 21]. Initial rolling is mediated mainly by the interaction between P-
selectin and its ligand PSGL-1. E-selectin is vital for leukocyte slow rolling. Apart from PSGL-1, 
E-selectin also binds with ESL-1 (E-selectin ligand-1), CD44 also known as Hermes antigen, Pgp-
1 (phagocytic glycoprotein-1) and HCAM (homing cell adhesion molecule). In addition to slow 
rolling, E-selectin-CD44 interaction also signals leukocytes to redistribute L-selectin (leukocyte-
expressed selectin) on their surface [9, 22]. Leukocyte-expressed 41 integrin binds to VCAM-1 
while 47 integrin interacts with both VCAM-1 and MAdCAM-1 (mucosal addressin cell 
adhesion molecule-1). Besides mediating 2-ICAM-1 independent firm leukocyte adhesion, these 
interactions are capable mediating leukocyte rolling independent of selectins [23-25]. Rolling 
leukocytes may adhere firmly by activation-induced interactions of leukocyte integrins with 
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endothelial counter-receptors and transmigrate through the endothelium into the surrounding tissue 
[20, 21]. 
1.1.2.2 Leukocyte adhesion  
 In addition to adhesion molecules, activated endothelium also present chemokines such as 
chemokine (C-X-C motif) ligands 1, 2 and 5 (CXCL1, CXCL2 and CXCL5) on the surface. 
Positively charged chemokines are immobilized on the endothelial surface by binding to nega-
tively charged heparan sulphates thereby creating a chemotactic gradient within the inflamed 
vessel. The contact between leukocytes and chemokines (on the endothelial surface) is facilitated 
by leukocyte rolling which is crucial for leukocyte activation. Leukocyte full activation is 
generally considered to be a two-step process which began with priming of leukocyte by pro-
inflammatory cytokines or leukocyte-endothelial cell contact. Following initial priming, 
leukocytes get activated by their exposure to chemoattractants, growth factors or PAMPs 
(pathogen-associated molecular pattern) [14, 26]. Leukocytes, specifically neutrophils, 
constitutively express high level of 2 integrins, i.e., LFA-1 and Mac-1 on their surface [14]. 
Chemokine binding activates the chemokine receptors (CXCR or CCR; which are G-protein 
coupled receptors) on the surface of rolling leukocytes results in an inside-out signaling and 
subsequent conformational changes of the cell surface-expressed integrins, e.g., LFA-1 and Mac-
1. This conformational change (activation) increases the affinity of the integrins for their ligands 
including ICAMs as well as integrin valency (density of integrin heterodimers per unit area of 
plasma membrane) [27-30]. Enhanced integrin affinity is a prerequisite of initial leukocyte arrest 
(Figure 1.1) while increased valency strengthens adhesion. Clustering of activated integrins 
initiates the so-called integrin outside-in siganling. LFA-1 plays a more prominent role in the slow 
rolling and initial leukocyte arrest while Mac-1 comes into play during leukocyte firm adhesion 
and crawling along the endothelium which ultimately facilitates leukocyte extravasation [9, 30]. 
Among the endothelial adhesion molecules, ICAM-1 binds with both LFA-1 and Mac-1 and is 
hence considered as the most important endothelial adhesion molecule for leukocyte adhesion. 
Antibody-mediated ICAM-1 ligation and cross-linking are considered equivalent to leukocyte 
rolling and adhesion, respectively in vitro. On the other hand, VLA-4 and VCAM-1-mediated 
adhesion is also reported which is 2 integrin and ICAM-1 independent.   
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1.1.2.3 Leukocyte crawling 
 Leukocytes are ready for transmigration during adhesion. However, for a large number of 
adherent leukocytes, transmigration does not occur right at the site of their firm adhesion. Many 
adherent leukocytes elongate themselves and continuously keep sending out pseudopods in search 
for a suitable spot for transmigration [31, 32]. Adherent leukocytes that are away from the 
endothelial cell-cell junction (the optimal transmigration site) actively crawl to the junction. 
Interactions between leukocyte-expressed Mac-1 and LFA-1 and endothelial cell-expressed 
ICAM-1 and ICAM-2 dictate intraluminal crawling (Figure 1.1) [32, 33]. Crawling leukocytes 
especially under flow maintain adhesion by breaking and simultaneously forming new bonds 
between adhesion molecules expressed on leukocytes and on the endothelium. Mechanotactic 
behavior of leukocytes plays a role in the process. Coordinated signaling involving cell division 
control protein 42 (CDC42); a major regulator of the organization of the actin cytoskeleton during 
leukocyte polarization and migration and VAV1 (a guanine exchange factor for the Rho-family 
GTPase Rac) is also believed to be important for leukocyte intraluminal crawling [14, 34]. 
Chemotactic gradient is not required for leukocyte crawling in vivo or in vitro, however, it helps 
direct the crawling leukocytes to the site of transendotehlial migration [14]. 
1.1.2.4 Leukocyte transmigration 
 For transmigration, leukocytes must cross two layers of barrier: first the endothelial barrier 
[35]. Transmigration is one of the most studied steps of leukocyte recruitment. A wide variety of 
cell adhesion molecules are known to be important for leukocyte transmigration. In addition to 
integrins and CAMs (ICAM-1, ICAM-2 and VCAM-1) that are necessary for transmigration, a 
number of junctional proteins such as platelet/endothelial cell adhesion molecule-1 (PECAM-1; 
also known as CD31), CD99, junctional adhesion molecules (JAMs), epithelial cell adhesion 
molecules (ECAM) play an important role in the process. Some other endothelial cell molecules 
including leukocyte-specific protein 1 (LSP1), poliovirus receptor and vascular adhesion protein 
1 (VAP1) are also shown to be important for leukocyte transmigration, even though, the 
mechanism is not very clear [35-38]. Leukocytes take either paracellular (between endothelial 
cells; Figure 1.1) or transcelluar (through the endothelial cell) route to cross the endothelial barrier, 
although the latter is less prevalent. Paracellular transendothelial migration requires release of the 
junctional intercellular protein bonds. Probably, this is why, paracellular migration preferentially 
occurs at the tricellular corners where the junctional barrier is the least [39]. Interaction between 
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endothelial cell- and leukocyte-expressed adhesion molecules initiates many signaling pathways 
in the endothelial cells [10, 40, 41]. For example, ICAM-1 engagement-mediated elevated levels 
of intracellular Ca2+ activate myosin light chain kinase in endothelial cells resulting in the 
contraction of these cells. Endothelial cell contraction opens up the endothelial cell-cell adherens 
junctions leading to enhanced vascular permeability and leukocyte transmigration [9, 42, 43]. 
Endothelial cells form microvilli-like projections called “transmigratory cups” that move 
up the side of the leukocytes migrating transcellularly. In vivo, these projections go all the way up 
to the top of the leukocyte and was named as dome. However, the dome structure is always 
incomplete in vitro. These ICAM-1- and VCAM-1-rich projections form cup-like structures 
surrounding adherent leukocyte in a LFA-1- and VLA-4 (also known as 41 integrin)-dependent 
manner, respectively [44, 45]. The F-actin–binding protein LSP1 is important for endothelial dome 
formation [37]. In this process, the transmigrating leukocyte never enters the intracellular 
compartment of the endothelial cells; the leukocyte is just covered and sealed away from the blood 
stream by the endothelium [14, 37]. 
 Once passed through the endothelial layer, basement membrane imposes itself as the 
second, continuous and tougher barrier on the migrating leukocyte. The basement membrane is 
mainly composed of extracellular matrix proteins such as different vascular laminins and collagen 
type IV interconnected by glycoproteins such as nidogens and perlecan [9, 46]. Although the 
basement membrane is a continuous barrier, there are regions with thinner protein layers. These 
thinner regions express less collagen, laminin and nidogen 2, but not perlecan and usually overlap 
with interpericyte gaps [14, 47]. These are the areas where extravasating leukocytes would face 
the least resistance and therefore a well suited place for transmigration [47]. Homophilic PECAM-
1 interaction during leukocyte transendothelial migration upregulates the surface expression of 
61 integrin on the migrated leukocytes. This integrin is a laminin receptor and another important 
role player in leukocyte extravasation across the basement membrane [48]. Moreover, 
extravasating leukocytes also secrete proteases such as matrix metalloproteinases and elastase. 
These proteases create holes in the basement membrane by degrading the matrix proteins thereby 
facilitates the escape of leukocytes from the vasculature [9, 49, 50]. 
1.1.2.5 Leukocyte extravascular tissue chemotaxis  
Chemokine gradient across the vascular lumen is sufficient to move neutrophils out of the 
blood vessels. Once outside, these neutrophils need to quickly find a way to move against this 
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gradient in order to reach the site of injury or infection suggesting the presence of a new 
chemotactic gradient in the tissue capable of overriding the first gradient. Indeed, some recent 
studies suggest that different sets of chemoattractant molecules are released at different distance 
from the infection or injury sites. For example, the complement component C5a or bacteria-derived 
N-formyl-methionyl-leucyl-phenylalanine (fMLP) is dominant in the close proximity to the site of 
infection whereas CXCL8 (chemokine (C-X-C motif) ligand 8) and LTB4 (leukotriene B4) are 
predominatly released at intermediary sites. It is interesting to note that chemoattractants closer to 
the infection site override the signals from the chemoattractants present further away from the site 
of infection indicating the presence of a hierarchy of chemoattractants [51]. Based on these 
observations, chemoattractant molecules are functionally divided as 'end-target' and 'intermediate' 
chemoattractants. Neutrophil tissue chemotaxis was thought to be regulated solely by 
phosphatidylinositol 3-kinase (PI3K) pathway. It was largely accepted that the binding of 
chemokine to their receptors on the surface of neutrophils causes PI3K-mediated phosphorylation 
of phosphatidylinositol (4,5)-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3) at the leading edge of neutrophils [52], which favors their directional migration. Recent 
studies, however, support the presence of the hierarchy of intracellular signaling pathways as 
mentioned earlier. These studies also provide evidence that p38 mitogen-activated protein kinase 
(p38 MAPK) is crucial in end-target chemoattractants-induced signaling in neutrophils [14, 53].  
Extravascular neutrophil chemotaxis is a very complex but relatively less studied step of 
the recruitement cascade. Neutrophil transmigration across endothelium may also affect tissue 
chemataxis specifically by affecting the surface expression of integrins in the transmigrating 
neutrophils [48]. Extravascular tissue locomotion also requires coordinated engagement and 
detachment of different neutrophil integrins with their ever-growing population of ligands in 
extravascular tissues. Morever, integrin cross-talk is also important for neutrophil tissue 
chemotaxis [54]. Because of the complex nature and insufficient knowledge of leukocyte tissue 
chemotaxis, more investigations are needed to uncover the molecular mechanisms of extravascular 
neutrophil chemotaxis. 
1.1.2.6 Reverse neutrophil migration 
It is widely accepted that transmigrated neutrophils die in the tissue and macrophages eat 
them up. However, in junctional adhesion molecule C (JAMC)-deficient mice, transmigrated 
neutrophils were shown to migrate back into circulation [10]. Similar observation was reported in 
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zebrafish embryo under sterile injury [11, 20]. Moreover, another report confirming the presence 
of reverse-transmigrating neutrophils in the blood of rheumatoid arthritis patients which were more 
resistant to apoptosis [21] poses a serious doubt on the generally accepted concept about death of 
all transmigrated neutrophils at the site of inflammation. The existence of reverse transmigration 
is unquestionable now, however, its implications are far from our understanding.   
1.1.3 Endothelium in wound healing and tissue repair  
Wound healing and tissue regeneration require the formation of new blood vessels from 
the existing ones, a process commonly known as angiogenesis. Migration of capillary endothelial 
cells is one of the essential steps of angiogenesis which consists of a series of events and is finely 
controlled by angiogenic factors [55]. Angiogenic agents stimulate endothelial cells to break their 
cell-cell contacts, proliferate, migrate into the perivascular space where they unite together by 
establishing their cell-cell association to form the vascular sprouts [8]. Maturation of these sprouts 
into blood vessels involves their continuous remodeling and recruitment of smooth muscle cells 
[56].  
Many inflammatory disorders are characterized by excessive angiogenesis. Recruited 
leukocytes release a large number of angiogenic agents such as vascular endothelial growth factor 
(VEGF), transforming growth factor-1 (TGF-1), angiopoietin 1 (Ang1), platelet-derived growth 
factor (PDGF), basic fibroblast growth factor (bFGF), tumor necrosis factor- (TNF-), monocyte 
chemoattractant protein-1 (MCP-1), insulin-like growth factor-1 (IGF-1), hepatocyte growth 
factor (HGF), and many more [57, 58]. Leukocytes also help degrade barriers for migrating 
endothelial cells by releasing proteinases [59]. Angiogenesis is also turned off by hematopoietic 
cells via releasing or making some angiogenesis inhibitors [60, 61]. Inflammatory cells are also 
involved in adaptive arteriogenesis, a process of growing pre-existing collateral arterioles when 
the supply artery is occluded [62, 63]. In this process, high level of MCP-1 ensures large monocyte 
infiltrate and monocyte-mediated proteolytic remodeling of the vessel wall [8, 62] in favour of 
endothelial cell migration. Finally, TGF--, bFGF- and PDGF-B-mediated accelerated growth of 
endothelial cells and smooth muscles completes adaptive arteriogenesis to reduce the severity of 
the detrimental effects of blood vessel obstruction [8, 63].  
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1.2 Post-translational modification of proteins 
 Cellular functions in both eukaryotes and prokaryotes are largely dependent on gene 
expression that involves multiple complex processes such as transcription and translation. These 
processes are intricately regulated by cells for their growth and survival. In a cell, protein functions 
are finely regulated amidst ever-changing (internal or external) cellular conditions. After 
translation, functions of a protein are usually regulated by its interaction with other proteins and 
small molecules or by modifications (usually enzymatic in nature) of the protein molecule itself. 
One of the commonest mechanisms by which chemical structures, properties and functions of 
proteins are regulated is post-translational modification (PTM). PTM usually takes place during 
or after protein synthesis. It refers to the covalent and generally enzymatic modification of proteins 
necessary for the maturation of the modified proteins. PTM, in general, increases the functional 
diversity of the proteome and specifically crucial for cell signaling. So far, more than 300 different 
kinds of PTMs are known [64, 65] and over 200 of them are enzyme-mediated [65]; among them, 
the most notable are: phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, 
acetylation, SUMOylation, lipidation and proteolysis. Phosphorylation, ubiquitination and 
SUMOylation will be discussed in details below.   
1.2.1 Phosphorylation 
Scientific community knew for a long time (as early as the 19th century) that phosphate 
could bind to proteins. In the old days, however, they thought that this was a common metabolic 
process of incorporating phosphorus as nutrient. Their belief was based on the fact that the then 
phosphate containing proteins were selectively available only in nutritious foods such as milk 
(casein) and egg yolk (phosvitin) [66]. It took until the late 1950’s for the scientists to understand 
the fact that phosphoproteins are one of the key regulators of cellular life. The change in perception 
began with the discovery of the enzyme kinase and its role in transferring phosphate into another 
protein, a biological process called ‘phosphorylation’ [67]. In 1955, the stunning discovery by 
Fischer and Krebs [68], and Wosilait and Sutherland [69], revealed the functional regulation of 
phosphorylase by the addition or removal of phosphate. These studies first initiated the idea that 
reversible phosphorylation could control enzyme activity which was later proven to be true. For 
their extensive work and monumental contribution in establishing reversible phosphorylation-
mediated regulation of enzymatic activity, Fischer and Krebs were awarded Nobel Prize in 
Physiology or Medicine in 1992. 
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At present, phosphorylation is considered to be the most prevalent reversible covalent PTM 
that regulates the functions of almost all different kinds of proteins such as enzymes, membrane 
channels, and other target proteins. In fact, almost every metabolic process in eukaryotes is 
regulated by phosphorylation of metabolic enzymes. Two groups of enzymes involved in this 
reversible process are namely protein kinases which are responsible for transferring a phosphoryl 
group from adenosine triphosphate (ATP) to the modified proteins and phosphatases which 
catalyze the hydrolytic removal of phosphoryl group from the phosphorylated proteins.  
In eukaryotes, there are two classes of protein kinases, serine and threonine kinases and 
tyrosine kinases. Serine and threonine kinases mediate the transfer of the phosphoryl group to 
specific serine and threonine residues while tyrosine kinases mediate the transfer to specific 
tyrosine residues. Specificity of a protein kinase primarily depends on the amino acid sequence 
surrounding the serine/threonine or tyrosine phosphorylation sites known as phosphorylation 
motif. Because protein phosphorylation depends largely on the availability of phophoryl group 
donor ATP, it is usually restricted for intracellular proteins only. Reversible phosphorylation does 
not regulate extracellular proteins. The most exciting thing about phosphorylation is that the subtle 
change in protein conformation due to addition or removal of a phosphoryl group turns the 
modified protein on or off. 
1.2.1.1 Phosphorylation in health and disease 
Human genome codes more than 500 protein kinases and many protein phosphatases and 
about a third of total human proteins are phosphoproteins. These numbers are sufficient to guess 
that the imbalance in protein phosphorylation can be a cause or a consequence of some human 
diseases. Indeed, mutations of protein kinases and phosphatases are reported to cause a good 
number of diseases (Table 1.1). Interestingly, naturally occurring pathogens and toxins exert their 
effects by altering the phosphorylation states of proteins. A major virulence factor of Yersinia is a 
protein tyrosine phosphatase whereas, okadaic acid and microcystin are potent inhibitors of Type 
1 and 2A protein phosphatases [70, 71]. These naturally occurring substances and their ability to 
modulate protein phosphorylation provide a nice opportunity of developing new therapeutics for 
diseases associated with altered protein phosphorylation. Some novel drugs that work by altering 
phosphorylation of proteins are listed below: cyclosporin is a lifesaving drug that made 
transplantation possible. It forms a complex with cyclophillin which inhibits calcineurin also 
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known as protein phosphatase 2B (PP2B) [1], an enzyme related to the Type 1 and 2A protein 
phosphatases. 
Table 1.1: Diseases caused by mutations in particular protein kinases and phosphatases (used 
with permission [71]). 
Disease Kinase/phosphatase 
Myotonic muscular dystrophy Myotonin protein kinase 
X-Linked agammaglobulinaemia Bruton tyrosine kinase 
Hirschsprung’s disease Ret2 kinase 
Autosomal recessive SCID Zap70 kinase 
X-Linked SCID Jak3 kinase 
Craniosynostosis FGF receptor kinase 
Papillary renal cancer Met receptor kinase 
Chronic myelomonocytic leukemia 
leukaemia 
Tel-PDGF receptor kinase 
Chronic myelogenous leukaemia Abelson tyrosine kinase 
Non-Hodgkins lymphoma Alk kinase 
Peutz–Jeghers syndrome Lkb1 kinase 
Coffin–Lowry syndrome MAPKAP-K1b (RSK-2) 
Ataxia-telangiectasia Atm kinase 
Li–Fraumeni syndrome Chk2 kinase 
Williams syndrome Lim kinase-1 
Leprechaunism, diabetes Insulin receptor kinase 
Wolff–Parkinson–White syndrome AMP activated kinase 
Wolcott–Rallison syndrome eIF2A-kinase 3 
X-Linked myotubular myopathy MTM1 Tyr phosphatase 
 
There are quite many protein kinase inhibitors under development that have the potential 
to fight diseases like cancer, chronic inflammatory disease and diabetes. Some examples include 
Erlotinib (CP 358774) that potently, selectively and reversibly inhibits epidermal growth factor 
receptor (EGFR) tyrosine kinase (useful in cancer treatment), SB 203580 that inhibits p38 MAPK 
(useful in chronic inflammation) and some glycogen synthase kinase 3 (GSK3) inhibitors to treat 
diabetes and stroke [71]. 
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1.2.2 Ubiquitination 
Ubiquitin is a small molecule (76-amino acid peptide), present in most cells, which is 
capable of being attached to a target protein in a process called ubiquitination. Ubiquitination is a 
post-translational modification of protein which determines whether the modified protein will be 
destined for degradation via 26S proteasome or enter into protein trafficking pathways [72].  
Ubiquitination is a covalent modification of a protein which is carried out in a sequential 
manner by three distinct families of enzymes, namely, ubiquitin activating enzyme (E1), ubiquitin 
conjugating enzyme (E2), and ubiquitin ligase (E3). E1 enzyme initiates ubiquitination by ATP-
dependent ubiquitin adenylation which is required for the activation of ubiquitin C-terminal 
glycine residue. Eventually, the activated ubiquitin forms a high energy thiolester bond with a thiol 
site of E1. Cysteine residue of the E2 active site receives ubiquitin from E1 through transacylation. 
E2 either directly mediates the conjugation of the C-terminus of the ubiquitin to the -amino group 
of a lysine residue of the target protein or forms an intermediate linkage between ubiquitin and E3 
prior to transferring ubiquitin to the target protein (Figure 1.2) [73]s.  
So far, there are only two E1 enzymes, ~40 E2 enzymes, and more than 600 E3 ligases 
reported in eukaryotes [74]. Although ubiquitination begins with activation by E1, E3 ligases 
provides substrate specificity to the activated ubiquitin [72]. Because E3 ligases are responsible 
for ubiquitin substrate recognition, there is a huge diversity of E3 ligases discovered and the growth 
of the family continues [73]. HECT (homologous to E6AP C-terminus) and RING (really 
interesting new gene) are the two well described families of ubiquitin ligases (E3). RING E3s 
facilitate ubiquitin transfer from E2 active site to substrate lysine(s) by acting as scaffolds whereas 
HECT E3s accept the ubiquitin from E2s and then transfer them to the substrate protein (Figure 
1.2) [72]. Ubiquitination is classified as mono or polyubiquitination depending upon the nature 
and number of attached ubiquitin with its substrate. Modification of a protein by a single ubiquitin 
at a single site is called monoubiquitination whereas modification by multiple monomeric 
ubiquitins at several places on a single protein is defined as multi-monoubiquitination. However, 
attachment of ubiquitin chains containing at least four ubiquitin molecules, usually via 48 or 63 
lysines on ubiquitin, to a protein is commonly known as polyubuquitination. 
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Figure 1.2: Schematic representation of the steps involved in ubiquitination. 
The multistep ubiquitination process begins with ubiquitin activation, an ATP-dependent reaction 
which is immediately followed by the formation of thioester bond between the carboxyl terminus of a 
ubiquitin and a cysteine residue of a ubiquitin-activating enzyme (E1) and transfer of the ubiquitin to a 
specific cysteine residue of a ubiquitin-conjugating enzyme (E2). Ubiquitin can then be transferred from 
the E2 enzyme to the substrate either through E2-ubiquitin-E3 ligase complex (in case of RING E3 ligases) 
or through specific HECT E3 ligases. Final outcome is the formation of an isopeptide bond between 
ubiquitin C-terminus and specific lysine residue(s) of the target protein (used with permission from [75]). 
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Factors that dictate whether a substrate protein will undergo mono, multimono or 
polyubiquitination are largely unknown. Evidence suggests that a single substrate can follow all 
these modifications by different ligases and the same ligase can mono-, multimono-, or 
polyubiquitinate different substrates [76]. 
According to common understanding: polyubiquitination via lysine 48 leads the substrate 
protein to proteasomal degradation while polyubiquitination via lysine 63 linkage on ubiquitin 
follows non-proteasomal pathways, such as mediating DNA damage tolerance and protein 
trafficking [77]. Mono- and multimonoubiquitinations, on the other hand, are primarily believed 
to serve as signals for internalisation and entry into endocytic pathway [76, 78]. 
Monoubiquitination regulates a myriad of biological processes, such as transcription, DNA repair, 
histone modification and viral budding [79, 80]. However, recently, exceptions to these widely 
accepted functional changes due to ubiquitin modifications are rapidly growing in numbers.  
1.2.3 SUMOylation 
Small ubiquitin-like modifiers (SUMO) are a family of small proteins, reversibly but 
covalently attach to specific lysine residues of target proteins and modify their functions [81]. This 
process is known as SUMOylation, one of the relatively new PTMs. In vertebrates, there are four 
distinct members of the SUMO family (SUMO1, SUMO2, SUMO3 and SUMO4) [82]. Ran-
GTPase-activating protein 1 (Ran-GAP1) is the first protein known to be modififed by SUMO. In 
1997, Mahajan et al. identified two forms of Ran-GAP1, 70 kDa and 90 kDa in mammalian cells. 
They confirmed that the 90kDa form of RanGAP1 was modified by a novel small ubiquitin like 
modifier (SUMO) [83, 84].  
SUMO2 and SUMO3 share about 98% sequence similarity, hence, are often referred as 
SUMO2/3. On the other hand, SUMO1 has only 50 % identical sequences as of SUMO2/3 [85, 
86]. SUMO4, however is very similar to SUMO2/3, the major difference being substitution of 
glutamine at position 90 with proline. This substitution makes SUMO4 functionally distinct from 
the other SUMOs so that it is used by cells for modification of proteins only under stressful 
conditions such as starvation [87]. SUMO proteins are around 100 amino acid and about 12 kDa 
in molecular weight, however, the molecular weight may vary depending on the SUMO family 
member and the cell type where the protein is expressed.   
Recent proteomic analysis using different SUMOs and various types of mammalian cells 
has led to the identification of a bulk of SUMO substrates. SUMOylation can regulate cellular 
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actions such as regulation of transcription, DNA repair and cell signalling by affecting a number 
of functions of the modified protein including localization, trafficking, protein-protein 
interactions, protein activity and protein stability [81, 88-94]. Dysregulation of protein 
SUMOylation was shown to be involved in many diseases such as cancer, diabetes, 
neurodegenerative diseases and many others suggesting an integral role of SUMOylation in 
regulating normal and abnormal cellular behavior [82]. 
1.2.3.1 SUMO conjugation, deSUMOylation and SUMO consensus motif 
SUMO proteins are inactive precursors and requires C-terminus cleavage to expose its di-
glycine motif, which is available for subsequent activation and conjugation. Sentrin/SUMO-
specific proteases (SENP) are responsible for this cleavage [86]. In each conjugation cycle, SUMO 
is first activated in an ATP-dependent manner by the E1 activating enzymes (SUMO activating 
enzyme 1/2 (SAE1/SAE2)) and then passed to the active site of the only E2 conjugating enzyme 
Ubc9 (ubiquitin-conjugating 9). Finally, SUMO E3 ligases (protein inhibitor of activated STAT 
(PIAS)  proteins) covalently attach SUMO to lysine residues of the target protein by forming 
isopeptide bonds between the terminal glycine residue of SUMO and the ε-amino group of a lysine 
residue(s) on the target protein [95-97]. Even though Ubc9 was shown to SUMOylate some SUMO 
substrates independently of any E3 enzymes, it is generally accepted that E3 increases SUMO 
transfer efficiency and substrate specificity of Ubc9 [98]. Like many other PTMs, SUMOylation 
is also a highly dynamic process and can be easily reversed by SUMO deconjugating enzymes 
such as the SENP enzymes [99] (Figure 1.3). 
The SUMO consensus motif is a sequence of conserved residues around the modified 
lysine residue and is present in many SUMO substrates [100]. It is a tetrapeptide consensus motif 
ΨKxD/E, where Ψ is a large hydrophobic residue (such as Val, Ile, Leu, Met, or Phe). K is the 
lysine to which SUMO is conjugated, X is any amino acid and D/E is an acidic residue [82, 101]. 
About two-thirds of the known SUMO substrates contain this consensus motif [82, 101]. On the 
other hand, proteins lacking this motif can also undergo SUMOylation [102-104]. Moreover, 
lysine residues within this consensus motif are not always SUMOylated [95]. However, 
SUMOylation consensus motif is still used as a helpful tool for predicting SUMOylation sites. 
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Figure 1.3: The SUMOylation cycle. Small ubiquitin-like modifier proteins (SUMOs) are 
synthesized as precursors and requires sentrin/SUMO-specific proteases (SENPs)-mediated 
cleavage of the SUMO C-terminus to reveal a Gly-Gly motif to enter into the SUMOylation cycle. 
This motif is essential for all subsequent steps of the SUMO cycle and mediates the direct linkage 
of SUMO to each enzyme and target molecule. Mature SUMO is activated by and covalently 
linked to a catalytic cysteine residue in the SUMO-activating enzyme 1 (SAE1–SAE2 heterodimer 
(E1 enzyme)). Activated SUMO is transferred to the catalytic cysteine residue of the SUMO-
conjugating enzyme UBC9 (E2 enzyme). UBC9 catalyses the conjugation of SUMO to lysine 
residues in target proteins, either independently of or in concert with a SUMO E3 ligase, both of 
which determine target and lysine specificity. SENPs can cleave SUMO from target substrates 
(deconjugation), thus releasing an unmodified target and free SUMO capable of re-entering into 
the SUMOylation cycle (used with permission from [98, 105]). 
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1.2.3.2 SUMOylation versus ubiquitination 
Ubiquitination and SUMOylation are two of the most important PTMs through which cells 
regulate the functions of many proteins. Even though they have some commonalities, they differ 
in many ways [54]. Both SUMO and ubiquitin are synthesized as inactive precursor proteins which 
are activated by the enzymatic (SENP) cleavage of the di-glycine motif from the C-terminal. They 
are similar in protein size, tertiary structure and a C-terminal di-glycine motif. Additionally, 
SUMOylation and ubiquitination requires the same set of enzymes, namely, E1 (activating 
enzyme), E2 (conjugating enzyme) and E3 ligases [86, 106]. While ubiquitination is well known 
for tagging the modified protein for degradation, SUMOylation, on the other hand, regulates the 
functions of modified proteins mainly by altering the stability, intracellular localization, nuclear 
trafficking, protein-protein interaction and transcription factor activity. Moreover, the ubiquitin 
pathway has been studied well for a long time and has a large number of E2 and E3 enzymes 
compared to SUMOylation [107]. 
1.2.3.3 SUMOylation and diseases 
Like many other PTMs, SUMOylation plays an important role in favor of maintaining 
normal functions of many proteins while it may hinder the normal functions of many other 
proteins. This is why SUMOylation is critical for health and many diseases. In the recent past, 
several proteins that have key roles in pathogenesis of several human disease states, such as tau, 
Parkinson’s disease 7 (PARK7) also known as DJ-1, ataxin-1, huntingtin and superoxide 
dismutase 1 (SOD1) were reported to be substrates of SUMO [86]. Many of these recent studies 
provide evidence on how SUMOylation could be involved in pathogenesis of human diseases, 
including cancer, neurodegenerative and heart diseases.  
1.2.3.3.1 SUMOylation and cancer 
Multiple lines of evidence suggest that the SUMOylation machinery plays an important 
role in different types of cancers. It was reported that hepatocellular carcinoma patients with 
elevated level of E1 (SUMO activating) enzyme had lower survival rates [108]. Ubc9, the only E2 
conjugating enzyme for SUMOylation expression is upregulated in a number of human cancers. 
Ubc9 overexpression usually increases cancer cell growth [109, 110]. Upregulation of PIAS3, a 
SUMO E3 ligase was also observed in many cancer types [111]. Additionally, SUMOylation is 
known to modulate the functions of tumor suppressor proteins, such as p53, retinoblastoma protein 
(pRB), p63, p73, and murine double minute 2 (Mdm2) [112]. However, upregulation of the SUMO 
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protease SNEP1 was observed in prostate and thyroid cancers. This upregulation promotes the 
pathogenesis of cancer at least in the prostate [86, 113, 114]. These interesting findings make the 
relationship between cancer and SUMO pathway more complicated. Probably SUMOylation and 
deSUMOylation both play their distinct role in tumorigenesis of different tissues. 
1.2.3.3.2 SUMOylation and neurodegenerative diseases 
A number of proteins that play important role in the pathogenesis of several 
neurodegenerative diseases are known SUMO substrates. Most notable ones are huntingtin 
(Huntington’s disease), ataxin-1 (spinocerebellar ataxia type 1), tau (Parkinson’s and Alzheimer’s 
disease), SOD1 (amyotrophic lateral sclerosis) and amyloid precursor protein (APP; Alzheimer’s 
disease). However, the exact mechanism of how SUMOylation of these proteins relates the 
pathogenesis of the respective diseases is not completely understood.  
SUMOylation was associated with increased stability of huntingtin while mutation of 
SUMOylation sites reduced aggregation of the mutant huntingtin. These findings indicate that 
SUMOylation possibly increases the levels of toxic intermediate poly-Q oligomers thereby 
increasing its ability to repress transcription [115]. 
1.3 Protein-protein interactions  
Every cellular process practically depends on some sort of protein-protein interactions. 
Proteins rarely act alone and indeed protein-protein interactions are at the center of interatomics 
of virtually all living organisms. That is why, these interactions have enormous potential in the 
pathogenesis of diseases and to be targeted in the development of new therapeutic agents such as 
inhibitors of mouse double minute 2 (MDM2)–p53 interaction. These interactions can be divided 
into groups in several ways, such as homo- versus hetero-oligomers, stable versus transient 
interactions and covalent versus non-covalent interactions. Oligomers are macromolecular 
complexes. When a single protein forms a complex it is called homo-oligomer whereas protein 
complexes made up of different proteins are known as hetero-oligomers. In a stable interaction, 
proteins stay together for a long time and usually provide structural and functional support to the 
interacting proteins. On the other hand, transient interactions are reversible, brief and takes place 
only in specific cellular contexts such as stage of cell cycle, cell type and presence of other binding 
proteins. Most biochemical processes (signal transduction, transport across membranes, cellular 
metabolism, muscle contraction, etc.) are governed by transient protein-protein interactions. 
Protein-protein interactions usually affect protein functions in many ways including by changing 
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affinity and/or specificity for its substrate, by altering its kinetic properties, by inactivating a 
protein and even by opening up new binding sites [116].  
Proteins are efficient in performing their functions (catalysis or transport) in the individual 
level. Crowded intracellular environment limits their effectiveness only to short-range. Sustaining 
life in this environment necessitates proteins to manage their long-range effectiveness via 
extremely organized and responsive protein networks called interactomes. Interactomes efficiently 
relay protein functions throughout the cell by means of protein-protein interactions [117-119]. 
Theoretically, many protein-protein interaction involved in disease pathogenesis is a potential drug 
target and ubiquitous nature of protein-protein interactions and related networks in cellular 
physiology provides ample opportunities for drug discovery [119, 120]. The interactome is not 
easy to solve because protein-protein interactions in cellular environment are very dynamic, some 
of these interactions takes place only in particular cellular contexts or at a certain stage of 
development and many of these interactions are transient [117]. For this reason, finding a protein-
protein interaction is tricky even though of utmost importance. Below are the commonly used 
laboratory techniques to identify protein-protein interactions:  
Physical methods to select and detect proteins that bind another protein  
Protein affinity chromatography   
Affinity blotting  
Immunoprecipitation 
Cross-linking  
Library-based methods 
Protein probing 
Phage display 
Antibody phage  
Peptides on plasmids 
Two-hybrid system 
1.4 Transcriptional regulation of gene expression  
Extensive genomic studies identified 30,000 genes in human genome [117]. It is interesting 
to note that these 30,000 genes are encoded in only about less than 2% of the genome. It is 
intriguing to wonder what exactly the remaining 98% of our DNA does. Although many mysteries 
remain about this majority of genome sequences, now we certainly know that some of those extra 
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sequences carry complex instructions for directing the intricate process of turning on or off gene 
transcription. These regulators of gene transcription also solve the mysteries about how and why 
specific stimuli lead to the synthesis of specific proteins in a cell type and why different cell types 
express very different proteins even though their DNA content is virtually the same [121]. 
Regulation of transcription is of utmost importance in gene expression. While post-transcriptional 
and translational regulation are well known, post-transcriptional steps of gene expression can take 
place automatically once the gene is transcribed into ribonucleic acids (RNA) [121].  Regulation 
of gene expression in eukaryotic cells is very intricate and requires combined efforts of several 
different types of transcription regulatory proteins. DNA methylation and packaging of DNA into 
chromatin make this tightly regulated process even more complex. Factors that usually regulate 
gene transcription are briefly discussed below. 
1.4.1 Transcription factors 
Transcription factors are proteins capable of controlling transcription of DNA to messenger 
RNA by binding to specific DNA sequences. They regulate transcription positively or negatively 
by themselves or by forming a complex with other transcription regulatory proteins via promoting 
or blocking RNA polymerase recruitment, respectively [122, 123]. 
 
1.4.2 Transcription regulatory DNA elements 
Transcriptional regulation depends on the binding of the regulatory proteins to specific 
DNA sites which are usually organized into several distinct elements such as promoters, enhancers 
and silencers. [121]. 
1.4.2.1 Promoters 
These cis-acting elements usually encompasses about 100 base pairs. Most promoters 
consist of transcriptional regulator binding site, a transcription initiation site and the TATA box 
[121, 123]. The TATA box is an AT-rich site located at 25 to 30 base pairs upstream of the 
transcription initiation site in higher eukaryotes. The TATA box is the binding site for the TATA-
binding protein (TBP), so named because of its binding to the TATA box. Core promoters can be 
composite (containing both TATA and initiator (Inr) elements), TATA- or Inr-directed or null 
(neither of these elements) [124]. Many viral genes contain composite promoters. Some class II 
genes may contain Inr-directed promoter. However, most of class II genes contain TATA-directed 
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promoters. Transcription initiation for null promoters containing genes is not very precise because 
very often they have multiple initiation sites [125-127]. 
1.4.2.2 Enhancers  
Unlike promoters, eukaryotic gene transcription can also be regulated by further distant 
DNA elements mostly upstream of the gene commonly known as enhancers or, sometimes, 
upstream activating sequences.  Enhancers mostly contain multiple but same activator binding 
sites that are found immediately upstream of the promoter or binding sites for multiple different 
factors. Enhancers cannot drive transcription themselves, however, they increase promoter 
activity. Moreover, the presence of a cluster of binding sites enables enhancers to function 
independent of their location (upstream or downstream and up to 1,000,000 base pairs away from 
the transcription initiation site) and orientation relative to the promoter [121, 123]. 
1.4.2.3 Silencers  
Silencers are DNA elements where repressors bind to repress promoter activity [128]. 
Mechanisms of repressor-mediated inhibition of transcription include prevention of transcription 
apparatus recruitment, inhibition of activator binding, and modification of chromatin structure 
[123, 129]. 
1.4.3 Transcription factor-mediated regulation of gene transcription  
Upon binding to different DNA elements, transcription factors regulate transcription of a 
gene either positively or negatively. Transcription factors possess both DNA-binding and 
activation domains. Activation domains may directly interact with basal transcription complex or 
they may need coactivator molecules for this interaction. Binding of basic transcription complex 
to TATA box is sufficient to begin gene transcription, however, the speed is greatly increased by 
binding of other transcription factors to enhancers. On the other hand, transcriptional repressors 
negatively regulate transcription by blocking the activator binding site or forming a complex with 
activator that cannot bind to DNA or by organizing DNA into chromatin structure. Additionally, 
transcription is also regulated by controlling the level of transcription factor mainly in two ways: 
by modifying their synthesis and affecting their activity. Many transcription factors are only 
produced in specific cell types often in a stimulus-dependent process. For example, interleukin-6 
(IL-6), usually secreted by some immune cells, induces the synthesis of NF-IL6 (a transcription 
factor) in cells expressing IL-6 receptors. This transcription factor ultimately stimulates the 
expression of its target genes in those cells. De novo synthesis of transcription factor is not always 
24 
 
necessary. In fact, in many instances, presynthesized transcription factors are turned on or off in 
response to appropriate stimuli. For example, in addition to NF-IL6 synthesis, IL-6 activates 
STAT-3 and NF-IL6, two transcription factors which are readily available in those cells [121, 123]. 
1.5 Leukocyte-specific protein 1 (LSP1) 
 Leukocyte-specific protein 1 (LSP1), was initially identified in normal and transformed B 
cells, in normal T lymphocytes but not (or in smaller amounts) in transformed T cells [130, 131] 
and later on, it was found in thymocytes, monocytes, macrophages, dendritic cells, and neutrophils 
[132-134]. LSP1 was first identified in murine and human lymphocytes hence given the name 
lymphocyte-specific protein 1. However, because of the subsequent discovery of the presence of 
this protein in all different kind of leukocytes, the scientific community renamed the protein as 
leukocyte-specific protein 1 [135]. Further investigations established that LSP1 was also expressed 
in mouse and human endothelial cells [136], and the amino acid sequences between leukocyte- 
and endothelial cell-expressed LSP1 were almost identical [137], indicating that LSP1 genes in 
leukocyte and endothelial cells have the same origin. [135]. 
LSP1 is an intracellular, Ca2+- and F-actin-binding protein [138-141].  Human and mouse 
LSP1 proteins, which are 339 and 330 amino acid peptides respectively, share 67% identical 
sequences [131, 142, 143]. Ca2+ binding sites are identified in the N-terminus with mostly acidic 
residues and only 53% identical between the two species. In contrast, the C-terminus of LSP1, 
enriched in basic amino acids, holds two F-actin binding sites and is 85% identical between mouse 
and human LSP1 proteins [130, 138]. LSP1 transcription is regulated collectively by Ets, SP1 and 
C/EBP transcription factors. An Inr element determines a single transcription initiation site for 
LSP1 and the transcription is driven by a TATA-less promoter. Its expression in different cell 
types largely depends on the presence of anti-NRE (negative regulatory element), an anti-silencer. 
In the absence of anti-NRE, the silencer NRE inhibits the expression of LSP1 [144, 145]. 
1.5.1 Leukocyte-expressed versus endothelial cell-expressed LSP1 
As opposed to predominant cytoplasmic distribution of LSP1 in neutrophils and B 
lymphocytes, endothelial cell-expressed LSP1 is mostly found in the nucleus, with small level of 
LSP1 found in F-actin-rich microfilaments [136, 138]. LSP1 translocates from nucleus to 
extranuclear compartments (predominantly to cytoskeleton) when endothelial cells are treated with 
TNF-α [37]. Conflicting findings in previous studies from different research groups showed that 
neutrophil-expressed LSP1 played a tissue-specific and either positive or negative regulatory role 
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on neutrophil adhesion, polarization, and migration [146, 147]. Using bone marrow transplanted 
chimeric mice, decreased transendothelial migration of neutrophils was observed in mice deficient 
in endothelial cell-expressed LSP1 in response to chemokine CXCL1 and cytokine IL-1β or TNF-
α, effects attributed to the supportive role of endothelial-expressed LSP1 in neutrophil 
extravasation [136]. More recently, endothelial cell-expressed LSP1 was shown to regulate 
microvascular permeability by participating in endothelial dome formation during neutrophil 
transmigration [37]. 
During chemotaxis, LSP1 in neutrophils binds with F-actin in filopodia, lamellipodia, and 
membrane ruffles; while in B cells, LSP1 is recruited into anti-IgM-induced B cell receptor caps 
enriched in F-actin aggregates [139]. When binding F-actin during chemotaxis, LSP1 does not 
change the rate of actin polymerization, however, it rearranges polymerized F-actin into bundles 
[147, 148]. LSP1 is a major substrate of mitogen-activated protein kinase (MAPK)-activated 
protein kinase 2 (MK2) in the p38 MAPK pathway in neutrophils. MK2 phosphorylates LSP1 at 
serine 195 and 243 in murine neutrophils [143]. This signaling pathway is known to be important 
in neutrophil migration and chemotaxis in response to bacterial product formyl-methionyl-leucyl-
phenylalanine (fMLP) and to CXC chemokine KC (keratinocyte-derived chemokine, CXCL1) 
[149-151].  LSP1 is also a substrate for protein kinase C (PKC) in B cells. PKC phosphorylates 
serine residues at 202 and 283 in the C-terminal of murine LSP1 [152, 153]. All these signaling 
kinases contribute to leukocyte migration. However, the mechanisms of endothelial cell-expressed 
LSP1 activation during leukocyte recruitment remain completely unknown. The complexity of 
cell-specific LSP1 signaling has, thus, promulgated discrepancies in the putative role of LSP1. 
Whether LSP1 modulates other steps of neutrophil recruitment such as intraluminal crawling and 
post-transendothelial extravascular chemotaxis is not known. Whether LSP1 has a role in 
endothelial cell functions such as endothelial cell proliferation and motility is yet to be studied. 
1.5.2 LSP1 and human diseases 
Neutrophil actin dysfunction with 47- and 89-kDa protein abnormalities (NAD47/89) is 
the first disease reported to be associated with abnormal LSP1 expression [154, 155]. Patients with 
NAD47/89 are susceptible to bacterial infections because their neutrophils exhibit defective 
migration, chemotaxis and phagocytosis. Neutrophils of these patients overexpress LSP1 with 
concomitant reduced expression of an 89 kDa protein, fail to increase actin polymerization in 
response to chemotactic factors and display numerous thin, hair-like, F-actin-rich filamentous 
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projections on their surfaces. Further studies revealed that indeed overexpression of LSP1 creates 
filamentous projections even in cells that do not constitutively express LSP1 and adversely affects 
motility of normally motile cells. However, it was also reported that a certain level of LSP1 is 
required for normal leukocyte motility and downregulation or upregulation negatively affects their 
motility [156-158]. 
A single nucleotide polymorphism in LSP1 gene was also reported to be associated with 
increased breast cancer risk [159, 160]. These reports are bioinformatics-based and predictive in 
nature. Whether LSP1 is indeed involved in the pathogenesis of breast cancer is yet to be studied. 
A recent report, however, demonstrated that LSP1-deficiency results in increased proliferation and 
migration of hepatocytes and hepatocellular carcinoma [161].  
1.5.3 LSP1 binding partners  
During chemotaxis of neutrophils, LSP1 co-localizes with F-actin in filopodia, 
lamellipodia, and membrane ruffles [146]. In B cells, LSP1 co-localizes with anti-IgM–induced B 
cell receptor caps enriched in F-actin aggregates [139]. LSP1 was found to directly interact with 
PKCβI but not with PKCα and βII. This interaction is required for extracellular signal-regulated 
kinases 2 (ERK2) activity, which is necessary for the survival of B cell lymphoma cells against 
anti-IgM–induced apoptosis [162]. This is a complex interaction involving a number of molecules 
e.g., ERK scaffold protein KSR (kinase suppressor of Ras), the ERK (MAPK), and mitogen-
activated protein kinase kinase 1 (MEK1), the direct upstream activator of ERK. LSP1 functions 
as a targeting protein directing the KSR/MEK/ERK complex to a cytoskeletal location [163]. By 
interacting with cytoskeletal proteins, LSP1 interacts with DC-SIGN (dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin) signalosome to facilitate virus transport 
into the proteasome of dendritic cells [164]. During carbohydrate signaling, scaffold proteins 
LSP1, KSR1 and CNK (connector enhancer of KSR) and the kinase Raf-1 constitutively forms a 
signalosome complex with DC-SIGN [165]. In macrophage, LSP1 interacts with myosin 1e and 
forms a complex in phagocytic cups where both members of this complex co-localize with actin 
[166]. Inhibition of these interactions largely impairs internalization of opsonized targets by 
impairing pseudopod formation. LSP1–myosin 1e interaction is crucial in Fcγ receptor–driven 
phagocytosis because this interaction regulates cytoskeleton remodeling [166]. 
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1.6 Ezrin/Radixin/Moesin (ERM) proteins 
 Ezrin/Radixin/Moesin (ERM) proteins serve as linkers between the plasma membrane and 
the cortical F-actin cytoskeleton and they are very important for various cellular functions such as 
cell adhesion, cell motility and cell survival [167-171]. The amino terminal of the ERM proteins, 
also known as FERM (four-point-one ezrin, radixin, moesin) domain, mediates direct and indirect 
association with the plasma membrane whereas the carboxy terminal (C-ERMAD; C-terminal 
ERM-associated domain) domain is capable of binding to F-actin and intramolecular binding to 
the amino terminus. These two domains are linked by an -helical linker. ERMs activity is 
regulated by an intramolecular association between the N-terminal and C-terminal domain that 
masks binding sites for partners and the proteins stay in a cytosolic ‘dormant’ state [172]. 
Activation of ERMs is a two-step process: a) binding of ERMs to the phosphatidylinositol 4,5-
bisphosphate (PIP2) and other membrane proteins, such as CD44, ICAM-2 and EBP50 (ERM-
binding phosphoprotein 50) [173, 174] making ERMs susceptible to phosphorylation at the 
conserved threonine residue, followed by b) phosphorylation at threonine residue by different 
kinases [175].  
Upon activation, ERMs bind directly to the cytoplasmic tails of many membrane proteins 
via FERM domain, such as CD44, CD43 (also known as SPN) and intercellular adhesion 
molecules (ICAM-1/2/3) [174, 176]. They are also capable of binding to the related scaffolding 
proteins: ERM-binding phosphoprotein 50 (EBP50; also known as NHERF1; Na+/H+ exchanger 
regulatory factor 1) and NHE3 kinase A regulatory protein (E3KARP; also known as NHERF2; 
Na+/H+ exchanger regulatory factor 2). Both of them bind to multiple different membrane 
associated proteins themselves [177]. Thus, FERM domain of ERMs can bind to a large number 
of proteins directly or indirectly. Due to their ability to interact with cytoskeletal F-actin and 
diverse groups of other proteins, ERMs have the potential to bring cytoskeletal regulatory proteins 
in close apposition to the actin cytoskeleton. Though it has already been established that ERMs 
are capable of remodelling actin cytoskeleton, they appear to lack F-actin cross-linking or branch 
forming abilities [176]. Moreover, ERMs were reported to be abundantly present at both uropod 
of T-lympocyte and docking structure in endothelium. In both cases, they interact with adhesion 
receptors and are important for cell adhesion [178, 179]. In endothelial cells, moesin is the 
predominant (> 90%) ERM protein that regulates thrombin- and advanced glycation end products-
induced endothelial hypermeability [180, 181].  
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1.7 Rationale for the study 
LSP1 is an intracellular, Ca2+- and F-actin binding protein [138-141] that plays an 
important role in leukocyte recruitment. Despite being near identical, leukocyte-expressed and 
endothelial cell-expressed LSP1 differ in many ways such as subcellular distribution (cytoplasmic 
versus nuclear) [136, 138] and functions (controversial role in leukocyte recruitment versus 
specific and limiting function in neutrophil transmigration and endothelial permeability). 
Information regarding how endothelial cell-expressed LSP1 functions is not available at all. 
Moreover, some intriguing albeit yet unexplored observations were recently reported about murine 
LSP1 in general and murine endothelial cell-expressed LSP1 in particular. Examples of such 
observations include appearance of LSP1 band in Western blotting (always > 50kDa as opposed 
to predicted m.w. of 37 kDa) [130, 141, 143, 182], characteristic distribution pattern of endothelial 
cell-expressed LSP1 and nucleus-to-extranuclear translocation upon TNF-α-treatment. Although 
PTMs often result in uplift of molecular weight [81, 183], compartmentalization and translocation 
of many proteins [88, 184, 185], they remain completely unexplored for endothelial cell-expressed 
LSP1. It is not clear whether endothelial cell-expressed LSP1 is activated by and act in the same 
singling pathways as leukocyte-expressed LSP1. Striking differences between leukocyte-
expressed and endothelial cell-expressed LSP1 and characteristic features of endothelial cell-
expressed LSP1 prompted us to speculate that murine LSP1, specifically the endothelial cell-
expressed LSP1, is modified post-translationally and mechanism of action of these two versions 
of LSP1 may vary significantly. In addition to unraveling the role of endothelial cell-expressed 
LSP1 in leukocyte recruitment and endothelial cell functions, the study of molecular mechanism 
of this protein may reveal potential and hopefully specific target for novel anti-inflammatory 
therapeutics.  
1.8 Hypothesis 
Post-translational modifications, specifically SUMOylation/ubiquitination and 
phosphorylation, regulate the functions and characteristic properties of endothelial cell-expressed 
LSP1. 
1.9 Objectives 
Specific objectives of the investigations presented in this thesis are: 
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Specific objective 1: To elucidate the mechanism of phosphorylation of endothelial cell-
expressed LSP1 with a view to understanding the significance of LSP1 activation in 
endothelium.  
1a) To determine the level of LSP1 phosphorylation in SVEC4-10EE2 cells in the 
presence of various types of stimuli by Western blotting.  
1b) To examine whether phosphorylated LSP1 is associated with cytoskeleton-
binding proteins and regulate permeability changes in endothelial cells by co-
immunoprecipitation followed Western blotting and Transwell permeability assay.  
Specific objective 2: To assess the role of endothelial cell-expressed LSP1 in regulating 
other nuclear proteins and associated endothelial cell functions. 
2a) To evaluate the role of LSP1 on GATA-2-dependent PECAM-1 expression in 
endothelial cells by Western blotting, RT-qPCR and confocal microscopy.   
2b) To determine the effect of LSP1-mediated altered PECAM-1 expression on 
endothelial cell motility and migration by Scratch Wound Healing assay and 
Transwell migration assay. 
Specific objective 3: To explore post-translational modification of endothelial cell-
expressed LSP1 by SUMO1 and the consequences of this modification. 
3a) To study whether endothelial cell-expressed LSP1 is modified by SUMO1 by 
coexpression, His pull-down, immunoblotting and confocal microscopy.  
3b) To observe the effect of LSP1 SUMOylation on its distribution and stability 
using subcellular fractionation, cycloheximide chase assay and immunoblotting.  
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2.0 MATERIALS AND METHODS 
2.1 Mice 
Lsp1/ mice on the 129/SvJ background were generated by homologous recombination by 
Jongstra-Bilen and colleagues [148]; both mouse strains were then transferred to the University of 
Saskatchewan. Lsp1/ (knock-out; KO) mice were crossbred with Lsp1+/+ (wild-type; WT) mice 
to generate heterozygotes and homozygotes (F2). The Lsp1/ (KO) and Lsp1+/+ (WT) 
homozygotes were confirmed by genotyping. Mice of these two genotypes were bred to obtain 
age- and sex-matched controls. Five- to 7-day-old and 8- to 16-wk-old mice were used in the 
experiments. The study was carried out with the approval of animal protocols from the University 
Committee on Animal Care and Supply at the University of Saskatchewan and following the 
standards of the Canadian Association of Animal Care. All surgeries were performed under 
ketamine-xylazine anesthesia, as previously described [136], and all efforts were made to 
minimize animal suffering. Bone marrow chimeric mice were generated according to a previously 
described protocol [136] and were housed in specific pathogen-free facilities for 6–8 wks to allow 
full humoral reconstitution before use in experiments. Bone marrows from WT mice transplanted 
into WT and KO mice are designated as WT→WT and WT→KO mice, and bone marrows from 
KO mice transplanted into WT and KO mice are designated as KO→WT and KO→KO mice, 
respectively. Chimeric mice generated according to this protocol were confirmed to have ~99% of 
leukocytes from donor mice [186].  
2.2 DNA constructs  
Mouse pCMV-SPORT6-His-LSP1, pCMV-SPORT6-Ubc9, pCMV-SPORT6-SUMO1, 
and pCMV-SPORT6-SENP1 plasmids were purchased from Thermo Scientific. HA-ubiquitin 
(Addgene plasmid # 18712) and pEGFP-moesin plasmids (Addgene plasmid # 20671) were 
purchased from Addgene, Cambridge, MA, USA [187]. All of these constructs were amplified in 
Escherichia coli DH5α and extracted using Midi Plasmid Kit (Qiagen, Toronto, ON). Mutations 
of potential SUMOylation sites of LSP1 lysine (K) residues at K270, K318 or K321 were 
introduced by performing one-step mutation PCR (Life Technologies Inc., Burlington, ON, 
Canada) on mouse pCMV-SPORT6-His-LSP1, using primers containing the respective lysine (K) 
to alanine (A) mutations as following: 
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LSP1K270A forward: AGTCAGTCTGCTTCTGCGACACCCTCCTGCCAG  
LSP1K270A reverse: CTGGCAGGAGGGTGTCGCAGAAGCAGACTGACT  
LSP1K318A forward: GCCACTGGACATGGGGCGTACGAGAAAGTACT  
LSP1K318A reverse: AGTACTTTCTCGTACGCCCCATGTCCAGTGGC 
LSP1K321A forward: CATGGGAAGTACGAGGCAGTACTTGTGGATGAGGG 
LSP1K321A reverse: CCCTCATCCACAAGTACTGCCTCGTACTTCCCATG  
2.3 Cell culture  
2.3.1 HEK 293T and SVEC4-10EE2 cell (ATCC) culture  
Frozen human embryonic kidney 293T (HEK 293T; ATCC, Manassas, VA) cells and 
SVEC4-10EE2 (ATCC, Manassas, VA), a murine microvascular endothelial cell line (EE2) cells 
(cryovial containing ~6 x 106 cells in 1 ml) in 5% DMSO and 10% fetal bovine serum (Hyclone, 
UT, USA) containing Dulbecco’s modified Eagle’s medium (DMEM; Cellgro, VA, USA) were 
rapidly thawed at 37C, added to 10 ml DMEM and spun at 200g for 3 minutes. The supernatant 
was removed and the cell pellet was resuspended in DMEM supplemented with 10% fetal bovine 
serum, penicinllin (100 units/ml; Amresco, OH, USA) and streptomycin (100 µg/ml; Amresco, 
OH, USA) and plated in 100-mm cell culture dishes. Cells were cultured in a 5% CO2 incubator 
at 37°C and passaged and replated prior to reaching confluence. 
2.3.2 Murine endothelial cell isolation and culture  
Murine microvascular endothelial cells were isolated from the lungs (LVEC) or hearts 
(HVEC) of 5-7-days-old Lsp1/ (KO) or 129/SvJ (WT) mouse pups. After isoflurane anesthesia, 
pups were dipped into 70% ethanol and decapitated. Hearts and lower lobes of the lungs were 
collected, minced into smallest possible pieces and digested in collagenase A (Roche Diagnostics 
GmbH, Mannheim, Germany) at 37°C. Cells were dissociated from the digested tissue by a 50-um 
cell strainer. Endothelial cells were then immunomagnetically isolated utilizing rat-anti-ICAM-2 
(CD102) primary antibody (clone 3C4, BD Pharmingen, Quebec City, QC, Canada) and magnetic 
beads-conjugated anti-rat IgG secondary antibody (Miltenyi Biotec Inc., Cornerstone Court East, 
San Diego, CA, USA), seeded in laminin-coated 6-well plates or 35-mm petri dishes, and cultured 
in microvascular endothelial cell culture medium (EBM-2) supplemented with the EGM-2 MV 
BulletKit (Lonza, Mississauga, ON, Canada). Contaminating dead leukocytes were carefully 
washed off on the very next day and medium replacement was continued every other day. After 
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the cells reached confluency, they were passaged only once on laminin-coated 24-well plates, 6-
well plates or glass cover slips before being used in respective experiments (usually within 15 days 
of isolation).  
2.4 HEK 293T and EE2 cell transfection 
 HEK 293T or EE2 cells were cultured in 2 ml of DMEM supplemented with 10% FBS and 
penicillin/streptomycin in 6-well plates. All transfections were performed when the cells reached 
70% confluency. Shortly before transfection, the media was replaced with 1 ml of antibiotic and 
serum-free DMEM. For gene silencing, siRNA targeting genes of interest and scrambled RNA. 
For overexpression studies, plasmid DNA containing the cDNA of proteins of interest and empty 
vector were diluted in sterile Eppendorf tube containing basic DMEM without antibiotics or serum 
(100 μl). In a separate Eppendorf tube, siRNA transfection reagent (Santa Cruz) for siRNA 
transfection or Lipofectamine 2000 (Invitrogen) for plasmid DNA transfection was also diluted in 
100-μl basic DMEM and subsequently added to the tube containing the diluted cDNA within 5 
minutes. The mixture (200 μl) was gently mixed and allowed to sit for ~30 minutes at room 
temperature for siRNA-transfection reagent or plasmid-Lipofectamine complexes to form before 
adding the mixture drop-wise to the well of a 6-well plate. After 4 hours of incubation in a cell 
culture incubator, 1ml of fresh DMEM with antibiotics and 20% FBS was added to each well of 
the 6-well plate. Cells were allowed to grow for 1248 hours after transfection. Transfection 
efficiency of expression plasmids was 70% in HEK 293T cells and 40-50% in EE2 cells as 
determined by expressing GFP-tagged plasmids in the respective cells. Transfection (determined 
by imaging of fluorescently labeled control siRNA) and knockdown efficiency (determined by 
RT-qPCR and western blotting followed by densitometric analysis of the respective protein bands) 
of the siRNAs used were in the range of 45-60% and 50-70%, respectively.  
2.5 Isolation of murine neutrophils 
2.5.1 Bone marrow neutrophils 
Femurs and tibias from mice were dissected, and the marrow was flushed with ice-cold 
Ca2+- and Mg2+-free PBS solution. Bone marrow cells were separated by gentle mixing with a 
transfer pipette. Neutrophils were isolated using three-step Percoll (GE Healthcare, Uppsala, 
Sweden) gradient (72%, 64%, and 52%) centrifugation at 1,060×g for 30 min, as described 
previously [55]. This procedure yielded 80-90% morphologically mature neutrophils. These 
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neutrophils were stimulated with chemoattractant and used in in vitro adhesion and transmigration 
assays.  
2.5.2 Peritoneal lavage neutrophils 
Acute mouse peritonitis was induced to obtain emigrated neutrophils 4 hours after an i.p. 
injection of 0.5 µg macrophage inflammatory protein-2 (MIP-2, also known as CXC chemokine 
CXCL2; R & D Systems, Burlington, ON, Canada). The peritoneal cavity was then lavaged and 
the harvested cells (≥ 95% neutrophils) were briefly centrifuged before resuspension in ice-cold 
PBS containing 0.5% BSA.  
2.6 Flow cytometry 
Neutrophils transmigrated into the peritoneal cavity were collected by peritoneal lavage 
and integrin expression was determined as described previously [65] using the following FITC-
conjugated fluorescent antibodies and the respective isotype controls (purchased from 
eBioscience, San Diego, CA) against α2 (CD49b, 1:250 dilution, clone HMa2), α4 (CD49d, 1:200 
dilution, clone R1-2), α5 (CD49e, 1:200 dilution, clone HMa5-1), α6 (CD49f, 1:100 dilution, clone 
GoH3) and β1 (CD29, 1:100 dilution, clone HMb1-1).  
PECAM-1 expression in murine peripheral blood neutrophils was determined following a 
previously reported protocol [73] with minor modification. Mouse blood was collected by cardiac 
puncture in a heparinized syringe. Blood sample (100 µl) was incubated with FITC-conjugated 
anti-mouse PECAM-1 (CD31) mAb (1:100 dilution, clone 390, eBioscience) for 30 min at room 
temperature. The erythrocytes were lysed using a lysis buffer (Beckman Coulter, Mississauga, 
Ontario, Canada). The cells were then washed and analyzed by flow cytometry. For FACS 
analysis, neutrophils were gated on a linearly plotted forward scatter-side scatter dot plot. 
2.7 In vitro adhesion assay 
 Freshly isolated mouse bone marrow neutrophils were stimulated for 5 min with MIP-2 
(CXCL2), 100 nM; R & D Systems], keratinocyte chemokine (KC, also known as CXC chemokine 
CXCL1, 100 nM; Peprotech, Rocky Hill, NJ, USA), or thapsigargin (100 nM; Sigma, St. Louis, 
MO, USA). The neutrophils were allowed to adhere onto confluent monolayers of murine primary 
endothelial cells or SVEC4-10EE2 (EE2) cells, a mouse endothelial cell line in 24-well plates. 
Where indicated, unstimulated neutrophils were allowed to adhere onto tumor necrosis factor- 
(TNF-)-stimulated (20 ng/ml for 4 hours; R & D Systems) endothelial cells. Unlike MIP-2- or 
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KC-stimulated neutrophils, thapsigargin-treated neutrophils were subsequently washed twice in 
ice-cold PBS before they were allowed to adhere onto endothelial cells. The ratios of the number 
of neutrophils to endothelial cells were 0:1, 0.5:1, 1:1, 2:1, and 5:1. Where indicated, the p38 
MAPK inhibitor SB-203580 (10 µM; EMD Millipore, Billerica, MA, USA) or a PKC inhibitor 
[staurosporine (100 nM; Selleckchem, Houston, TX, USA), sotrastaurin (5 µM; Selleckchem), or 
Gö-6983 (1 µM; Tocris, Bristol, UK)] was added during the assay. Unbound cells were removed 
by two washes with prewarmed (37°C) PBS, and the adherent neutrophils were stained using a 
three-step staining set (Richard-Allan Scientific, Kalamazoo, MI, USA), counted microscopically 
in triplicates, and averaged from five different fields of view (325 µm2/field of view). To assess 
the role of endothelial LSP1, neutrophils from WT mice were placed on primary endothelial cells 
from KO or WT mice. To study phosphorylation of LSP1 in endothelial cells, only KO neutrophils 
were used in all experiments to rule out the influence of neutrophil LSP1. 
To exclude the possibility of endothelial LSP1 activation by soluble mediators released 
from activated neutrophils or endothelial cells during neutrophil adhesion, endothelial cells were 
additionally treated with conditioned medium. Freshly isolated bone marrow neutrophils were 
stimulated with MIP-2 (100 nM for 10 min, 37°C) and then allowed to adhere to endothelial cells 
at 37°C for 30 min before centrifugation and collection of the supernatant (conditioned medium). 
Another confluent monolayer of endothelial cells was treated with this conditioned medium for 30 
min at 37°C before endothelial phosphorylated LSP1 was detected. 
2.8 In vitro neutrophil transendothelial migration assay 
Murine microvascular EE2 endothelial cell line cells were cultured onto tissue culture-
treated polycarbonate transwell inserts (3 µm pore size, Corning, Corning, NY, USA) until 85% 
confluence. After endothelial cells were treated with or without GATA-2-specific or non-targeting 
silencing RNA for 24 h, neutrophil transendothelial migration was examined as previously 
described [87, 95] with minor modification. In brief, freshly isolated murine neutrophils were 
suspended at 5×106 cells/ml in DMEM medium supplemented with 5% FBS. Neutrophils in 
suspension (1×106 cells) and chemoattractant (CXCL2; 200 ng/ml) were added to the top inserts 
and bottom wells, respectively. Neutrophils were allowed to migrate for 2 h at 37°C in 5% CO2. 
Then, 60 μL of 0.5 M EDTA was added to the bottom chamber, and the plate was incubated for 
1015 min at 4°C. Inserts were removed from the well, and the total number of transmigrated cells 
in each bottom well was counted using a hemocytometer. 
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2.9 In vitro endothelial cell migration assay 
Both non-directional lateral and chemoattractant-induced directional migration of 
endothelial cells were analyzed using the following in vitro assay systems:  
2.9.1 Scratch wound healing assay 
EE2 cells were grown in 6-well plates and treated with LSP1 or GATA-2-specific or non-targeting 
siRNA at 65% confluence. They were grown till 100% confluence and the monolayer was scraped 
in a straight line with a 1000 l pipet tip to introduce a longitudinal scratch. Cell monolayers were 
washed with pre-warmed PBS and growth medium to remove the cellular debris and to get a 
smooth-edged scratch. Culture plates were marked properly at close proximity to the scratch 
imaging points when the images were acquired for the zero time point. These marks helped in 
obtaining the same field of view during image acquisition at indicated time points. All the images 
were acquired using an Olympus 1X51 inverted microscope (Olympus America, Center Valley, 
PA, USA) and analyzed quantitatively by ImageJ software (http://rsb.info.nih.gov/ij/). Endothelial 
cell migration was measured by comparing the distances (m) between one side of scratch and the 
other for all the treatment groups at indicated intervals [188, 189]. 
2.9.2 Transwell migration assay  
Bottom surfaces of the tissue culture-treated polycarbonate transwell inserts (3 µm pore 
size, Corning, Corning, NY) were coated with laminin overnight. SVEC4-10EE2 cells, treated 
with or without silencing RNA targeting LSP1, GATA-2 or non-targeting silencing RNA for > 24 
h were trypsinized and suspended at 2×106 cells/ml in serum-free DMEM medium. Endothelial 
cell suspension (100 l) was added to the upper chamber while 600-l serum free DMEM medium 
was added to the bottom chamber. Cells were allowed to adhere onto the top surfaces of transwell 
inserts for 10 minutes.  FBS (2% of the total volume) was added at the bottom chamber to induce 
cell migration and the cells were allowed to migrate along the FBS gradient for 2 h at 37°C in 5% 
CO2. Inserts were removed from the well, the remaining cell suspension from the top chamber 
was carefully removed, placed into new wells containing trypsin solution (0.025%) and incubated 
for 30 minutes at 37C. Transmigrated cells were completely dislodged from the insert membrane 
by putting plate on a shaker several times for about a minute during incubation. Inserts were 
removed from the well, and the total number of transmigrated cells in each bottom well was 
counted using a hemocytometer [190-192].  
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2.10 Endothelial cell proliferation assay 
Endothelial cell proliferation was evaluated by counting cells in a hemocytometer under a 
bright-field microscope [193]. SVEC4-10EE2 cells at 70% confluence were treated with or 
without silencing RNA targeting LSP1, moesin, GATA-2 or non-targeting silencing RNA for 12 
hours. Then, these cells were trypsinized and seeded at 5104 cells/well in 60 mm petri dishes and 
allowed to grow for 72 hours. Endothelial cells were then washed with PBS, trypsinized and 
suspended in medium for counting in a hemocytometer [194].  
2.11 In vitro endothelial permeability assay 
Endothelial permeability was determined by measuring FITC-albumin flux across 
confluent EE2 cell monolayers cultured on the luminal (upper) chamber of a Transwell system as 
described earlier [195]. EE2 cells were grown in cell culture-treated and laminin-coated 6.5 mm 
polycarbonate Transwell inserts (3 µm pore size, Corning, Corning, NY) until 70% confluence. 
Cells were then treated with or without silencing RNA targeting LSP1, moesin, GATA-2 or non-
targeting silencing RNA and allowed to grow until confluence (> 24 h). Once the monolayer 
become uniformly confluent, ICAM-1 was cross-linked (on LSP1- or moesin-silenced cells) after 
4 hours of TNF- (20 ng/ml) treatment or neutrophils were allowed to transmigrate along a MIP-
2 gradient in a Transwell system.  Uniform confluency of endothelial monolayers was established 
by observing some stained control inserts under microscope. FITC-albumin (200 μg/ml) was added 
to the luminal chamber in 100 μl DMEM medium. After 1 or 2 hours, 100 μl samples were removed 
from both the luminal and abluminal chambers and their fluorescence was quantified using a 
Fluoroskan Ascent plate reader (Thermo Scientific). The excitation and emission wavelengths 
were 485 and 520 nm, respectively. Permeability index (%) was calculated using the following 
formula: ((mean lower chamber intensity – background) / (mean upper chamber intensity – 
background)) × 100 [37].  
2.12 Cycloheximide chase assay 
 Cycloheximide chase assay was performed according to a previously reported protocol 
[196] with some minor modifications. HEK 293T cells were co-transfected with 2 μg of His-LSP1 
or His-LSP1K270A and 2 μg of SUMO1. Twelve hours after transfection, cells were treated with 
100 μg/ml cycloheximide (Sigma-Aldrich, Oakville, ON, Canada) and then chased at 37°C for 0 
to 12 h. At the appropriate chase time, cells were rinsed with ice-cold PBS and lysed in Ni-NTA 
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lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 0.05% Tween, pH 8.0) containing 10 mM imidazole 
supplemented with protease inhibitor cocktail (Sigma-Aldrich) on ice. His-tagged proteins were 
pulled-down using Ni-NTA slurry, resolved by SDS-PAGE and immunoblotted with anti-LSP1 
antibody. The detected bands were then quantified using ImageJ software (v 1.47; 
http://rsbweb.nih.gov/ij). Relative protein quantity values for each time point were used for linear 
regression analysis, plotted as linear fits using origin software (OriginLab Corporation, 
Northampton, MA) and half-life values were calculated using the slopes obtained from the straight 
line equations for each fitted curve. 
2.13 Proteasome inhibition and in vitro ubiquitination assay 
 HEK 293T cells were co-transfected with His-LSP1 and SUMO1; His-LSP1, SUMO1 and 
SENP1 or His-LSP1K270A and SUMO1. After 12 hours, cells were treated with proteasome 
inhibitor MG132 (10 μΜ) for 12 h, lysed and proteins were immunoblotted with an anti-LSP1 
antibody. For the in vitro ubiquitination assay, HEK 293T cells were co-transfected with His-
LSP1, SUMO1 and HA-Ub; His-LSP1, SUMO1, SENP1 and HA-Ub  or His-LSP1K270A, 
SUMO1, HA-Ub in the presence or absence of proteasome inhibitor, MG132 (10 μΜ; 12 h). At 
the appropriate time, cells were rinsed with ice-cold PBS and lysed in a lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl, 0.05% Tween, pH 8.0) containing 10 mM imidazole supplemented with 
protease inhibitor cocktail (Sigma-Aldrich Canada Co., Oakville, ON) on ice. His-tagged proteins 
were pulled-down using Ni-NTA slurry, resolved by SDS-PAGE and immunoblotted with anti-
Ubiquitin antibody (Sigma-Aldrich Canada Co., Oakville, ON) [197].  
2.14 Subcellular fractionation 
 Four different subcellular fractions were prepared using Calbiochem ProteoExtract 
Subcellular Extraction Kit (Millipore Canada) according to the supplier’s protocol [37]. Confluent 
monolayers of EE2 cells transfected with His-LSP1 and SUMO1; His-LSP1, SUMO1 and SENP1 
or His-LSP1K270A and SUMO1 were subjected to four different lysis buffers (I-IV) in a sequential 
manner. Buffers were supplemented with protease inhibitor cocktails and necessary enzymes. All 
the fractions (fraction I, cytosol; Fraction II, membrane/organelle; Fraction III, nuclear material 
and Fraction IV, cytoskeleton) were collected and used for immunoblotting. 
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2.15 ICAM-1 cross-linking 
 ICAM-1 cross-linking was used to mimic leukocyte adhesion. To study the effect of 
ICAM-1 cross-linking in vivo, circulating neutrophils were depleted in WT mice by intraperitoneal 
administration of 200 µg of anti-mouse Ly-6G (Gr-1) antibodies (1 mg/ml; clone RB6-8C5, 
eBioscience) 24 h prior to treatment with cross-linking antibodies (62), thus ruling out the 
detection of neutrophil LSP1. For ligation of ICAM-1, rat anti-mouse ICAM-1 antibody (100 
µg/mouse; clone YN1/1.7.4, eBioscience) and the respective isotype control (100 µg/mouse rat 
IgG2b κ; eBioscience) were administered as described previously (43). Saline was administered 
to control mice. ICAM-1 expression was upregulated by an intrascrotal injection of TNF-α (300 
ng) 20 h after administration of Gr-1 antibody. After 4 h of TNF-α treatment, ICAM-1 ligation 
antibody or isotype control was infused via the jugular vein followed by the secondary anti-rat 
crosslinking IgG2b (1:100 dilution; clone R2B-7C3, eBioscience). After 30 min of ICAM-1 cross-
linking, the cremaster muscle from the TNF-α-treated scrotum was carefully excised and snap-
frozen in liquid nitrogen for the detection of total and phosphorylated LSP1 and p38 MAPK by 
immunoblotting. 
ICAM-1 engagement in vitro was performed as previously described (50) by incubation of 
TNF-α-pretreated (20 ng/ml, 4 hours) endothelial cells (EE2) with ICAM-1 ligation antibody or 
the isotype control antibody for 30 min. Following two washes with pre-warmed (37°C) PBS, cells 
were incubated with secondary cross-linking antibody for 30 min. Endothelial cells were then 
prepared for immunoblotting to determine the abundance of phosphorylated LSP1 and total LSP1. 
2.16 Functional blocking of β2-integrins and ICAM-1  
 For determination of the role of β2-integrins in KO neutrophil adhesion and endothelial 
LSP1 phosphorylation, freshly isolated and unstimulated KO bone marrow neutrophils were 
preincubated with CD18 blocking antibodies (10 µg/ml; clone M18/2, BD Pharmingen) or the 
isotype control (10 µg/ml rat IgG2a κ; clone R35-95, BD Pharmingen) for 20 min at 37°C, as 
described elsewhere (38), prior to incubation with MIP-2 (10 min, 37°C). Next, the neutrophils 
were allowed to adhere to murine heart (HVEC) or lung (LVEC) endothelial cells from WT mice 
or EE2 cells.  
To study the role of ICAM-1, following stimulation with TNF-α (20 ng/ml, 4 h), murine 
EE2 endothelial cells were treated with ICAM-1 blocking antibody (10 µg/ml; clone YN1/1.7.4, 
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eBioscience, San Diego, CA) or isotype control (10 µg/ml rat IgG2b κ; eBioscience) for 1 h, as 
described elsewhere (60). Then, freshly isolated and unstimulated KO bone marrow neutrophils 
were added on the endothelial cells. After incubation for 30 min, non-adherent neutrophils were 
removed by two washes with pre-warmed (37°C) PBS. Endothelial cells were lysed for detection 
of phosphorylated LSP1 or fixed and stained for counting of the number of adherent neutrophils. 
2.17 Immunoprecipitation and Nickel-affinity pull-down 
His-LSP1-, HA-Ubiquitin- or GFP-moesin-overexpressed HEK 293T or EE2 cells or 
native EE2 cells were treated as indicated in the figure legends, washed twice with ice-cold PBS 
and lysed in a lysis buffer containing 150 mM sodium chloride, 1.0% NP-40, 50 mM Tris, pH 8.0 
supplemented with protease inhibitor cocktail (Sigma-Aldrich Canada Co., Oakville, ON) on ice. 
Cell lysates were incubated with appropriate antibody for 2 hours at 4°C in a rotary incubator. 
Protein A-agarose (Sigma Chemical Co., St. Louis, MO) beads were added to the lysate to catch 
the respective antibodies. The beads were washed five times with the lysis buffer without protease 
inhibitor. The immunecomplexes were collected from the beads by adding 50 µl of Laemmli 
sample buffer and heating at 95°C for 5 min followed by centrifugation in a microfuge for 2 min. 
Nickel affinity pull-down under native condition was performed at 4°C. 
Nickel affinity pull-down under native condition was performed at 4°C according to a 
protocol described earlier [88]. HEK 293T cells transfected with various expression plasmids and 
treated as indicated in the figure legends, were lysed in Ni-NTA lysis buffer (50 mM NaH2PO4, 
300 mM NaCl, 0.05% Tween, pH 8) containing 10 mM imidazole supplemented with protease 
inhibitor cocktail (Sigma-Aldrich) on ice. Cell lysates were centrifuged at 10,000×g for 10 min in 
Eppendorf microcentrifuge tubes to remove cell debris. His-tagged proteins were pulled-down 
overnight by Ni-NTA agarose slurry (QIAGEN) and washed four times with the lysis buffer 
containing 10 mM imidazole and once with the same lysis buffer containing 20 mM imidazole. 
After the last wash, His-tagged proteins were eluted in the lysis buffer containing 250 mM 
imidazole. 
2.18 Immunoblotting 
For native protein samples, immunoprecipitation and Nickel-affinity pull-down, cells were 
lysed in a lysis buffer (pH 8.0) containing 150 mM NaCl, 50 mM Tris, 1% NP-40, and protease 
and phosphatase (whenever phosphorylated proteins were of interest) inhibitor cocktails (Fisher 
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Scientific, Toronto, ON, Canada), the lysate was centrifuged (10,000g, 4°C, 10 min), and the 
supernatant was collected and stored at -80°C. The same protocol was followed to prepare 
homogenates from mouse cremaster muscle. For the detection of phosphorylated LSP1, 
immunoblotting was performed in the non-reduced and non-denatured state, as described 
previously (8). In brief, the native protein samples were resolved in Mini-PROTEAN TGX precast 
gels (Bio-Rad, Mississauga, ON, Canada) by electrophoresis. Proteins were transferred onto an 
Immobilon-FL membrane (Millipore, Billerica, MA) followed by dual blotting of total and 
phosphorylated LSP1. Total LSP1 was detected using rabbit -LSP1 serum (1:500 dilution; a 
generous gift from Dr. J. Jongstra, University of Toronto) and goat -rabbit IgG tagged with Alexa 
Fluor 647 (1:5,000 dilution; Invitrogen, Burlington, ON, Canada) as the secondary antibody. 
Phosphorylated LSP1 was detected using mouse monoclonal antibody against phosphorylated 
LSP1 (recognizing phosphorylated serine 195 and surrounding residues; 1:500 dilution; clone AT-
1E6, Cyclex, Nagano, Japan) and goat -mouse IgG tagged with Alexa Fluor 488 (1:5,000 
dilution; Invitrogen) as the secondary antibody. Membranes were developed with Versa Doc 5000 
using appropriate filters. Band densities were quantified using ImageJ. As proteins in their native 
condition do not run according to their molecular weight, the identity of the protein was confirmed 
using mass spectrometry in manually excised bands from Coomassie blue stained gel.  
All of the other proteins of interest were detected in reduced and denatured conditions, as 
previously described (29). Protein samples as prepared and mentioned above were solubilized in 
equal volume of Laemmli sample buffer at 95°C and resolved by 10% SDS-PAGE. For 
immunoblotting, proteins were transferred onto a nitrocellulose membrane and blocked with 5% 
BSA in Tris-buffered saline-Tween 20 at room temperature for 1 h. Then the membrane was 
incubated with affinity-purified rabbit-α-PECAM-1 (1:1000 dilution; Thermo Fisher Scientific), 
rat-α-ICAM-1 (1: 1000 dilution; eBioscience), rat-α-VCAM-1 (1:1000 dilution; Abcam Inc, 
Toronto, ON, Canada), rabbit-α-GATA-2 (1:1000 dilution; Santa Cruz Biotechnology), α-LSP1 
rabbit serum (1:1000 dilution; a generous gift from Dr. J. Jongstra, University of Toronto), mouse-
α-GFP, rabbit-α-His, mouse-α-moesin, rabbit -phosphorylated p38 MAPK (1:1,000 dilution; Cell 
Signaling Technology, Danvers, MA), rabbit -p38 antibody (1:1,000 dilution; Cell Signaling 
Technology), rabbit-α-phosphorylated moesin (recognizing phosphorylated threonine 558 and 
surrounding residues; 1:500 dilution; Santa Cruz Biotechnology) or mouse-α-β-actin (1:2500 
dilution; Santa Cruz Biotechnology) antibody at 4°C overnight. After incubation with horseradish 
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peroxidase-conjugated respective secondary antibody (1:5000 dilution; Santa Cruz 
Biotechnology) for 1 h at room temperature, antibody binding was detected with enhanced 
chemiluminescence detection reagent (GE Healthcare, Baie d’Urfe, QC, Canada). ImageJ software 
(v1.47; http://rsbweb.nih.gov/ij) was used for densitometric quantification of the detected bands. 
Intensity values for the proteins were normalized to β-actin. 
2.19 Mass spectrometry 
 Polyacrylamide gel bands containing protein of interest were excised and processed using 
a MassPrep Station (Waters, Milford, MA, USA) using the methods supplied by the manufacturer 
[198]. Briefly, the gel fragments were first destained, reduced, alkylated, digested with trypsin, 
and extracted overnight at room temperature. The resulting tryptic digest was then analyzed by 
mass spectrometry. For electrospray, quadruple time-of-flight (Q-TOF) analysis, 1 μl of the 
solution was used. Liquid chromatography/mass spectrometry (LC/MS) was performed on a 
CapLC high-performance liquid chromatography unit (Waters) coupled with Q-TOF-2 mass 
spectrometer (Micromass). A mass deviation of 0.2 was tolerated and one missed cleavage site 
was allowed. Resulting values from mass spectrometry analysis (MS/MS) were used to search 
against the SwissProt database with Rodentia specified. We used the Mascot 
(www.matrixscience.com) search engine to search the protein database. 
2.20 RT-qPCR 
 RT-PCR was performed to determine PECAM-1, ICAM-1 and β-actin mRNA expression 
in EE2 cells or LSP1 and β-actin mRNA expression in His-LSP1 or His-LSP1K270A transfected 
HEK 293T cells as described previously [199]. Briefly, total RNA was extracted from respective 
cells using the RNEasy Mini Kit (Qiagen, Toronto, ON) and reverse-transcribed using QuantiTect 
Reverse Transcription Kit (Qiagen, Toronto, ON). Relative levels of specific mRNAs were 
determined with the QuantiTect SYBR Green PCR Kit (Qiagen, Toronto, ON) and predesigned 
primers targeting murine PECAM-1 (QT01052044; Qiagen), ICAM-1 (QT00155078; Qiagen), β-
actin (QT00095242; Qiagen), LSP1 (QT01046227; Qiagen, Toronto, ON) and human β-actin 
(QT00095431; Qiagen, Toronto, ON). All PCRs were performed in triplicate and run for 30 cycles 
at 95°C for 30 sec, 55°C for 30 sec, and 72°C for 40 sec. 
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2.21 Confocal imaging 
  EE2 cells were cultured on glass coverslips, co-transfected with GFP-LSP1 and pCMV-
SPORT6-SUMO1 plasmid, and allowed to grow for 24 hours. Medium was removed and the cells 
were washed once with 37C pre-warmed PBS before they were fixed in 4% formaldehyde for 30 
min, washed thrice with PBS, permeabilized with 0.1% Triton X-100 and blocked with 5% BSA 
for 30 min. The cells were incubated with mouse anti-SUMO1 monoclonal antibody (Life 
Technologies Inc., Burlington, ON) for 2 hours at room temperature, washed thrice in PBS and 
incubated with Alexa Fluor 532 conjugated goat anti-mouse IgG (Life Technologies Inc., 
Burlington, ON) in the dark at room temperature for 1 hour. Coverslips were mounted on glass 
slides using prolong gold anti-fade reagent (Life Technologies Inc., Burlington, ON), the edges of 
the coverslips were sealed with a nail polish and visualized with a laser scanning confocal 
microscope (Zeiss, ConfoCor2/LSM510) [199]. 
2.22 Statistical analysis  
Data are shown as arithmetic means ± SD or SEM. Statistical analysis was made using 
Student t test or ANOVA with Tukey’s post-hoc comparison test. n denotes the number of different 
mice, different batches of endothelial cells or neutrophils studied in each group. Values of P < 0.05 
were considered statistically significant.  
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3.0 ICAM-1-MEDIATED NEUTROPHIL ADHESION IS CRITICAL FOR 
LEUKOCYTE-SPECIFIC PROTEIN 1 (LSP1) PHOSPHORYLATION 
 
A major part of the data presented in this chapter were used in a research paper entitled 
“ICAM-1-mediated leukocyte adhesion is critical for the activation of endothelial LSP1” published 
by Mokarram Hossain, Syed M. Qadri, Yang Su and Lixin Liu in the American Journal of 
Physiology – Cell Physiology, 2013; 304: C895–C904.   
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3.0 ICAM-1-MEDIATED NEUTROPHIL ADHESION IS CRITICAL FOR 
LEUKOCYTE-SPECIFIC PROTEIN 1 (LSP1) PHOSPHORYLATION 
In acute inflammation, leukocyte adhesion on the endothelium is mediated by the β2-
integrins, e.g., LFA-1 and Mac-1 [13, 200-202]. Chemokine stimulation upregulates surface 
expression of integrins on leukocytes which allows enhanced binding of leukocyte integrins to 
endothelial ligands such as ICAM-1 [203, 204]. This binding, in turn, initiates ICAM-1 signaling 
in endothelial cells which is mediated by receptor multimerization [205] and modulates the actin 
cytoskeleton by interacting with ERM proteins (ezrin, radixin, moesin), β-tubulins, caveolin-1, 
cortactins, and filamins A and B [15, 22, 26, 27, 206]. ICAM-1 engagement also triggers tyrosine 
phosphorylation of cytoskeleton-associated proteins, such as focal adhesion kinase, paxillin, and 
p130cas [28], and phosphorylation of junctional proteins, such as vascular endothelial cadherin, 
which fosters the subsequent transendothelial migration of leukocytes [29, 30]. Leukocyte 
adhesion-triggered ICAM-1 signaling regulates transcellular and paracellular leukocyte 
transmigration [31] and microvascular permeability increases [207]. 
Despite being biochemically almost identical, functional differences between neutrophil 
and endothelial LSP1 are remarkable. In neutrophils, LSP1 is mainly distributed in the cytoplasm 
[138] and serves as a substrate for PKC and p38 MAPK [143, 152]. Contradictory reports are 
available concerning regulatory roles of neutrophil LSP1 on adhesion, polarization, and migration 
[147].  However, in endothelial cells, LSP1 is mostly located in the nuclei, with small level of 
LSP1 found in F-actin-rich microfilaments [136]. Interestingly, LSP1-deficient (KO) mice showed 
a compromised formation of endothelial transmigratory dome-like structures, resulting in a 
disproportionate increase in vascular permeability, despite impaired transendothelial migration of 
leukocytes [32, 37]. In leukocytes, LSP1 has been shown to be activated by chemoattractants 
[208]. However, the mechanisms of endothelial LSP1 activation during leukocyte recruitment 
remain completely unknown. 
3.1 Activation of either neutrophils or endothelial cells results in similar level of 
neutrophil adhesion in vitro  
  In neutrophils, functions of LSP1 are thought to be regulated by the 
phosphorylation of LSP1 by MAPK-activated protein kinase 2 (MK2), a specific downstream 
target of p38 MAPK whereas in T cells, protein kinase C-mediated LSP1 phosphorylation is more 
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important [143, 153, 182]. Phosphorylated LSP1 was shown to be colocalized with F-actin at the 
leading edge of the fMLP-induced polarized neutrophils [208]. Moreover, phosphorylation of 
LSP1 was documented to be the link between p38 MAPK activation and cytoskeletal 
reorganization in bacterial homoserine lactone AHL-12-induced chemotaxing neutrophils [34]. In 
addition, in dendritic cells, using pharmacological inhibitors, it was shown that viral protein 
gp120-induced dendritic cell migration and phosphorylation of LSP1 was p38 MAPK-dependent 
[35].  In hematopoietic cells, phosphorylation was shown to be essential for the activation of LSP1 
which can be induced by numerous types of stimulants, e.g., chemokine, bacterial peptide or viral 
protein. However, phosphorylation of endothelial LSP1 has not been reported and it is yet to be 
determined whether similar stimuli can phosphorylate LSP1. It is well known that binding of 
surface adhesion molecules of leukocytes with their ligands on endothelium itself can trigger a 
large number of endothelial signaling events [28, 36, 38, 45, 205]. To address this issue, we 
investigated whether chemokine, cytokine or neutrophil adhesion stimulates phosphorylation of 
endothelial LSP1. Activation of endothelial cells with TNF- is a common event in inflammation. 
However, TNF--treatment itself initiates multiple signaling in endothelial cells including p38 
MAPK and Rho kinase activation. To avoid this, we first established an in vitro adhesion assay 
where activated neutrophils were allowed to adhere onto unstimulated endothelial monolayers. In 
this connection, we stimulated neutrophils with chemokines (KC and MIP-2) and a calcium signal-
initiation activator called thapsigargin (designated as TG). Using a series of thapsigargin 
concentration, we found 100 nM to be the most effective thapsigargin dose for activating 
neutrophil (Figure 3.1A). We then stimulated neutrophils isolated from KO mice with TG, KC and 
MIP-2 and allowed them to adhere onto unstimulated endothelial cells for 30, 60 or 90 min just 
after washing once with PBS. Neutrophil adhesion was significantly higher in all the treatment 
groups compared to control at all time points. For the subsequent studies, we used 30 min 
incubation time for adhesion assays since it was sufficient to show the difference and at this time 
point adhesion was at a very similar level in all the treatment groups (Figure 3.1B). Finally, we 
compared whether adhesion level is similar when endothelial cells are activated by TNF- 
treatment (20 ng/ml; 4 hours). As illustrated in Figure 3.1C, stimulation of neutrophils with MIP-
2 or thapsigargin or of endothelial cells with TNF-α significantly enhanced the number of adherent 
neutrophils. Figure 3.1C also shows that activation of either neutrophil or endothelial cells 
provided similar level of neutrophil adhesion onto EE2 cell monolayers.  
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Figure 3.1: Activation of either endothelial cells or neutrophils is sufficient to ensure neutrophil 
adhesion onto endothelial monolayers. (A) Number of adherent KO neutrophils (counted in a 
325-μm2 area) in the absence (control) and presence of stimulation with a wide range of 
thapsigargin doses or DMSO was determined after 30 min of incubation on EE2 cells. Values are 
means ± SD (n = 4). **Significantly different (P < 0.01) from control. (B) Number of adherent 
KO neutrophils (counted in a 325-μm2 area) in the absence (control) and presence of stimulation 
with 100 nM thapsigargin (TG), 100 nM keratinocyte chemokine (KC) or 100 nM macrophage 
inflammatory protein-2 (MIP-2) was determined after 30, 60 or 90 min of incubation on EE2 cells. 
Values are means ± SD (n = 3). **; ***Significantly different (P < 0.01; < 0.001) from control. 
(C) Number of adherent KO neutrophils (counted in a 325-μm2 area) on murine EE2 endothelial 
cells in the absence (control) and presence of stimulation with 100 nM MIP-2 or after pretreatment 
of neutrophils with 100 nM thapsigargin (TG). Unstimulated neutrophils were allowed to adhere 
to endothelial cells stimulated with 20 ng/ml TNF-α. Values are means ± SD (n = 3–6). 
**Significantly different (P < 0.01) from control. 
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3.2 Neutrophil adhesion is critical for endothelial LSP1 phosphorylation 
Figure 3.2: Phosphorylation of endothelial LSP1 by neutrophil (PMN) adhesion. (A) Left 
panel: original dual immunoblots (n = 3) demonstrating expression of phosphorylated LSP1 (p-
LSP1, green), total LSP1 (LSP1, red), and overlay (p-LSP1 + LSP1, yellow) in endothelial cells 
after 30 min in the presence (+) or absence (−) of neutrophils with (+) or without (−) stimulation 
with 20 ng/ml TNF-α or 100 nM MIP-2 or pretreatment with 100 nM thapsigargin. Right panel: 
densitometric analysis of abundance of phosphorylated LSP1 relative to total LSP1 in endothelial 
cells after 30 min in the presence or absence of neutrophils with or without stimulation with 20 
ng/ml TNF-α or 100 nM MIP-2 or pretreatment with 100 nM thapsigargin. Values are means ± 
SD (n = 3). **Significantly different (P < 0.01) from −PMN with TNF-α or MIP-2 or +PMN (by 
ANOVA). (B) Left panel: original dual immunoblots (n = 3) demonstrating expression of 
phosphorylated LSP1, total LSP1, and overlay in endothelial cells after 30 min of incubation in 
the presence or absence of neutrophils, MIP-2 (100 nM), or conditioned medium collected from 
MIP-2-elicited neutrophil adhesion to endothelial cells. Right panel: densitometric analysis of 
abundance of phosphorylated LSP1 relative to total LSP1 in endothelial cells after 30 min of 
incubation with or without neutrophils, MIP-2 (100 nM), or conditioned medium collected from 
MIP-2-elicited neutrophil adhesion to endothelial cells. Values are means ± SD (n = 3). 
***Significantly different (P < 0.001) from controls without neutrophils or with conditioned 
medium collected from MIP-2-elicited neutrophil adhesion to endothelial cells (by ANOVA). 
 
A 
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In the adhesion assay, we used KO neutrophils to rule out the contribution of leukocyte-
expressed LSP1 in the detection of phosphorylated LSP1 after the adhesion assay. Phosphorylated 
LSP1 was quantified in endothelial cells in the presence and absence of adherent KO neutrophils. 
Neutrophils stimulated with MIP-2 or pretreated with thapsigargin and allowed to adhere onto 
endothelial cells significantly increased phosphorylated LSP1 in endothelial cells compared with 
endothelial cells treated with MIP-2 alone or with untreated neutrophils (Figure 3.2A). Similarly, 
the addition of untreated KO neutrophils to TNF-α-stimulated endothelial cells significantly 
augmented endothelial LSP1 phosphorylation. In contrast, TNF-α stimulation did not enhance 
phosphorylation of endothelial LSP1 in the absence of neutrophils. These data clearly indicate that 
adhesion of neutrophils to endothelial cells is critical for LSP1 phosphorylation in endothelial cells 
which is not affected by cytokine or chemokine stimulation alone (Figure 3.2A).  
During adhesion, neutrophils may secrete a variety of soluble mediators and substances 
that might lead to activation of endothelial LSP1. To exclude this possibility, we tested whether 
the conditioned medium harvested after neutrophil adhesion to endothelial cells triggered the 
activation of endothelial LSP1. As shown in Figure 3.2B, not the presence of conditioned medium 
and MIP-2 but, rather, the adherence of KO neutrophils in the presence of MIP-2 elicited 
phosphorylation of endothelial LSP1. Mass spectroscopic analysis of the protein bands confirmed 
the identity of mouse endothelial LSP1 (Mowse/ions score: 881; queries matched: 42; sequence 
coverage: 52%; pI/mol wt: 4.7/36.7). Ion score is ‒10×log (P), where P is the probability that the 
match is a random event. Individual ion score >32 indicates identity or extensive homology (P < 
0.05). 
3.3 p38 MAPK plays a major role in endothelial LSP1 phosphorylation 
In neutrophils, activation of LSP1 is effectively accomplished by the phosphorylation of 
LSP1 in Ser243 by p38 MAPK-mediated signaling events downstream of receptor-mediated 
activation signals from chemoattractants [34, 143, 208]. We provided direct and specific 
experimental verification that phosphorylation of endothelial LSP1 is blunted by pharmacological 
inhibition of p38 MAPK. It is documented that inhibition of p38 MAPK signaling downregulates 
the expression of β2-integrins [209] and decreases leukocyte adhesion to endothelial cells [10, 40-
42]. In light of these results, LSP1 phosphorylation in endothelial cells could be diminished as a 
result of decreased neutrophil adhesion to endothelial cells. To address this issue, we analyzed 
neutrophil adhesion using different ratios of added KO neutrophils to endothelial cells, which 
49 
 
affected the number of adherent cells. As the first step, we show that neutrophil adhesion and 
abundance of phosphorylated endothelial LSP1 were significantly enhanced with increased 
neutrophil-to-endothelial cell ratio (Figure 3.3A–C). As illustrated in Figure 3.3D, we exploited 
the effects of increased neutrophil-to-endothelial cell ratio to demonstrate that the number of 
adherent neutrophils was significantly higher at 2:1 than 1:1 neutrophil-to-endothelial cell ratio, 
and addition of SB-203580 (10 µM) significantly decreased the number of adherent neutrophils. 
However, the number of adherent neutrophils in the group with a 1:1 neutrophil to endothelial cell 
ratio and without SB-203580 did not significantly differ from the neutrophil adhesion number in 
the group with a 2:1 neutrophil-to-endothelial cell ratio and in the presence of SB-203580 (Figure 
3.3D). Accordingly, analysis of phosphorylated LSP1 in these treatment groups showed that 
pharmacological inhibition of p38 MAPK by SB-203580 indeed blunted the phosphorylation of 
endothelial LSP1, despite similar numbers of adherent neutrophils (Figure 3.3D–F). This indicates 
that phosphorylation of endothelial LSP1 is downstream of p38 MAPK signaling in endothelial 
cells.  
In neutrophils and T cells, LSP1 was previously described as a substrate for PKC [153, 
182, 208]. A further series of experiments were performed to elucidate the role of PKC in the 
modulation of endothelial LSP1 phosphorylation triggered by neutrophil adhesion. Treatment of 
endothelial cells with the PKC inhibitors staurosporine (100 nM), sotrastaurin (5 µM), or Gö-6983 
(1 µM) tended to decrease neutrophil adhesion triggered by MIP-2, an effect not reaching statistical 
significance. The number of adherent neutrophils (counted in a 325-µm2 area) was 38.3 ± 7.3, 40.2 
± 6.5, and 41.2 ± 5.9 in the presence of staurosporine, sotrastaurin, and Gö-6983, respectively, 
compared with 49.2 ± 3.7 in the control group without PKC inhibition (n = 3 each, P >0.05, 
ANOVA). Similarly, enhanced expression of phosphorylated endothelial LSP1 triggered by MIP-
2-activated neutrophils did not significantly differ upon treatment with staurosporine, sotrastaurin, 
or Gö-6983. The relative LSP1 phosphorylation was 65.0 ± 7.0 in the absence of PKC inhibitors 
and 47.3 ± 10.2, 49.6 ± 9.9, and 49.8 ± 8.5 in the presence of staurosporine, sotrastaurin, and Gö-
6983 (arbitrary units, n = 3 each, P > 0.05, ANOVA), respectively. Clearly, p38 MAPK plays a 
more prominent role than PKC in endothelial LSP1 activation. 
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Figure 3.3: Suppression of endothelial LSP1 phosphorylation by pharmacological inhibition of 
p38 MAPK. (A) Number of adherent KO neutrophils (counted in a 325-μm2 area) stimulated with 
MIP-2 (100 nM) on murine EE2 endothelial cells at neutrophil-to-endothelial cell ratio (PMN:EC) 
of 0:1, 0.5:1, 1:1, 2:1, and 5:1. Values are means ± SD (n = 3). (B) Original dual immunoblots 
(representative of 3 similar experiments) demonstrating expression of phosphorylated LSP1 
(Alexa Fluor 488, green), total LSP1 (Alexa Fluor 647, red), and overlap of phosphorylated and 
total LSP1 (yellow) in endothelial cells with neutrophil-to-endothelial cell ratios of 0:1, 0.5:1, 1:1, 
2:1, and 5:1. (C) Densitometric analysis of abundance of phosphorylated LSP1 relative to total 
LSP1 in endothelial cells with neutrophil-to-endothelial cell ratios of 0:1, 0.5:1, 1:1, 2:1, and 5:1. 
Values are means ± SD (n = 3). ***Significantly different (P < 0.001) from 0:1 (by ANOVA). (D) 
Number of adherent KO neutrophils (counted in a 325-μm2 area) stimulated with MIP-2 (100 nM) 
on primary endothelial cells from WT mice in neutrophil-to-endothelial cell ratios of 1:1 and 2:1, 
in the absence (0 μM) and presence of the specific p38 MAPK inhibitor SB-203580 (10 μM). 
Values are means ± SD (n = 3). **Significantly different (P < 0.01) from 1:1 (by ANOVA). 
##Significantly different (P < 0.01) from 0 μM SB-203580 (by ANOVA). ns, Not significant. (E) 
Original dual immunoblots (representative of 3 similar experiments) demonstrating expression of 
phosphorylated LSP1 (Alexa Fluor 488, green), total LSP1 (Alexa Fluor 647, red), and overlap of 
phosphorylated and total LSP1 (yellow) in the absence and presence of SB-203580 (10 μM) with 
neutrophil-to-endothelial cell ratios of 1:1 and 2:1. (F) Densitometric analysis of abundance of 
phosphorylated LSP1 relative to total LSP1 of endothelial cells in the absence and presence of SB-
203580 (10 μM) with neutrophil-to-endothelial cell ratios of 1:1 and 2:1. Values are means ± SD 
(n = 3). **Significantly different (P < 0.01) from 0 μM SB-203580 (by Student's t-test). 
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3.4 β2 integrins and ICAM-1 are involved in neutrophil adhesion and subsequent 
endothelial LSP1 phosphorylation  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Blocking neutrophil β2-integrins/CD18 or endothelial ICAM-1 inhibits neutrophil 
adhesion and phosphorylation of endothelial LSP1. (A, D, and G) number of adherent KO 
neutrophils (counted in a 325-μm2 area) stimulated with 100 nM MIP-2 in the absence (control) 
EE2 
EE2 
HVEC 
LVEC 
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and presence of β2-integrin blocking antibodies or respective isotype control (isotype) on primary 
lung (LVEC; A) and heart (HVEC; D) endothelial cells from WT mice and murine EE2 endothelial 
cells (G). Values are means ± SD (n = 3). Significantly different from control and isotype: **P < 
0.01 and ***P < 0.001 (by ANOVA). (B, E, and H) original dual immunoblots (n = 3) 
demonstrating expression of phosphorylated LSP1 (green), total LSP1 (red), and overlay of 
phosphorylated and total LSP1 (yellow) in primary lung (B) and heart (E) endothelial cells from 
WT mice and murine EE2 endothelial cells (H) after 30 min of incubation in the presence of 
neutrophils stimulated with MIP-2 (100 nM) and in the presence or absence of anti-β2-integrin 
blocking antibodies or the respective isotype control antibodies. (C, F, and I) densitometric 
analysis of abundance of phosphorylated LSP1 relative to total LSP1 in primary lung (C) and heart 
(F) endothelial cells from WT mice and murine EE2 endothelial cells (I) after 30 min of incubation 
in the presence of neutrophils stimulated with MIP-2 (100 nM) and in the absence (control) or 
presence of anti-β2-integrin blocking antibodies or the respective isotype control antibodies. 
Values are means ± SD (n = 3). ***Significantly different (P < 0.001) from control and isotype 
(by ANOVA). (J) Number of adherent KO neutrophils (counted in a 325-μm2 area) in the absence 
(control) and presence of anti-ICAM-1 blocking antibodies or the respective isotype control on 
TNF-α-stimulated (20 ng/ml, 4 h) murine EE2 endothelial cells. Values are means ± SD (n = 3). 
***Significantly different (P < 0.001) from control and isotype (by ANOVA). (K) original dual 
immunoblots (representative of 3 similar experiments) demonstrating expression of 
phosphorylated LSP1 (Alexa Fluor 488, green), total LSP1 (Alexa Fluor 647, red), and overlap of 
phosphorylated LSP1 and total LSP1 (yellow) determined in TNF-α-stimulated (20 ng/ml, 4 h) 
murine EE2 endothelial cells after 30 min of incubation in the presence of adherent neutrophils 
and in the presence or absence of anti-ICAM-1 blocking antibodies or the respective isotype 
control antibodies. (L) densitometric analysis of abundance of phosphorylated LSP1 relative to 
total LSP1 in TNF-α-stimulated (20 ng/ml, 4 h) murine EE2 endothelial cells after 30 min in the 
presence of adherent neutrophils and in the absence (control) or presence of anti-ICAM-1 blocking 
antibodies or the respective isotype control antibodies. Values are means ± SD (n = 3). 
***Significantly different (P < 0.001) from control and isotype (by ANOVA). 
 
It has been documented that neutrophil recruitment in the lung can be integrin- and ICAM-
1-independent [43, 46]. To test whether these organ-specific mechanisms affect phosphorylation 
of endothelial LSP1, a series of experiments were performed using blocking antibodies against β2-
integrins to analyze neutrophil adhesion and subsequent LSP1 phosphorylation in endothelial cells 
derived from different organs. In murine primary lung endothelial cells (LVEC), MIP-2-triggered 
neutrophil adhesion and subsequent endothelial LSP1 phosphorylation were significantly blunted 
by the β2-integrin blocking antibodies (Figure 3.4A–C). Similarly, murine primary heart 
endothelial cells (HVEC) and EE2 cells showed inhibition of neutrophil adhesion (Figure 3.4D 
and G) and phosphorylation of endothelial LSP1 (Figure 3.4E, F, H, and I). As depicted in Figure 
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3.4, blocking neutrophil β2-integrins resulted in 45%, 65%, and 63% decreased neutrophil 
adhesion to primary lung endothelial cells, primary heart endothelial cells, and murine EE2 
endothelial cells, respectively. Similarly, blocking neutrophil β2-integrins resulted in 69%, 73%, 
and 85% reduction of phosphorylated LSP1 in primary lung endothelial cells, primary heart 
endothelial cells, and EE2 cells, respectively. 
To further substantiate our findings, we assessed the effects of blocking endothelial ICAM-
1 on neutrophil adhesion and activation of endothelial LSP1 in vitro. Treatment with anti-ICAM-
1 blocking antibodies significantly reduced neutrophil adhesion (Figure 3.4J) and resulted in 
significant inhibition of LSP1 phosphorylation in TNF-α-treated endothelial cells (Figure 3.4K 
and L). Treatment with isotype control antibodies, however, did not significantly modify 
neutrophil adhesion to endothelial cells (Figure 3.4J) and the phosphorylation of endothelial LSP1 
(Figure 3.4K and L). 
3.5 ICAM-1 cross-linking mimics the function of neutrophil adhesion  
ICAM-1 is the most important endothelial adhesion molecule for firm neutrophil adhesion. 
In fact, ICAM-1 cross-linking is routinely used to mimic neutrophil adhesion in vivo and in vitro 
[207]. ICAM-1 has been identified as a critical signaling molecule connecting leukocyte adhesion 
with downstream events in endothelial cells. ICAM-1 cross-linking was previously shown to 
activate endothelial p38 MAPK signaling [47], which is partially mediated by xanthine oxidase 
[49]. ICAM-1 engagement by cross-linking antibodies or human rhinovirus binding was also 
shown to induce phosphorylation of p38 MAPK in a Syk tyrosine kinase-dependent manner [50]. 
Therefore, to verify that the phosphorylation of endothelial LSP1 induced by KO neutrophils was 
indeed triggered by the binding through endothelial adhesion molecules, we used ICAM-1 
antibody cross-linking, which engages ICAM-1 on endothelial cells, to determine the effect of 
ICAM-1-mediated adhesion in triggering of endothelial LSP1 phosphorylation. After stimulation 
of endothelial cells with TNF-α in vitro, ICAM-1 cross-linking significantly enhanced the 
phosphorylation of LSP1 in endothelial cells compared with that in the presence of the control 
isotype immunoglobulins on TNF-α-treated endothelial cells or the same cross-linking on 
unstimulated endothelial cells (Figure 3.5). After ICAM-1 ligation and then cross-linking on 
unstimulated endothelial cells, we observed a subtle, but significant, increase in the abundance of 
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phosphorylated endothelial LSP1 underlining baseline levels of ICAM-1 expression and its 
functions in LSP1 activation upon crosslinking on unstimulated endothelial cells (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Phosphorylation of endothelial LSP1 by ICAM-1 engagement in vitro. (A) Original 
dual immunoblots (n = 3) demonstrating expression of phosphorylated LSP1 (green), total LSP1 
(red), and overlay (yellow) determined in endothelial cells after stimulation with TNF-α (20 ng/ml) 
in the presence of cross-linking antibodies following addition of anti-ICAM-1 antibodies (ICAM-
1) or isotype controls (isotype). (B) Densitometric analysis of abundance of phosphorylated LSP1 
relative to total LSP1 of endothelial cells determined in endothelial cells without stimulation with 
TNF-α and in the presence of cross-linking antibodies and after stimulation with TNF-α (20 ng/ml) 
in the absence (control) or presence of cross-linking antibodies following addition of anti-ICAM-
1 antibodies (ICAM-1) or the isotype control. Values are means ± SD (n = 3). Significantly 
different from control and isotype: *P < 0.05 and ***P < 0.001 (by ANOVA). ###Significantly 
different (P < 0.001) from cross-linking antibodies + TNF-α stimulation (by ANOVA). 
 
As an additional approach, we determined the effect of ICAM-1 engagement on endothelial 
LSP1 phosphorylation in vivo. Administration of ICAM-1 cross-linking antibodies to KO mice 
following depletion of circulating neutrophils significantly enhanced the abundance of 
phosphorylated LSP1 in cremaster muscle. Administration of isotype control immunoglobulins, 
however, did not modify the level of phosphorylated LSP1 (Figure 3.6A and B). These results 
indicate that ICAM-1-mediated adhesion is important for the phosphorylation of endothelial LSP1. 
Consistent with our findings that pharmacological inhibition of p38 MAPK attenuates 
phosphorylation of endothelial LSP1 (Figure 3.3), we observed robust phosphorylation of p38 
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MAPK in cremaster muscle upon ICAM-1 cross-linking, but not upon administration of the 
isotype immunoglobulins (Figure 3.6C and D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: LSP1 and p38 MAPK phosphorylation in cremaster muscle by ICAM-1 engagement 
in vivo. (A and C) original dual immunoblots (n = 3) demonstrating expression of phosphorylated 
LSP1 (green), total LSP1 (red), and overlay (yellow) and expression of phosphorylated p38 MAPK 
(p-p38), total p38 MAPK (p38), and respective β-actin protein abundance (β-actin) determined in 
TNF-α-stimulated (300 ng, intrascrotal injection, 4 h) cremaster muscle of neutrophil-depleted WT 
mice after administration of saline (control) or cross-linking antibodies following addition of anti-
ICAM-1 antibodies (ICAM-1) or isotype controls (isotype). (B and D) densitometric analysis of 
abundance of phosphorylated LSP1 relative to total LSP1 and phosphorylated p38 MAPK relative 
to total p38 MAPK determined in TNF-α-stimulated (300 ng, intrascrotal injection, 4 h) cremaster 
muscle of neutrophil-depleted WT mice after administration of saline (control) or cross-linking 
antibodies following addition of anti-ICAM-1 antibody (ICAM-1) or isotype controls. Values are 
means ± SD (n = 3). **Significantly different (P < 0.01) from control or isotype (by ANOVA). 
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Interestingly, leukocyte adhesion further enhanced the phosphorylation of endothelial p38 
MAPK elicited by TNF-α, pointing to a synergism between leukocyte adhesion and cytokine 
stimulation [17]. Our observation that basal abundance of phosphorylated p38 MAPK in TNF-α-
stimulated cremaster muscle tissue was increased after ICAM-1 crosslinking is consistent with a 
previous observation [210]. Moreover, various other studies have shown that ICAM-1 engagement 
may also induce PKC activation [18, 23, 211]. It is intriguing to speculate that endothelial LSP1 
phosphorylation following leukocyte adhesion contributes to the physiological functions of 
microvascular permeability and transendothelial migration of leukocytes, thus explaining the 
impaired inflammatory phenotypes in KO mice [32, 37, 136]. 
3.6 Summary 
This is the first report on the phosphorylation of endothelial LSP1. Here, we demonstrate 
that the adhesion of neutrophils to endothelial cells but not the stimulation with chemokine or 
cytokine alone, triggers phosphorylation of endothelial LSP1. This phosphorylation was easily, 
though partially, inhibited by inhibiting adhesion via functional blocking of neutrophil-expressed 
β2 integrins or endothelial cell-expressed ICAM-1, the most important adhesion molecules 
involved in firm neutrophil adhesion to endothelial cells. The role of ICAM-1 as the initiator of 
this signaling event was established by in vitro and in vivo ICAM-1 cross-linking studies. ICAM-
1 engagement is known to activate p38 MAPK and PKC. Both of them are capable of 
phosphorylating LSP1 in other cell types. However, using pharmacological inhibitor of both p38 
MAPK and PKC, we could establish the involvement of p38 MAPK pathway in the 
phosphorylation of endothelial LSP1. Our data provide mechanistic evidence that the ICAM-1-
mediated adhesion mechanism during leukocyte-endothelial cell interactions is essential for the 
phosphorylation of endothelial LSP1. 
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4.0 ENDOTHELIAL CELL-EXPRESSED LSP1 MODULATES ENDOTHELIAL 
CELL MIGRATION AND NEUTROPHIL RECRUITMENT BY REGULATING 
VASCULAR PECAM-1 EXPRESSION 
 
 
 
A major part of the data presented in this chapter were used in a research paper entitled 
“Endothelial LSP1 modulates extravascular neutrophil chemotaxis by regulating non-
hematopoietic vascular PECAM-1 expression” published by Mokarram Hossain, Syed M. Qadri, 
Najia Xu, Yang Su, Francisco S. Cayabyab, Bryan Heit and Lixin Liu in The Journal of 
Immunology, 2015; 195: 2408–2416.  
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4.0 ENDOTHELIAL CELL-EXPRESSED LSP1 MODULATES ENDOTHELIAL 
CELL MIGRATION AND NEUTROPHIL RECRUITMENT BY REGULATING 
VASCULAR PECAM-1 EXPRESSION 
On account of its predominantly cytosolic presence and its association with the 
cytoskeleton, leukocyte-expressed LSP1 was reported to be crucial in transmission of signals that 
regulate leukocyte polarization and motility [140]. On the contrary, nonhematopoietic endothelial-
expressed LSP1 is localized primarily in the nucleus [136]. In neutrophils, LSP1 is phosphorylated 
by soluble chemoattractants and then colocalizes with F-actin, thus contributing to the stability of 
cell polarization during chemotaxis [34, 208]. A similar mechanism was observed in migrating 
dendritic cells which showed enhanced phosphorylation of LSP1 concomitant with increased actin 
association in response to the HIV viral protein gp120 [35]. Surprisingly, these mechanisms are 
not operative in activation of endothelial cell-expressed LSP1 which becomes phosphorylated 
following ICAM-1-mediated adhesive engagement, but not by cytokine or chemokine stimulation 
alone (Figure 3.2 and Figure 3.5). 
Despite the existence of mounting evidence regarding differences between leukocyte-
expressed versus endothelial cell-expressed LSP1, there is no report on the role of endothelial cell-
expressed LSP1 in endothelial functions apart from involvement in leukocyte recruitment and 
vascular leakage. There is a large body of evidence that overexpression of LSP1 in normally LSP1-
null cells (sf9 and CV1-COS) induces the formation of filamentous projection in these cells [13]. 
Abundant expression of LSP1 affects motility of monocyte-differentiated phagocytes primarily by 
impairing their actin reorganizing capacity. However, constitutive low level of LSP1 expression is 
in fact, helpful for their motility [200]. In this study, we have explored whether and how LSP1 
expression modulates endothelial cell motility which is important in many diseases such wound 
healing, angiogenesis, vascular inflammation and cancer.  
4.1 Endothelial cell-expressed LSP1 is important for endothelial cell migration 
Endothelial cell migration is usually measured as single cells along a chemotactic gradient 
in a Transwell membrane or migration as a whole monolayer which similar to the in vivo 
endothelium using a scratch wound healing assay. First, we compared the migration rate of EE2 
cells before and after LSP1 silencing using a scratch wound healing assay.  
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Figure 4.1: Role of LSP1 on endothelial cell migration. 
(A) Confluent monolayers of EE2 cells before and after LSP1 silencing were wounded by making 
several straight scratches and wound closure was monitored for 24 hours. The percentage of open area at 
indicated time points was plotted. Beyond 12 hours, the wounds were completely healed, hence are not 
shown. Four independent wound healing migration assays were performed for each treatment groups. Data 
are means ± SD (n = 3). Significantly different from scrambled siRNA (***P < 0.001; ANOVA). (B) 
Number of migrated EE2 cells at the bottom of the polycarbonate membrane insert in response to serum 
gradient. Cells were counted in a hemocytometer after detaching them from the membrane by incubating 
the inserts in trypsin solution. LSP1 was silenced 24 hours prior to the migration assay. Data presented as 
means ± SD (n = 4). Significantly different from scrambled siRNA (*P < 0.05; ANOVA). 
 
Closure of wounds took significantly longer time in LSP1-silenced cells compared to non-
targeting siRNA-treated EE2 cells (Figure 4.1A). Closure of wounds requires cell migration as 
well as cell proliferation. In an attempt to distinguish whether LSP1-deficiency affects endothelial 
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cell motility, proliferation or both, we next measured the rate of migration of individual EE2 cells 
along serum gradient in Transwell systems. We noticed that EE2 cells treated with non-targeting 
siRNA transmigrated across the Transwell insert membrane of 3 m pore size more efficiently 
than the LSP1-silenced EE2 cells (Figure 4.1B). Taken together, these results suggest that 
endothelial cell-expressed LSP1 promotes endothelial cell migration.   
4.2 Deficiency of endothelial cell-expressed LSP1 plays a subtle role in the regulation of 
endothelial cell proliferation and apoptosis 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Role of LSP1 on endothelial cell proliferation. (A) EE2 cell monolayers were 
transfected with LSP1 or non-targeting silencing RNA at 60-80% confluency. After 12 hours, 
equal number (200,000) of these cells were subcultured in 100 mm cell culture dishes and the total 
cell number was counted using a hemocytometer at 24, 48 and 72 hours post-transfection. Three 
C 
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independent cell proliferation assays were performed for each treatment groups. Data are means ± 
SD (n = 4). (B-C) EE2 cell monolayers were transfected with LSP1 or non-targeting silencing 
RNA at 60-80% confluency and grown for 48 hours. Spontaneous apoptosis of these cells was 
examined by flow cytometry using a FITC-Annexin and propidium iodide apoptosis detection kit. 
(B) Total count (% of total) of healthy, apoptotic and dead populations of EE2 cells presented as 
means ± SD (n = 3). Significantly different from scrambled siRNA (*P < 0.05; ANOVA). (C) 
Representative dot plots of FITC-Annexin vs propidium iodide-stained endothelial cells in non-
targeting and LSP1 siRNA transfected EE2 cells. Healthy, apoptotic and dead cells counts (% of 
total) are indicated in the respective quadrants.  
 
Regulators of endothelial cell migration often also modulate endothelial proliferation and 
apoptosis [212-214]. Furthermore, in B lymphocytes, LSP1 was shown to be a negative regulator 
of apoptosis ensuring better survival rate of WT B cells [215]. We have grown EE2 cells before 
and after LSP1 silencing for 72 hours to determine the role of LSP1 on endothelial cell 
proliferation. We found a consistent, subtle but significant reduction in the proliferation rate of 
LSP1-silenced EE2 cells compared to the non-targeting siRNA transfected EE2 cells (Figure 
4.2A). To examine whether endothelial cell-expressed LSP1 provides similar protection to 
endothelial cells against apoptosis, we tested the rate of spontaneous apoptosis in EE2 cells before 
and after LSP1 silencing.  
We found a subtle but a significantly increased tendency of endothelial cell apoptosis in 
LSP1-silenced EE2 cells (Figure 4.2B). Population of healthy cells was slightly smaller in LSP1-
silenced endothelial cells (Figure 4.2B). 
4.3 Endothelial cell-expressed LSP1 in neutrophil adhesion and transmigration 
Negative regulatory role of neutrophil-expressed LSP1 on neutrophil adhesion, emigration, 
polarization and chemotaxis has been reported [147, 148]. On the contrary, the positive regulatory 
role of neutrophil-expressed LSP1 on neutrophil motility, chemotaxis, F-actin polarization and 
cytoskeletal rearrangement was observed by other groups [146, 208]. In another study, using 
knockout and chimeric mice, it was reported that LSP1 deficiency generally tends to decrease 
neutrophil adhesion [136, 216]. Because of these discrepancies, we investigated whether 
endothelial cell-expressed LSP1 participates in neutrophil adhesion. Using an in vitro assay, we 
measured the adhesion of WT neutrophils to WT and KO endothelial cells. As depicted in Figure 
4.3A, incubation of chemokine-stimulated (KC or MIP-2, 100 nM) neutrophils with endothelial 
cells for 30 min remarkably enhanced the number of adherent neutrophils on WT and KO 
endothelial cells compared with neutrophil adhesion in the absence of chemokine stimulation.  
62 
 
B 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Role of endothelial cell-expressed leukocyte-specific protein 1 (LSP1) on neutrophil 
adhesion and transendothelial migration in vitro. (A) Number of adherent neutrophils (WT or 
KO; counted in a 325-μm2 area) in the absence (control) and presence of stimulation with 100 nM 
KC or 100 nM macrophage inflammatory protein-2 (MIP-2) after 30 min of incubation on primary 
endothelial cells (EC) from WT and KO mice. Values are means ± SD (n = 3). Significant 
difference (*P < 0.05; **P < 0.01) due to LSP1 deficiency in neutrophil or endothelial cells (by 
ANOVA). (B) Number of migrated neutrophils across EE2 cell monolayers cultured on 
polycarbonate membrane inserts of a Transwell system. EE2 cells were treated with or without 
LSP1 siRNA or non-targeting siRNA for at least 24 hours before the transmigration assay. 
Transmigrated neutrophils were counted in a hemocytometer. Data presented as means ± SD (n = 
4). Significantly different from negative control (***P < 0.001) or scrambled siRNA (#P < 0.05) 
(ANOVA). 
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The number of adherent neutrophils, however, was slightly, but significantly, lower on KO 
endothelial cells than on WT endothelial cells, suggesting that endothelial cell-expressed LSP1 
plays a subtle but significant role in neutrophil adhesion (Figure 4.3A). Deficiency of neutrophil-
expressed LSP1 also resulted in a subtle reduction in neutrophil adhesion which reached statistical 
significance only in KC treated neutrophils and only when these neutrophils were allowed to 
adhere onto WT endothelial cells (Figure 4.3A). We have also determined transmigration 
efficiency of neutrophils across EE2 cell monolayers cultured on Transwell inserts using MIP-2 
as a chemotactic factor in a Transwell system. Transmigration assay was performed before or after 
LSP1 silencing to determine the role of LSP1 on neutrophil transendothelial migration. Results of 
the transmigration assays (Figure 4.3B) is consistent with previously reported in vivo results [136].  
4.4 LSP1 deficiency affects PECAM-1 expression in the endothelium  
Endothelial cell migration is crucial for angiogenesis in many health and pathologic 
conditions [8]. In angiogenesis, endothelial cells break up intercellular contacts, proliferate and 
migrate across the peri-endothelial barrier usually in response to many angiogenic factors [8, 55]. 
Numerous reports, albeit contradictory, are available highlighting the role of PECAM-1 on 
endothelial cell migration, proliferation and angiogenesis [213, 217-220]. Like LSP1 (Figure 4.5), 
PECAM-1-deficiency was also reported to cause dysregulation of endothelial permeability [221]. 
Using bone marrow transplanted chimeric mice, we observed that the expression of α6 and β1 
integrins on the surface of neutrophils transmigrated across KO endothelium was dramatically 
reduced compared to neutrophils transmigrated across WT endothelium (Figure 4.4). Expression 
of 61 integrins on the surface of transmigrated neutrophils is known to be modulated by 
homophilic PECAM-1 interactions during neutrophil-endothelial cell interactions [54]. All of 
these results indicate that LSP1 and PECAM-1 are functionally connected in endothelial cells. 
Hence, we hypothesized that the deficiency of endothelial cell-expressed LSP1 may lead to 
deranged PECAM-1 expression in endothelial cells. Accordingly, we designed in vivo and in vitro 
experiments to explore whether endothelial cell-expressed or neutrophil-expressed LSP1 
modulates vascular PECAM-1 expression. Using fluorescence confocal imaging, we visualized 
the cremasteric microvasculature to examine vascular and neutrophil PECAM-1 expression in WT 
and KO mice. As depicted in Figure 4.5A, KO mice had a remarkably decreased level of 
microvascular PECAM-1 expression as compared to WT mice. Leukocyte PECAM-1-dependent 
fluorescence in cremasteric venule was, however, similar in both WT and KO mice. These results 
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indicate that endothelial cell-expressed LSP1 regulates endothelial PECAM-1 expression whereas 
neutrophil-expressed LSP1 does not regulate PECAM-1 expression in neutrophils.  
 
Figure 4.4: Expression of α6β1 integrin on the surface of transmigrated neutrophils is sensitive 
to endothelial cell-expressed LSP1. Means  SEM (n = 3) of integrin-dependent fluorescence 
intensity quantified in transmigrated neutrophils obtained from peritoneal cavities of WT→WT, 
KO→WT, WT→KO, and KO→KO chimeric mice by peritoneal lavage 3 h after an i.p. injection 
of MIP-2. Significantly different from WT→WT (**P < 0.01) or from KO→WT (#P < 0.05) 
(ANOVA).  
 
To corroborate these findings, we first detected PECAM-1 expression in mouse bone 
marrow neutrophils. As shown in Figure 4.5B, neutrophil PECAM-1 expression was not 
significantly different in either genotype (KO or WT mice). Using flow cytometry, we have also 
examined the PECAM-1 expression level in peripheral blood neutrophils and found that LSP1 
deficiency did not affect PECAM-1 protein expression in circulating neutrophils (Figure 4.5C). 
These results confirms that leukocyte-expressed LSP1 does not regulate PECAM-1 expression. To 
further evaluate the cell-specific regulation of PECAM-1 expression by LSP1 and to determine 
whether LSP1 regulates other adhesion molecules in endothelial cells, we analyzed PECAM-1 and 
ICAM-1 protein expression in primary endothelial cells from WT and KO mice. As shown in 
Figure 4.5D, PECAM-1 but not ICAM-1 protein expression was significantly reduced in 
endothelial cells of LSP1 KO mice as compared to WT mice. 
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Figure 4.5: Endothelial cell-expressed LSP1-sensitive vascular PECAM-1 expression. (A) 
Confocal micrographs (n = 5) of PECAM-1-dependent fluorescence in cremasteric postcapillary 
venules of WT (left panel) and LSP1-deficient (KO, right panel) mice. (B) Representative original 
Western blot and means ± SD (n = 4) of PECAM-1 protein expression (relative to β-actin) 
determined in neutrophils isolated from bone marrows of WT and KO mice. n.s., not significant. 
(C) Original histograms of PECAM-1-dependent fluorescence in peripheral blood neutrophils 
from WT (red lines) or KO (blue lines) mice. Neutrophils were stained with FITC-conjugated 
PECAM-1 (solid lines) or isotype control (dashed lines) antibodies. (D) Original Western blot and 
means ± SD (n = 3) of PECAM-1 and ICAM-1 protein expression (relative to β-actin) determined 
in murine primary endothelial cells isolated from WT and KO mice. * (P < 0.05) from WT. (E) 
Relative LSP1 mRNA level (relative to β-actin) in EE2 endothelial cells in the absence (Control) 
or in the presence of treatment with negative control scrambled siRNA or LSP1-targeted siRNA. 
*** (P < 0.001) from scrambled siRNA treatment.  (F) Representative original Western blot and 
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means ± SD (n = 4) of LSP1, PECAM-1 and ICAM-1 protein expression (relative to β-actin) 
determined in EE2 endothelial cells in the absence (Control) or in the presence of treatment with 
negative control scrambled siRNA or LSP1-targeted siRNA. ** (P < 0.01) from scrambled siRNA 
treatment. (G) Representative original Western blot and means ± SD (n = 4) of LSP1 and PECAM-
1 protein expression (relative to β-actin) determined in EE2 endothelial cells in the absence 
(Control) or in the presence of transfection with murine pCMV-SPORT6-LSP1 plasmids or empty 
vector as negative control. * (P < 0.05) and *** (P < 0.001) from the control empty vector.  
 
To support these data, we determined PECAM-1 protein expression after siRNA-targeted 
silencing of LSP1 in murine microvascular EE2 endothelial cells. As a result, siRNA-targeted 
silencing of endothelial cell-expressed LSP1 significantly reduced PECAM-1, without any effect 
on ICAM-1, expression in these murine endothelial cells (Figure 4.5F). Silencing LSP1 using gene 
targeted-siRNA significantly suppressed LSP1 protein expression indicating the experimental 
efficiency of LSP1 silencing in these endothelial cells (Figure 4.5E). Additional experiments 
explored whether overexpression of endothelial cell-expressed LSP1 modulates PECAM-1 
expression. Figure 4.5G shows that overexpression of LSP1 in EE2 endothelial cells resulted in 
increased PECAM-1. Taken together, these data confirms that endothelial cell-expressed LSP1 
selectively regulates PECAM-1 expression in endothelial cells whereas leukocyte-expressed LSP1 
does not regulate PECAM-1 expression in leukocytes.  
4.5 Endothelial cell-expressed LSP1 regulates vascular PECAM-1 expression via 
modulating GATA-2  
We performed an additional series of experiments to disclose the underlying mechanisms 
of endothelial cell-expressed LSP1-sensitive PECAM-1 expression. As shown in Figure 4.6A, 
targeted siRNA silencing of LSP1 in murine EE2 endothelial cells significantly blunted PECAM-
1, but not ICAM-1, mRNA levels suggesting that LSP1 transcriptionally regulates PECAM-1 
expression in endothelial cells. To elucidate the transcriptional regulation of PECAM-1 by LSP1, 
we explored the participation of the transcription factor GATA-2 that is expressed in microvascular 
endothelial cells [222]. As shown in Figure 4.6B, GATA-2 expression in LSP1-deficient murine 
primary endothelial cells was significantly lower as compared to that in WT endothelial cells. 
Furthermore, silencing LSP1 in EE2 endothelial cells significantly mitigated GATA-2 
expression alluding to LSP1 sensitivity of endothelial GATA-2 expression (Figure 4.6C). 
Overexpression of LSP1 in these endothelial cells significantly increased the expression of GATA-
2 (Figure 4.6D). To validate the role of LSP1-sensitive GATA-2 expression in selectively 
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regulating endothelial PECAM-1 expression, we silenced GATA-2 and analyzed adhesion 
molecule expression. Silencing endothelial GATA-2 significantly attenuated GATA-2 and 
PECAM-1, but not ICAM-1, protein expression in endothelial cells confirming the endothelial 
cell-specific regulation of PECAM-1 expression by GATA-2 (Figure 4.6E). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Endothelial cell-expressed LSP1-sensitive GATA-2 regulates PECAM-1 
transcription. (A) Means ± SD of mRNA levels (n = 6) encoding PECAM-1 and ICAM-1 
determined in EE2 endothelial cells in the absence (Control) or in the presence of treatment with 
negative control scrambled siRNA or LSP1-targeted siRNA. * (P < 0.05) from scrambled siRNA 
treatment. (B) Representative original Western blot and means ± SD (n = 4) of GATA-2 protein 
expression (relative to β-actin) determined in murine primary endothelial cells isolated from WT 
and KO mice. * (P < 0.05) from WT. (C) Representative original Western blot and means ± SD (n 
= 4) of GATA-2 protein expression (relative to β-actin) determined in EE2 endothelial cells in the 
absence (Control) or in the presence of treatment with negative control scrambled siRNA or LSP1-
targeted siRNA. * (P < 0.05) from scrambled siRNA treatment. (D) Representative original 
Western blot and means ± SD (n = 4) of LSP1 and GATA-2 protein expression (relative to β-actin) 
determined in EE2 endothelial cells in the absence (Control) or in the presence of transfection with 
murine pCMV-SPORT6-LSP1 plasmids or empty vector as negative control. * (P < 0.05) and *** 
(P < 0.001) from the control empty vector. (E) Representative original Western blot and means ± 
SD (n = 4) showing GATA-2, PECAM-1 and ICAM-1 protein expression (relative to β-actin) 
determined in EE2 endothelial cells in the absence (Control) or in the presence of treatment with 
negative control scrambled siRNA or GATA-2-targeted siRNA. ** (P < 0.01) from scrambled 
siRNA treatment. 
68 
 
 
4.6 GATA-2 silencing mimics the effect of LSP1 silencing on endothelial cells functions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: GATA-2 silencing mimics the effect of LSP1 silencing on endothelial cells 
functions. (A) Confluent monolayers of EE2 cells before and after LSP1 or GATA-2 silencing 
were wounded and wound closure was monitored for 24 hours. The percentage of open area at 
indicated time points was plotted. Beyond 12 hours, the wounds were completely healed, hence 
are not shown. Three independent wound healing migration assays were performed for each 
treatment groups. Data are means ± SD (n = 3). Significantly different from scrambled siRNA 
(**P < 0.01 and ***P < 0.001) or LSP1 siRNA (#P < 0.05) (ANOVA). (B) Number of migrated 
EE2 cells at the bottom of the polycarbonate membrane insert in response to serum gradient. Cells 
were counted in a hemocytometer after detaching them from the membrane by incubating the 
inserts in trypsin solution. LSP1 or GATA-2 was silenced 24 hours prior to the migration assay. 
Data presented as means ± SD (n = 3). Significantly different from scrambled siRNA (*P < 0.05 
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# 
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and **P < 0.01) or LSP1 siRNA (#P < 0.05) (by ANOVA). (C) Number of migrated neutrophils 
across EE2 cell monolayers cultured on polycarbonate membrane inserts of a Transwell system. 
EE2 cells were treated with or without LSP1, GATA-2 or non-targeting siRNA for at least 24 
hours before the transmigration assay. Transmigrated neutrophils were counted in a 
hemocytometer. Data presented as means ± SD (n = 3). Significantly different from negative 
control (***P < 0.001) or scrambled siRNA (#P < 0.05) (by ANOVA). (D) Representative original 
Western blot and means ± SD  (n = 5) showing VCAM-1 protein expression (relative to β-actin) 
in TNF--treated (4 h) EE2 endothelial cells in the absence (Control) or in the presence of 
treatment with negative control scrambled siRNA or GATA-2-targeted siRNA. * (P < 0.05) from 
scrambled siRNA treatment. (E) Representative original Western blot and means ± SD (n = 3) 
showing VCAM-1 protein expression (relative to β-actin) in TNF--treated (4h) EE2 endothelial 
cells in the absence (Control) or in the presence of treatment with negative control scrambled 
siRNA or LSP1-targeted siRNA. 
 
Finally, to verify whether LSP1-deficiency-mediated impaired endothelial cell functions 
studied here such as endothelial cell migration and neutrophil transendothelial migration were due 
to reduced PECAM-1 expression, respective assays were repeated upon GATA-2 silencing in EE2 
cells and the effect of LSP1 and GATA-2 deficiency was compared (Figure 4.7A-C). Both LSP1 
and GATA-2 silencing had similar effect on the above-mentioned endothelial functions, however, 
the effect of GATA-2 silencing was more profound (Figure 4.7A-C). This difference may be 
attributed to the fact that in addition to regulating PECAM-1 expression, GATA-2 is decisive in 
endothelial-selective gene expression of endothelial nitric oxide synthase, endomucin and VCAM-
1 [76-78, 216].  
Recently, endothelial GATA-2 was shown to participate in regulating angiogenesis [79] 
and maintenance of vascular integrity [80]. Although GATA-2 regulated the transcription of both 
PECAM-1 and VCAM-1 in endothelial cells, we found that LSP1 selectively regulated GATA-2-
mediated transcription of PECAM-1 but not ICAM-1 or VCAM-1 in these cells (Figure 4.5A, D, 
F-G; Figure 4.6 B-E &Figure 4.7 D-E). 
4.7 Summary  
In summary, these data provide a novel mechanistic insight into the cell-specific functions 
of endothelial cell-expressed LSP1 in regulating GATA-2-dependent vascular PECAM-1 
expression. These altered PECAM-1 expression answers many questions, at least in part, regarding 
how LSP1 deficiency regulates endothelial functions such as maintenance of endothelial integrity, 
endothelial cell migration, neutrophil transendothelial migration and even expression of α6β1 
integrin on the surface of extravasated neutrophils. 
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5.0 PHOSPHORYLATED LEUKOCYTE-SPECIFIC PROTEIN 1 
(LSP1) INTERACTS WITH MOESIN IN ENDOTHELIAL CELLS 
TO REGULATE VASCULAR PERMEABILITY 
 
Data presented in this chapter were used in a manuscript entitled “ICAM-1 cross-linking-
mediated LSP1-moesin interaction regulates endothelial permeability” to be submitted soon by 
Mokarram Hossain, Syed M. Qadri and Lixin Liu.   
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5.0 PHOSPHORYLATED LEUKOCYTE-SPECIFIC PROTEIN 1 
(LSP1) INTERACTS WITH MOESIN IN ENDOTHELIAL CELLS 
TO REGULATE VASCULAR PERMEABILITY 
 Leukocyte-specific protein 1 (LSP1) expressed in both leukocytes and endothelial cells 
interacts with cytoskeletal proteins, regulates cytoskeletal rearrangement and is an important 
regulator of endothelial permeability [136, 139]. While endothelial LSP1 was shown to be 
important for histamine-induced endothelial hypermeability, it was also reported to prevent 
neutrophil transmigration-mediated vascular leakage [37, 136]. However, the mechanistic role of 
LSP1 in regulating endothelial permeability is yet to be elucidated. Leukocyte-endothelial cell 
interactions involve very complex interactions of many adhesion molecules and are capable of 
initiating a wide range of signaling cascades in endothelial cells. In this study, we explored the 
molecular mechanisms of how endothelial cell-expressed LSP1 modulates endothelial 
permeability in a stimulus-specific manner. 
5.1 LSP1 interacts with moesin in HEK 293T and endothelial cells 
It is well known that during neutrophil adhesion, ICAM-1 clustering controls the 
cytoskeletal structure of endothelial cells very precisely by interacting, activating and recruiting 
many proteins capable of reorganizing endothelial cytoskeleton such as ERM 
(ezrin/radixin/moesin) proteins, myosin II, -actin and LSP1 ([44, 223]; Figure 3.5). All of these 
proteins are well known for regulating endothelial permeability usually by regulating contraction 
of endothelial cells. However, none of them can regulate cell shape independently; they either need 
to get activated by other signaling proteins or interact and collaborate with other proteins. ERMs 
are capable of remodeling the actin cytoskeleton, however, they lack F-actin cross-linking or 
branch-forming abilities [176]. Moreover, ERMs were reported to be abundantly present at both 
the uropod of T-lymphocytes and docking structures in endothelium [178, 179]. LSP1 was also 
reported to be necessary for endothelial dome formation during neutrophil transmigration [37]. 
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Figure 5.1: LSP1 interacts with moesin both in HEK 293T and endothelial cells. (A) HEK239T 
cells were transfected with His-LSP1, GFP-Moesin or co-transfected with His-LSP1 and GFP-
Moesin. After 24 hours, His-LSP1 was immunoprecipitated with rabbit-α-LSP1 serum and 
immunodetected by an anti-GFP antibody. Representative blots from one of the three independent 
experiments are shown. (B) Left panel: EE2 cells were treated with or without TNF-α (4h) before 
cross-linking endothelial surface ICAM-1 with rat-α-ICAM-1 primary (30 min) and goat-α-rat 
secondary antibodies (30 min). After ICAM-1 cross-linking, cells were lysed, LSP1 was 
immunoprecipitated with rabbit-α-LSP1 serum and immunoblotted with anti-moesin antibody. 
Representative blots from one of the three independent experiments are shown. Right panel: 
densitometric analysis of the relative abundance of moesin over β-actin. Data are means ± SD (n 
= 3). * indicates significant difference (P < 0.05) in comparison to control (ANOVA).   
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B 
73 
 
Therefore, we explored whether LSP1 interacts with moesin, the major (> 90% or the total 
ERM proteins) endothelial ERM protein. We overexpressed both His-LSP1 and GFP-moesin in 
HEK 293T cells. Pull-down of His-tagged LSP1 protein following immunoblotting with anti-GFP 
antibody provided the indication of this novel interaction (Figure 5.1A). In endothelial cells, we 
first explored whether constitutively expressed LSP1 and moesin interact with each other. To this 
end, we treated endothelial cells with or without a wide range of stimuli which were previously 
reported to activate endothelial LSP1 or moesin to address whether the potential interaction is 
stimuli-specific or not. Our results in Figure 5.1B show that constitutively expressed LSP1 and 
moesin interact in endothelial cells.  However, unlike LSP1- and moesin-overexpressing HEK 
293T cells, this interaction takes place only upon ICAM-1 cross-linking (Figure 5.1B) which is 
largely regarded as equivalent to leukocyte adhesion onto endothelial cells [224]. These findings 
indicate that LSP1 interacts with moesin and LSP1 phosphorylation is probably required for this 
interaction because ICAM-1 cross-linking is necessary for LSP1 (Figure 3.5) but not for moeisn 
phosphorylation.   
5.2 LSP1-moesin interaction enhances moesin but not LSP1 phosphorylation 
Protein-protein interactions often regulate phosphorylation of the interacting protein(s) 
either by acting as a kinase or a scaffold that can bring a substrate to its kinase in close proximity 
[225, 226]. Therefore, we investigated whether this interaction affects phosphorylation level of 
LSP1, moesin or both of them. In a series of experiments, we cross-linked ICAM-1 in TNF--
treated endothelial cells which were transfected with or without silencing RNA targeting LSP1 or 
moesin. Then, we compared the relative phosphorylation of LSP1 before and after moesin 
silencing and moesin phosphorylation before and after LSP1 silencing.  
Figure 5.2A clearly shows that this interaction does not affect LSP1 phosphorylation at all 
indicating LSP1 phosphorylation to be either upstream or independent of this interaction. 
However, LSP1-moesin interaction is capable of increasing the level of moesin phosphorylation, 
even though, it is not required for moesin phosphorylation in endothelial cells (Figure 5.2B). 
Phosphorylation of endothelial LSP1 is quite unique and requires ICAM-1 clustering. Moesin 
phosphorylation, on the other hand, is easily achieved by treating the cells with TNF- alone. In 
our experiment design, cells were treated with TNF- before ICAM-1 was cross-linked. TNF- 
pretreatment was sufficient to phosphorylate moesin (Figure 5.2B) whereas ICAM-1 cross-linking 
was necessary for LSP1 phosphorylation (Figure 3.5). 
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Figure 5.2: LSP1-moesin interaction enhances moesin but not LSP1 phosphorylation. (A) Left 
panel: original dual immunoblots (representative of 3 similar experiments) demonstrating 
expression of phosphorylated LSP1 (p-LSP1, Alexa Fluor 488, green), total LSP1 (LSP1, Alexa 
Fluor 647, red), and overlap of phosphorylated LSP1 and total LSP1 (p-LSP1 + LSP1, yellow) in 
moesin silenced or WT endothelial cells after ICAM-1 cross-linking. Right panel: densitometric 
analysis of the abundance of phosphorylated LSP1 relative to total LSP1 in moesin silenced or 
WT endothelial cells after ICAM-1 cross-linking. Values are means ± SD (n = 3). (B) Left panel: 
original immunoblots (representative of 3 similar experiments) demonstrating expression of 
phosphorylated moesin (p-moesin), total moesin (moesin) and β-actin in LSP1 silenced or WT 
endothelial cells before or after treatment with TNF-α, or ICAM-1 cross-linking before or after 
TNF-α treatment. Right panel: densitometric analysis of abundance of phosphorylated moesin and 
total moesin relative to β-actin in LSP1 silenced or WT endothelial cells before or after treatment 
with TNF-α, or ICAM-1 cross-linking before or after TNF-α treatment. Values are means ± SD (n 
= 3). Significantly different from untreated cells (**P < 0.01) or from TNF-α + ICAM-1 cross-
linking before moesin silencing (#P < 0.05) (ANOVA). 
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LSP1 phosphorylation was unaffected by the presence or absence of its binding partner 
moesin (Figure 5.2A) suggesting LSP1 phosphorylation to be independent or upstream of this 
interaction. Absence of LSP1, however, significantly reduced moesin phosphorylation (Figure 
5.2B) even though LSP1 is not a kinase itself. This observation indicates that LSP1 acts as a 
scaffold or at least a component of a scaffold that can recruit both moesin and the upstream effector 
kinase(s) necessary for moesin phosphorylation. In dendritic cells LSP1 was indeed shown to 
interact with scaffolds KSR1 and CNK in DC-SIGN signalosome where LSP1 is required for the 
recruitment of Raf-1 and its effector LARG and Rho A and subsequent Raf-1 phosphorylation 
upon mannose-expressing microbial challenge [165]. ERM proteins are well known substrates of 
Rho kinase, however, whether LSP1 aids moesin phosphorylation by bringing them together is yet 
to be explored.  
5.3 Both p38 MAPK and Rho kinase pathways are involved in LSP1-moesin 
interaction 
Activation of endothelial LSP1 is mainly mediated by p38 MAPK whereas moesin can be 
activated by p38 MAPK and Rho kinases. Thus, we investigated whether either of these two 
pathways is involved in the regulation of LSP1-moesin interaction and if this interaction is 
upstream or downstream of these kinases in endothelial cells. In this regard, we treated the cells 
with pharmacological inhibitors of p38 MAPK (SB 203580) and Rho kinase (Y-27632 and C3 
transferase) before measuring this interaction.   
From our results, it is evident that inhibition of either of these pathways blunts this 
interaction significantly (Figure 5.3). However, p38 MAPK pathway plays a more prominent role 
in this interaction (Figure 5.3). These results suggest that both p38 MAPK and Rho kinase 
pathways regulate this interaction and are upstream of this interaction indicating that LSP1 and 
moesin interact with each other upon activation. Phosphorylation may change the physico-
chemical properties, stability, kinetics, and dynamics of a protein [227]. By activating or inhibiting 
protein functions, phosphorylation regulates many cellular processes. Recent studies involving 
phosphoproteomic analyses have revealed that the majority of mammalian proteins are modified 
by transient phosphorylation [226, 228, 229] which suggests that the regulatory property of protein 
phosphorylation to be very extensive. Phosphorylation is also known to regulate the nature and the 
strength of protein-protein interactions either directly when phosphorylation takes place at a site 
close to the binding site or via allosteric mechanism when phosphorylation occurs at site distant 
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from the binding site [226, 230, 231]. Phosphorylation of LSP1 (Figure 3.5) and LSP1-moesin 
interaction both require ICAM-1 cross-linking. Moreover, LSP1-moesin interaction enhances 
moesin phosphorylation without affecting LSP1 phosphorylation at all. This observation confirms 
that ICAM-1 cross-linking-mediated LSP1 phosphorylation is necessary for LSP1-moesin 
interaction in endothelial cells. 
 
Figure 5.3: Both p38 MAPK and Rho kinase pathways regulate LSP1-moesin interaction. Left 
panel: endothelial cells were treated with TNF-α (4h) before cross-linking endothelial surface 
ICAM-1 with rat-α-ICAM-1 primary (30 min) and goat-α-rat secondary antibody (30 min). Cells 
were treated with SB 203850, Y-27632 and Rho inhibitor I (C3 transferease) right before ICAM-
1 cross-linking. After ICAM-1 cross-linking cells were lysed, LSP1 was immunoprecipitated with 
rabbit-α-LSP1 serum and immunoblotted with anti-Moesin antibody. Right panel: densitometric 
analysis of the relative abundance of moesin over β-actin. Data are means ± SD (n = 3). Significant 
difference from control (**P < 0.01; ***P < 0.001) in comparison to control (ANOVA). 
 
5.4 LSP1-moesin interaction helps regulate endothelial permeability  
 Endothelial LSP1-deficiency was reported to impair histamine-induced endothelial 
permeability in vivo which is mediated by endothelial cell contraction [136]. However, neutrophil 
migration-induced endothelial hypermeability usually mediated by endothelial injury was 
significantly higher in LSP1-deficient mice [37]. This clear contrast in the role of LSP1 in 
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stimulus-specific endothelial hypermeability and the well-known ability of both LSP1 and moesin 
to remodel cellular shape (cytoskeleton) prompted us to determine the effect of LSP1-moesin 
interaction on endothelial permeability. TNF- treatment resulted in a steady increase in 
endothelial permeability of FITC-albumin in EE2 cells before LSP1 or moesin silencing (Figure 
5.4A).  
 
Figure 5.4: Lack of LSP1-moesin interaction impairs ICAM-1 cross-linking-mediated 
endothelial hepermeability. EE2 cells were grown to confluence on Transwell insert membranes 
before or after silencing the genes of interests. Cells were treated with or without TNF- (20 ng/ml; 
4 hours) before ICAM-1 cross-linking for 30-60 min (A-B) or neutrophils were allowed to 
transmigrate across the endothelial monolayer along a MIP-2 gradient for 60 min (B). FITC-
albumin (200 μg/ml) was placed in the upper chamber, and samples of medium from both the 
upper and lower chambers were then taken at indicated time points. FITC-albumin contents in the 
upper and lower chambers was measured in a plate reader in the beginning and end of each time 
points. Data are means ± SD (n = 3-4). (A) Significant difference from control (***P < 0.001), 
TNF- control (P < 0.05; P < 0.01; P < 0.001) or scrambled siRNA treatment (#P < 0.05; ##P 
< 0.01) (ANOVA). (B) Significant difference from scrambled siRNA treatment (*P < 0.05; **P < 
0.01), ICAM-1 cross-linking (##P < 0.01) (ANOVA). 
 
However, this TNF--mediated hypermeability was less prominent in LSP1- or moesin-
silenced EE2 cells. ICAM-1 cross-linking following TNF--treatment significantly increased 
permeability of EE2 cells before LSP1- or moesin-silencing but not after silencing LSP1 or moesin 
(Figure 5.4A). Interestingly, when neutrophils were allowed to transmigrate across these EE2 cells 
in place of ICAM-1 cross-linking after TNF--treatment, permeability increase was significantly 
A B 
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higher in LSP1- and GATA-2- but not moesin-silenced cells compared to the non-targeting 
siRNA-treated cells (Figure 5.4B). It is known that vascular leakage induced by different type of 
stimuli is mediated by different molecular mechanisms. These complicated findings suggest that 
LSP1 plays a differential role likely via different pathways in regulating vascular leakage. 
Hypermeability inducing agents capable of modulating cell shape such as histamine and ICAM-1 
clustering utilize LSP1-moesin interaction and related pathway. Taken together, these observations 
confirm that LSP1-moesin interaction plays a crucial role in LSP1-mediated regulation of 
endothelial permeability. On the other hand, neutrophil-mediated endothelial injury causes direct 
endothelial cell detachment by damaging the endothelial junctional proteins like VE-cadherin and 
PECAM-1 [6]. Because we know that LSP1-deficient endothelial cells express significantly lower 
level of PECAM-1 (Figure 4.5), PECAM-1-deficiency makes the LSP1-deficient cells more 
vulnerable to injury-mediated hypermeability.  
5.5 Summary 
Both LSP1 and moesin are capable of interacting with cellular actin cytoskeleton and 
remodel it. Here, we report for the first time that LSP1 and moesin interact with each other in 
endothelial cells. LSP1-moesin interaction is regulated by p38 MAPK and Rho kinase pathways 
and phosphorylation of LSP1 is necessary for this interaction. This interaction plays a major role 
in regulating endothelial permeability primarily by modulating endothelial cell contraction.  
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6.0 SUMOYLATION PROTECTS ENDOTHELIAL LSP1 FROM 
UBIQUITINATION-MEDIATED PROTEASOMAL DEGRADATION 
AND PROMOTES ITS NUCLEAR EXPORT 
 
 
Data presented in this chapter were used in a manuscript entitled “SUMOylation protects 
endothelial LSP1 from ubiquitination-mediated proteasomal degradation and helps its nuclear 
export” (currently in revision in The Journal of Biological Chemistry) prepared by Mokarram 
Hossain, Jiannan Huang, Francisco S. Cayabyab and Lixin Liu.   
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6.0 SUMOYLATION PROTECTS ENDOTHELIAL LSP1 FROM 
UBIQUITINATION-MEDIATED PROTEASOMAL DEGRADATION 
AND PROMOTES ITS NUCLEAR EXPORT 
The mouse LSP1, with 330 amino acids, is predicted to be 37 kDa in molecular weight 
[130]. However, in Western blotting, LSP1 has always been detected at a much higher molecular 
weight range (˃50 kDa) both in leukocytes and endothelial cells [130, 141, 143, 182]. 
Posttranslational modifications often result in uplift of molecular weight of the modified proteins 
[81, 183] and are linked to compartmentalization and translocation of many proteins [88, 184, 
185]. This discrepancy in LSP1 molecular weight (15 kDa) and its characteristic distribution 
pattern in endothelial cells and nucleus-to-extranuclear translocation upon endothelial stimulation 
with TNF-α [37] indicate ‘SUMOylation’ to be the most likely posttranslational modifications of 
LSP1. Scarcity of information regarding posttranslational modifications of LSP1, despite having 
multiple indications like the ones mentioned above, prompted us to explore the possibility of LSP1 
SUMOylation in endothelial cells and determine whether SUMOylation-mediates changes in 
LSP1 function. 
6.1 LSP1 is modified by SUMO1 in endothelial cells and HEK 293T cells 
Even after having multiple indications (as mentioned above), nothing is known about 
posttranslational modifications of endothelial cell-expressed LSP1. Using anti-LSP1 rabbit sera, 
we detected three distinct bands at 37 kDa, 45 kDa and 52 kDa molecular weight range in mouse 
primary endothelial cells isolated from lungs (LVEC) or hearts (HVEC) and in untransfected as 
well as LSP1-overexpressed endothelial cell line (EE2) cells (Figure 6.1A). This indicates post-
translational modifications of LSP1 or non-specific nature of the antibody. To address this issue, 
we excised the respective bands from Coomassie blue-stained gel and performed mass 
spectrometric analysis. Mass spectrometry confirmed the presence of LSP1 in 37 kDa band 
(Mowse/ions score: 89; queries matched: 2; sequence coverage: 7%; pI/mol wt: 4.7/36.7) and 52 
kDa band ((Mowse/ions score: 98; queries matched: 3; sequence coverage: 11%; pI/mol wt: 
4.7/36.7). Ion score is −10×log (P), where P is the probability that the match is a random event. 
Individual ion score >32 indicates identity or extensive homology (P < 0.05)). However, mass 
spectrometric analysis of the 45 kDa band was unsuccessful. Immunoblotting of pulled-down His-
tagged proteins from His-LSP1- and SUMO1-overexpressed EE2 cells using monoclonal anti-
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SUMO1 antibody revealed a single band at 52 kDa indicating this band to be SUMO1-LSP1 
conjugate (Fig. 1A). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: LSP1 is modified by SUMO1. (A) Representative (n = 3) original Western blots 
showing LSP1 protein expression in murine primary vascular endothelial cells isolated from heart 
(HVEC) and lungs (LVEC) of 129/SvJ mice and untransfected murine endothelial cell line (EE2) 
cells (left); LSP1 (middle) and SUMO1 (right) protein expression in pulled-down His-tagged 
proteins from His-LSP1- and SUMO1-overexpressed EE2 cells. Arrow indicates LSP1 or 
SUMO1-LSP1 conjugate and * indicates an unknown signal. (B) Representative (n = 3) confocal 
images of LSP1 (Green; left), SUMO1 (Red; middle) and overlay (right) in LSP1- and SUMO1-
overexpressed EE2 cells. (C) Representative (n = 3) original Western blot showing SUMO1 (top) 
and His (middle) protein expression in pulled-down His-tagged proteins and β-actin (bottom) 
protein expression in the whole cell lysate from His-LSP1- or  His-LSP1 and SUMO1-
overexpressed HEK 293T cells. Arrow indicates His or SUMO1-His conjugate and * indicates an 
unknown signal.  
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For a SUMOylated protein, relative abundance of the SUMOylated fraction is usually quite 
low though the opposite report is also available [83]. This relative abundance may also vary 
depending on the cell lysis procedure and the type of lysis buffer being used [83]. GFP-LSP1 and 
SUMO1 co-localization was also confirmed by confocal microscopy of GFP-LSP1 and SUMO1 
co-transfected EE2 cells (Figure 6.1B). 
Moreover, we examined SUMOylation of LSP1 with SUMO1 in His-LSP1 and SUMO1-
overexpressed HEK 293T cells. In these cells, LSP1 was SUMOylated by SUMO1 and its 
SUMOylation was further enhanced by co-transfection of SUMO1 (Figure 6.1C).  Taken together, 
the data suggest that LSP1 is SUMOylated by SUMO1. 
6.2 LSP1 SUMOylation is aided by Ubc9 and deSUMOylation is mediated by SENP1 
SUMOylation is catalyzed by a series of enzymes. SUMO is first activated by E1 enzymes 
(SAE1/SAE2), Ubc9 is the only E2 conjugating enzyme that precisely directs a SUMO molecule 
towards a specific target protein and E3 ligase enzymes (PIAS proteins) are important for the 
efficiency of SUMOylation [81, 96, 99, 232]. To study whether Ubc9 acts as the SUMO 
conjugating enzyme for LSP1, we co-expressed SUMO1 and His-LSP1 with or without Ubc9 in 
HEK 293T cells. Immunoblotting clearly showed that co-transfection of Ubc9 increased 
SUMOylation of His-LSP1 (Figure 6.2A, left panel) suggesting Ubc9 as the SUMO1 conjugating 
enzyme for LSP1.  
SUMOylation is reversible and SUMO is removed from target proteins by specific SUMO 
proteases (SENPs) in an ATP-dependent manner. SENP1 is the protease responsible for the 
cleavage of SUMO1 [233]. To examine whether SENP1 can affect SUMOylation of LSP1, we co-
expressed His-tagged LSP1 and SUMO1 in the presence or absence of SENP1 in HEK 293T cells. 
As shown in Figure 6.2A (right panel), the SUMOylated band of LSP1 was substantially reduced 
in cells transfected with SENP1 indicating SENP1 to be involved in the deSUMOylation of LSP1. 
We observed very similar effect of Ubc9 and SENP1 upon their overexpression in EE2 
endothelial cells (Figure 6.2B). These results provide clear evidence of Ubc9 and SENP1 being 
SUMO conjugase and protease, respectively, for LSP1 SUMOylation.  
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Figure 6.2: Ubc9 acts as SUMO conjugase and SENP1 as SUMO protease for LSP1. (A) Pulled-
down His-tagged proteins from His-LSP1 and SUMO1-; His-LSP1, SUMO1 and Ubc9- or His-
LSP1, SUMO1 and SENP1-overexpressed HEK 293T cells were immunoblotted with a 
monoclonal anti-SUMO1 or a polyclonal anti-His antibody. β-actin in the whole cell lysate was 
detected to ensure equal amount of total proteins was used for pulling down His-tagged proteins. 
Co-expression of Ubc9 (left) and SENP1 (right) substantially increased and decreased the LSP1-
SUMO-1 conjugation, respectively (n = 3). Arrow indicates His or SUMO1-His conjugate and * 
indicates an unknown signal. (B) Pulled-down His-tagged proteins from His-LSP1 and SUMO1-; 
His-LSP1, SUMO1 and Ubc9-; His-LSP1, SUMO1 and SENP1- or His-LSP1-overexpressed EE2 
cells were immunoblotted with anti-LSP1 rabbit serum. β-actin in the whole cell lysate was 
detected to ensure equal amount of total proteins was used for pulling down His-tagged proteins. 
Co-expression of SUMO1 and SENP1 significantly increased and reduced the LSP1-SUMO1 
conjugation respectively (n = 3). Arrow indicates LSP1 or SUMO1-LSP1 conjugate and * 
indicates an unknown signal. 
 
6.3 K270 and K318 are the primary sites of LSP1 SUMOylation 
Having determined the posttranslational modification of LSP1 by SUMO1, we then 
examined the SUMO1 acceptor sites in LSP1. Mouse LSP1 does not have any generally known 
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consensus motif (ΨKxD/E) for SUMOylation. However, recent advancement of SUMOylation 
studies has revealed that this so-called consensus motif is not always necessary for SUMOylation. 
A number of proteins e.g., C-terminal-binding protein 2 (CtBP2), murine double minute 2 (Mdm2) 
and death-associated protein 6 (Daxx) that are lacking this motif can be SUMOylated [102-104] 
whereas even mutation of consensus motif cannot block SUMOylation of some other proteins such 
as proliferating cell nuclear antigen (PCNA) [234]. Moreover, a recent study has also identified 
some other SUMOylation motifs [235]. Therefore, in this study, we performed bioinformatic 
screening using SUMOplot™ (http://www.abgent.com/sumoplot), as described previously [88, 
89, 236], to identify the most likely SUMO acceptor sites in LSP1. This screening revealed that 
K318 is the sole high probability SUMOylation site in the mouse LSP1 whereas in human LSP1, 
K279 and K327 are the high probability SUMOylation sites (Table 6.1).  
Thus, in addition to K318, we considered K270, the well conserved murine analog of K279 
of human LSP1 as the potential SUMOylation sites for mouse LSP1. Therefore, we performed 
site-directed mutagenesis of 270K→A (alanine), designated as His-LSP1K270A and 318K→A, 
designated as His-LSP1K318A in His-tagged LSP1 plasmids using PCR. Additionally, we randomly 
mutated K321 (321K→A, designated as His-LSP1K321A) in mouse LSP1 to ensure that the 
mutation itself does not affect LSP1 expression. Expression of these mutants in HEK 293T cells 
led to the identification of K270 and K318 as the primary SUMOylation sites for mouse LSP1 
(Figure 6.3). 
 
Table 6.1: The high probability SUMO1 acceptor sites in mouse and human LSP1 as predicted 
by SUMOplot™ 
No. Species Position Group Score 
1 
Mouse 
Human 
K318 
K327 
VATGH GKYE KVLVD 
VATGH GKYE KVLVE 
0.67 
0.67 
2 
Mouse 
Human 
K270 
K279 
QSQSA SKTP SCQDI 
QAQSA AKTP SCKDI 
--- 
0.69 
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Figure 6.3: Lysine residues 270 and 318 are the primary sites of LSP1 SUMOylation. Pulled-
down His-tagged proteins from SUMO1, Ubc9 and His-LSP1- or His-LSP1K270A- or His-
LSP1K318A- or His-LSP1K321A-co-expressed HEK 293T cells were immunoblotted with a 
monoclonal anti-SUMO1 or a polyclonal anti-His antibody. β-actin in the whole cell lysate was 
detected to ensure equal amount of total proteins was used for pulling down His-tagged proteins 
(n = 3). Arrow indicates His or SUMO1-His conjugate and * indicates an unknown signal. 
 
6.4 DeSUMOylation affects LSP1 stability 
SUMOylation is reported to affect a number of functions of the modified proteins; most 
notable of them are protein stability, nuclear localization of proteins, nuclear-cytosolic transport, 
and regulation of transcriptional activity [237-239]. At 24 hours of transfection, His-tagged protein 
band at 52 kDa was remarkably reduced in His-LSP1K270A and His-LSP1K318A transfected or His-
LSP1 and SENP1 cotransfected HEK 293T cells compared to His-LSP1 transfected cells. 
Intriguingly, there was no corresponding increase in the 37 kDa His-tagged protein band in these 
cells (Figure 6.3) indicating the fact that deSUMOylation of LSP1 either by mutation of 
SUMOylation sites or by the action of SENP1 resulted in reduced steady-state level of LSP1. To 
this end, HEK 293T cells were transfected with equal amount of His-LSP1 or His-LSP1K270A 
plasmids. Indeed, His-LSP1K270A transfected cells yielded significantly lower level of LSP1 
protein in total cell lysates compared to His-LSP1 transfected cells over a series of plasmid 
concentrations (Figure 6.4A). This observation indicates that reduction in SUMOyation decreases 
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steady-state protein level of LSP1. Steady-state protein level is altered because of the changes in 
either protein synthesis or protein degradation [240].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: DeSUMOylated LSP1 has reduced protein levels and stability. (A) HEK 293T cells 
were transfected with a range (1-10 µg) of His-LSP1 or His-LSP1K270A plasmid quantity. Twelve 
hours after transfection, cells were lysed and proteins were immunoblotted with a polyclonal anti-
LSP1 antibody (left). Blots were analyzed by densitometry; results (means ± SD; n = 3) of three 
independent experiments were plotted as arbitrary unit (right). * (P < 0.05), ** (P < 0.01) and *** 
(P < 0.001) from WT LSP1. (B) Twelve hours after His-LSP1 or His-LSP1K270A transfection, HEK 
293T cells were treated with 100 mg/ml cycloheximide (CHX) for the indicated time periods. Cells 
were lysed and proteins were immunoblotted using anti-LSP1 antibody (relative to β-actin; left). 
Blots were analyzed by densitometry; results (means ± SD; n = 3) of three independent 
experiments were plotted as arbitrary unit (relative to initial time points) and half-lives (t1/2) were 
calculated by linear regression analysis of the fitted curves (right).  
 
We then explored the role of SUMOylation on LSP1 stability. WT His-LSP1 or His-
LSP1K270A plasmids were transfected into HEK 293T cells. After 12 hours, cells were treated with 
cycloheximide for different time points to block any further protein synthesis. This is a commonly 
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used technique to follow the degradation kinetics of a particular protein over a certain period of 
time [81, 88, 89, 196]. Cycloheximide treated cells were lysed at indicated time points and 
immunoblotted with anti-LSP1 antibody. Densitometric quantification of the detected bands 
revealed that the mutant LSP1 was degraded at a much faster rate than its WT counterpart. Half-
lives of WT and mutant LSP1 were calculated from the fitted curves obtained by linear regression 
analysis of these densitometric data. Half-life of the mutant LSP1 was only 4.3 hours as opposed 
to the half-life of the WT LSP1 (9.6 hours) (Figure 6.4B). Moreover, to determine whether 
mutation of SUMOylation site affected the expression of LSP1, we measured the mRNA level in 
His-LSP1 or His-LSP1K270A plasmid transfected HEK 293T cells. Levels of LSP1 mRNA 
expression did not differ in WT or mutant LSP1 plasmid transfected HEK 293T cells at 12 hours 
after transfection (Figure 6.5A). These results indicate that the deSUMOylation-induced reduction 
of steady-state LSP1 level was related to increased degradation of LSP1 proteins.  
6.5 Inhibition of SUMOylation accelerates ubiquitination-mediated proteasomal 
degradation of endothelial LSP1 
Proteasomal degradation is one of the major pathways for the degradation of proteins in 
eukaryotic cells. To determine whether the deSUMOylated LSP1 is undergoing proteasomal 
degradation, HEK 293T cells were transfected with His-LSP1, His-LSP1K270A or co-transfected 
with His-LSP1 and SENP1 followed by treatment with  or without proteasome inhibitor MG132 
(10 μM) for 12 hours. Immunoblotting of pulled-down His-tagged proteins with anti-LSP1 rabbit 
serum clearly shows that in the absence of MG132 treatment, LSP1 degrades at a much faster rate 
when SUMOylation is inhibited by mutation of the SUMOylation site or by co-expressing SENP1. 
MG132 treatment recovered both WT and mutant LSP1 from proteasomal degradation, however, 
the recovery in the mutant group was more dramatic (Figure 6.5B).  
In eukaryotic cells, polyubiquitination often directs a protein to proteasomal degradation. 
To investigate the involvement of the ubiquitin-proteasome pathway in the accelerated degradation 
of deSUMOylated LSP1, HEK 293T cells were co-transfected with His-LSP1 or His-LSP1K270A 
and HA-tagged ubiquitin followed by treatment with  or without proteasome inhibitor MG132 
(10μM) for 12 hours. Immunoblotting of purified His-tagged proteins with anti-ubiquitin antibody 
revealed that without MG132 treatment, ubiquitination of the mutant LSP1 was much higher 
relative to WT LSP1 (Figure 6.5C). With MG132 treatment, very high level of ubiquitination was 
observed in mutant LSP1 compared to that of without MG132 treatment (Figure 6.5C). For the 
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WT LSP1, MG132 treatment caused a slight increase in ubiquitination compared to without 
MG132 treatment. Taken together, these results indicate that SUMOylation protetcts LSP1 from 
proteasomal degradation which is consistent with a number of previous reports [81, 197, 240]. 
Immunoblotting of His-tagged proteins pulled-down from His-LSP1K270A and His-LSP1K318A 
transfected or His-LSP1 and SENP1 cotransfected HEK 293T cells in the presence or absence of 
proteasome inhibitor MG132 with anti-LSP1 rabbit serum revealed that rapid degradation of 
deSUMOylated LSP1 can be inhibited by proteasome inhibitor MG132. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: DeSUMOylation leads to polyubiquitination and subsequent proteasomal 
degradation of LSP1. (A) Means ± SD of mRNA levels (n = 3) encoding LSP1 in His-LSP1- or 
His-LSP1K270A-transfected HEK 293T cells. (B) HEK 293T cells were transfected with His-LSP1 
and SUMO1; His-LSP1, SUMO1 and SENP1 or His-LSP1K270A and SUMO1 plasmids. After 12 
h, cells were treated with or without 10 µM MG132 for 12 h and lysed and proteins were 
immunoblotted with anti-LSP1 antibody (relative to β-actin; n = 3). (C) HEK 293T cells were 
transfected with His-LSP1, SUMO1 and HA-Ub; His-LSP1, SUMO1, SENP1 and HA-Ub or His-
LSP1K270A, SUMO1 and HA-Ub plasmids. After 12 h, cells were treated with or without µM 
MG132 for 12 h and lysed and proteins were immunoblotted with anti-ubiquitin antibody (relative 
to β-actin; n = 3). 
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Because ubiquitination is well known for directing the modified proteins to proteasomal 
degradation, we explored whether LSP1 is modified by ubiquitin in the presence or absence of 
proteasome inhibitor. Acceleration of ubiquitination pathway by overexpressing ubiquitin led to 
the identification of LSP1 ubiquitination which was increased in the presence of MG132. 
Moreover, at the earlier stages of expression, deSUMOylated LSP1 shows high level of 
ubiquitination which increases dramatically at later stages but visible only in the presence of 
MG132 (Figure 6.5C). This observation is in agreement with some previous reports showing that 
the attachment of SUMO-1 to proteins prevents their ubiquitination and subsequent proteasomal 
degradation either by blocking the ubiquitination site [241] or by making the ubiquitin binding site 
inaccessible to the ubiquitin machinery [240, 242]. For LSP1, the latter is more appropriate since 
SUMO and ubiquitin do not compete for the same lysine residue. These results also clarify that 
the stability of LSP1 is regulated by the interplay between its SUMOylation and ubiquitination. 
6.6 SUMOylation deficiency impairs nucleus to extra-nuclear translocation of LSP1 
SUMOylation is reported, in numerous occasions, to be associated with 
compartmentalization [88, 184] and or translocation [239, 243] of many proteins. LSP1 in 
endothelial cells is distributed unequally in different compartments: nucleus being the major one 
[136]. Endothelial activation by TNF-α treatment causes translocation of some nuclear LSP1 into 
extranuclear compartments [37]. We also explored the possibility of SUMOyolation being a 
regulator of these LSP1 compartmentalization and translocation.  
We overexpressed WT LSP1 with or without SENP1 or mutant LSP1 in EE2 cells and 
treated them with or without TNF-α. Immunoblotting followed by sub-cellular fractionation of 
these cells shows the evidence of LSP1 SUMOylation in all the sub-cellular compartments 
analyzed (Figure 6.6A) although the majority of SUMOylated LSP1 in unstimulated endothelial 
cells remain in the nucleus. Interestingly, the expression of the mutant LSP1 was almost 
exclusively in the nucleus. Moreover, TNF-α-induced translocation of the mutant LSP1 from 
nuclear to extra-nuclear compartments was minimal (Figure 6.6A-C). Coexpression of SENP1 also 
appeared to inhibit this translocation of the WT LSP1. These observations suggest the involvement 
of SUMOylation in nucleus to extra-nuclear translocation of LSP1. 
 
 
 
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: SUMOylation deficiency impairs the nucleus-to-extranuclear translocation of 
LSP1. (A) EE2 cells were transfected with His-LSP1 and SENP1, His-LSP1 or His-LSP1K270A 
plasmids. After 12 h, cells were treated with or without TNF-α for 4 h. Six million cells from each 
group were then subjected to subcellular fractionation and four different fractions (in the sequential 
order of cytosolic, membrane, nuclear and cytoskeletal) were collected. Proteins from all four 
fractions were immunoblotted with anti-LSP1 rabbit serum (relative to β-actin in the cytosolic 
fraction; n = 3). Arrow indicates LSP1 or SUMO1-LSP1 conjugate and * indicates an unknown 
signal. (B) Densitometric analysis of SUMO1-LSP1 conjugate bands (52 kDa) and (C) 
densitometric analysis of LSP1 bands (37 kDa) in four subcellular fractions before and after TNF-
α treatment. Data are presented as means ± SD (n = 3) of three independent experiments. * (P < 
0.05), ** (P < 0.01) and *** (P < 0.001) compared to without TNF-α treatment. 
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6.7 Summary 
 The present study is the first to reveal the posttranslational modification of LSP1 by 
SUMO1. During SUMOylation and deSUMOylation of LSP1, Ubc9 acts as SUMO conjugating 
enzyme whereas SENP1 acts as a SUMO protease. Using bioinformatics screening and site-
directed mutagenesis, we identified two lysine residues (K270 and K318) in the C-terminus of 
LSP1 as the primary SUMOylation sites of LSP1. SUMOylation of LSP1 increases its stability by 
inhibiting ubiquitination-mediated rapid proteasomal degradation. This could be the reason for low 
relative abundance of the deSUMOylated LSP1 in endothelial cells at any given time. 
Additionally, SUMOylation is also important for the translocation of LSP1 from nucleus to 
extranuclear compartments. Whether posttranslational modification of LSP1 by SUMOylation 
represents a novel regulator of microvascular permeability and leukocyte infiltration in 
inflammatory diseases remains to be determined. 
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7.0 GENERAL DISCUSSION 
7.1 Endothelial cell-expressed LSP1 regulates endothelial functions  
 Despite being nearly identical, endothelial cell- and leukocyte-expressed LSP1 differ 
dramatically in their functions and subcellular distribution [37, 136, 137]. In leukocytes, LSP1 has 
been shown to either enhance or decrease adhesion, emigration, polarization, chemotaxis, F-actin 
polymerization and cytoskeletal remodeling [146-148, 208]. In endothelial cells, LSP1 is shown 
to play an important role in neutrophil transmigration and endothelial permeability. However, how 
endothelial cell-expressed LSP1 regulates these functions is not well understood. Moreover, 
whether endothelial cell-expressed LSP1 affects other steps of leukocyte recruitment and other 
endothelial cells functions have not been addressed. To study the cell-specific role of a protein, 
the use of endothelial cells and neutrophils from the respective gene knock-out and their WT 
counterpart is considered ideal. However, in this thesis, we used LSP1-silenced endothelial cells 
(EE2 cells) because of the difficulty in isolating adequate primary endothelial cells from mouse 
pups.  
7.1.1 Endothelial cell-expressed LSP1 in neutrophil adhesion and 
transmigration 
 Existing literature, albeit sometimes contradictory, supports the regulatory role of 
neutrophil-expressed LSP1 on adhesion as well as motility phenotype of neutrophils in vitro [146-
149, 208]. Using intravital microscopy, it was also reported that LSP1-deficiency in general 
reduces neutrophil adhesion [136]. To address these discrepancies, we measured the adhesion of 
WT as well as KO neutrophils onto WT or KO endothelial cells in vitro. We observed that both 
neutrophil- and endothelial cell-expressed LSP1 are important for neutrophil adhesion on 
endothelial monolayers. However, endothelial cell-expressed LSP1 contributes more to this 
function as depicted in Figure 4.3A. Using WT and LSP1 silenced EE2 cells and WT or LSP1-
deficient neutrophils, we have also studied cell-specific role of LSP1 in neutrophil transmigration 
across endothelial cell monolayers. Unlike adhesion, neutrophil transendothelial migration is 
regulated by endothelial cell- but not neutrophil-expressed LSP1 (Figure 4.3B).  
 In leukocytes, chemoattractant stimulation results in p38 MAPK-mediated upregulation 
of Mac-1 and RhoA-mediated LFA-1 activation [216, 244]. These adhesion molecules are crucial 
for neutrophil adhesion. In endothelial cells, however, chemoattractant treatment as well as 
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neutrophil adhesion can activate p38 MAPK with different consequences [210, 245, 246]; Figure 
3.2, Figure 3.3 and Figure 3.5). LSP1 is a well-known signaling molecule downstream of both p38 
MAPK and PKC pathways [153, 208]. Neutrophil-expressed LSP1 is efficiently activated by these 
kinases when neutrophils are treated with chemokines whereas LSP1 activation in endothelial cells 
requires p38 MAPK activation specifically following neutrophil adhesion (Figure 3.2 and Figure 
3.3). Being downstream of these kinases, it is likely that LSP1 affects neutrophil adhesion by 
modulating these signaling pathways. Neutrophil-expressed LSP1 is likely to be involved in earlier 
stages of adhesion since it is activated directly upon chemokine exposure. On the other hand, 
endothelial cell-expressed LSP1 is probably involved in the later stages of adhesion (firm 
adhesion) since its activation requires neutrophil adhesion onto endothelial cells. Delayed 
activation may underscore a more important role of endothelial cell-expressed LSP1 in the 
subsequent steps of leukocyte recruitment.  
 Neutrophil transendothelial migration involves complex interactions between 
neutrophil- and endothelial cell-expressed adhesion molecules and subsequent cellular signaling 
[40]. Efficient transmigration requires cytoskeletal remodeling in neutrophils for extending 
pseudopods in search for a suitable place and in endothelial cells for opening up cell-cell junctions 
or the formation of transmigratory dome-like structures [14]. LSP1 interacts with F-actin and 
remodels cellular cytoskeleton. It regulates transcellular neutrophil migration via aiding in the 
formation of transmigratory domes in endothelial cells [37]. However, in most vascular beds, 
transcellular neutrophil migration is a less prevalent event [247, 248]. A more prominent role of 
endothelial cells-expressed LSP1 in neutrophil transmigration suggests its involvement also in 
paracellular neutrophil transmigration. Paracellular transmigration is primarily regulated by 
junctional adhesion molecules such as PECAM-1 and intracellular signaling events that lead to 
cytoskeletal rearrangement to open up the endothelial cell-cell contacts [14, 40]. Here, we have 
demonstrated that endothelial cell-expressed LSP1 regulates endothelial PECAM-1 expression by 
transcriptional regulation of the transcription factor GATA-2 (Figure 4.5 and Figure 4.6). So, 
reduced expression of PECAM-1 in LSP1-deficient endothelium surely affects paracellular 
migration of neutrophils. Interaction of LSP1 with moesin (Figure 5.1), a cytoskeleton binding 
protein involved in cytoskeleton remodeling, results in endothelial cell shape changes favouring 
its paracellular or transcellular migration. Thus, activated LSP1 significantly contributes to 
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endothelial cell shape changes. Taken together, it is clear that LSP1 regulates neutrophil adhesion 
and transmigration through several distinct mechanisms. 
7.1.2 Endothelial cell-expressed LSP1 in endothelial cell permeability and 
migration 
 Endothelial cell permeability is differentially regulated by different stimuli [3]. Agents 
that are capable of regulating cell contraction (shape) such as histamine and bradykinin, increase 
endothelial permeability by opening up the cell-cell contact. On the contrary, damages to the 
endothelium by oxidants released from activated neutrophils or by thermal injury cause endothelial 
cell death and detachment. Neutrophil transmigration-induced hypermeability was found to be 
higher in chimeric mice with WT neutrophils but selectively deficient in endothelial cell-expressed 
LSP1 compared to mice with LSP1-deficient neutrophils and WT endothelial cells when calculated 
as permeability changes per transmigrated neutrophil [37]. Depletion of neutrophils in both groups 
brought the permeability changes to identical level indicating an important but yet unknown 
interaction between neutrophils and endothelial cells (not neutrophil generated reactive oxygen 
species) is central to this permeability changes [37]. Histamine-induced endothelial permeability 
changes, however, have an opposite trend. Histamine-mediated hypermeability is mediated by 
endothelial cell retraction [3, 4]. This is found to be higher in WT mice compared to their LSP1-
deficient counterpart [136]. In our study, we used ICAM-1 cross-linking in TNF--treated 
endothelial monolayers or neutrophil migration in a MIP-2 gradient across endothelial monolayers 
before and after LSP1, moesin or GATA-2 silencing. We found striking differences in endothelial 
permeability changes between the neutrophil containing and lacking groups (Figure 5.4).  
 Neutrophil adhesion or transmigration is often associated with endothelial damage 
resulting in dysregulation of endothelial barrier function [249, 250]. Although neutrophil-
endothelial cell interactions initiate a large number of endothelial signaling pathways, vascular 
hypermeability mediated by activated neutrophils is historically credited to the disruption of 
endothelial barriers due to direct endothelial injury by neutrophil-derived reactive oxygen species 
and granular products [250]. PECAM-1 has been known for a long time to be linked to the 
regulation of endothelial barrier functions and vascular permeability changes [221, 251-253]. It is 
also known that PECAM-1 homophilic interaction but not PECAM-1-mediated endothelial 
signaling is crucial for maintaining endothelial permeability [253]. Reduced PECAM-1 expression 
in LSP1-deficient endothelial cells could explain the vulnerability of LSP1-deficient endothelium 
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to neutrophil transmigration-mediated hypermeability. In contrast, in the absence of neutrophils, 
ICAM-1 clustering-mediated endothelial hypermeability is significantly higher in WT or GATA-
2-silenced endothelial cells compared to LSP1- or moesin-silenced endothelial cells. During 
neutrophil-endothelial cell interactions, ICAM-1 engagement initiates many signaling pathways 
in endothelial cells including calcium signaling, activation of Rho kinase, PKC and p38 MAPK 
pathways [4, 7, 43, 254]. These pathways ultimately regulate endothelial cell retraction by 
remodeling intracellular cytoskeleton.  
 Taken together, our data confirms that in the absence of neutrophil adhesion or 
transmigration, endothelial cell-expressed LSP1 regulates endothelial permeability mainly by 
modulating endothelial cell retraction whereas in the presence of activated neutrophils, endothelial 
cell-expressed LSP1 regulates endothelial permeability mainly by affecting endothelial barrier 
function. More specifically, it reduces PECAM-1 homophilic interaction in the endothelial 
monolayer.   
7.2 Is nuclear localization of endothelial cell-expressed LSP1 
relevant to its function(s)?  
Endothelial cell contraction is crucial for paracellular migration and endothelial 
hypermeability, formation of docking structure that encapsulate transcellularly migrating 
neutrophils and endothelial cell migration requires rapid cytoskeletal remodeling. Upon activation, 
endothelial cell-expressed LSP1 per se or its interaction with moesin could regulate endothelial 
cell actin dynamics. It was reported that in TNF--treated endothelial cells, LSP1 migrates from 
nucleus to cytoskeletal compartment [37]. Based on this observation, Petri and colleagues [37] 
speculated that most of this cytoskeleton remodeling protein is stored in the nucleus away from 
cytoskeleton, like MK2 [255]. This is because LSP1 abundance could promote the formation of 
hair-like projections and adversely affect motility of other cell types [157, 158]. The exact reason 
for storing proteins in the nucleus is unknown. However, nuclear localization can serve as a 
temporary storage site for otherwise a very active protein or it may also imply that a particular 
protein has some function(s) in the nucleus. 
In this thesis, we found that both endothelial-specific PECAM-1 and GATA-2 were 
downregulated in LSP1 deficiency or upon LSP1 silencing whereas in LSP1-deficient neutrophils, 
PECAM-1 expression was unchanged. In light of the strategic nuclear localization of endothelial 
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LSP1 [136] in contrast to its cytosolic presence in neutrophils [146], it is intriguing to consider the 
role of endothelial-cell specificity of GATA-2 function [76, 216] in fostering cell-specific 
transcriptional regulation of PECAM-1 expression. Although more studies are needed to establish 
the exact nuclear function of endothelial cell-expressed LSP1, it can be concluded that nuclear 
LSP1 is not a mere stored inactive form of LSP1. Rather, it actively regulates the transcription of 
PECAM-1 by modulating GATA-2 expression in endothelial cells. There is no known DNA 
binding motif in LSP1. Therefore, it is difficult to speculate how LSP1 regulates GATA-2 
expression in endothelial cells. However, nuclear localization of endothelial cell-expressed LSP1 
and its ability to interact with a variety of signaling molecules tempted us to assume that LSP1 
may possibly regulate the expression of GATA-2 by 1) facilitating the activation of nuclear factor 
necessary for GATA-2 transcription, 2) binding to GATA-2 transcriptional repressor(s) thus 
making them unavailable, 3) making the DNA accessible to DNA polymerase via interacting with 
histone or even by 4) acting as a coactivator in GATA-2 transcription. Further research is necessary 
to examine which of these proposed mechanisms is operational in endothelial cells.  
7.3 Endothelial cell-expressed LSP1 functions require ICAM-1 
clustering-mediated phosphorylation  
LSP1 phosphorylation is considered to be functionally important for LSP1 activation 
which is evident from the fact that phosphorylated LSP1 is able to bind F-actin in lamellipodia of 
activated neutrophils while non-phosphorylated LSP1 fails to do so [208]. F-actin rich projections, 
cell motility and LSP1 were shown to be linked together which is important in health and disease 
[37, 141, 158]. LSP1 also plays an important role in cytoskeletal remodeling and motility of 
endothelial cells ([37]; Figure 4.1). Almost all of the functions of endothelial cell-expressed LSP1 
reported so far require endothelial shape change. LSP1 is important in transcellular neutrophil 
migration where it is necessary for the endothelial cells to form the docking structures via 
extending projections to the side of the neutrophils [37]. It also facilitates endothelial permeability 
increases in response to agents that increase endothelial permeability by contracting endothelial 
cells ([136]; Figure 5.4). In our studies, we have observed that ICAM-1 engagement-mediated 
permeability increase requires the interaction between LSP1 and moesin that does not exist in the 
absence of ICAM-1 clustering (Figure 5.1B). In leukocytes, LSP1 is phosphorylated very quickly 
when the cells are stimulated by soluble chemoattractants such as fMLP and chemokines [143, 
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153, 208]. On the contrary, ICAM-1-mediated neutrophil adhesion is essential for LSP1 
phosphorylation in endothelial cells (Figure 3.2, Figure 3.4 & Figure 3.5). The fact that ICAM-1 
engagement is required for both LSP1 phosphorylation and LSP1-moesin interaction related 
endothelial permeability changes indicates that LSP1 phosphorylation plays a key role in 
regulating cytoskeletal remodeling and contraction of endothelial cells. These results also provide 
the notion that LSP1-depndent endothelial cell motility or migration also relies on the 
phosphorylation of endothelial cell-expressed LSP1. So, LSP1 regulated endothelial functions are 
dependent on the phosphorylation of endothelial cell-expressed LSP1 which, in fact, relies mainly 
on ICAM-1 engagement.  
7.4 SUMOylation help maintain endothelial cell-expressed LSP1 
functions 
In spite of having a number of indications of probable post-translational modifications of 
endothelial cell-expressed LSP1 such as discrepancy in molecular weight (predicted versus 
presented in SDS-PAGE is 37 kDa versus 52 kDa; [130, 141, 143, 182]), predominant nuclear 
distribution [136] of endothelial LSP1 and its translocation from nucleus to extranuclear 
compartments upon TNF-α stimulation [37]; nothing is really known about any such 
modifications. The present work addresses this issue from the endothelial cell standpoint of 
phosphorylation of endothelial cell-expressed LSP1 (Chapter 03). Here, in addition to the well-
known 52-kDa form of LSP1, we have also detected a 37-kDa form of LSP1 in murine endothelial 
cells (Figure 6.1). Using recombinant LSP1, Ubc9, SENP1 and SUMO1 expression plasmids, we 
have successfully demonstrated that the abundant 52-kDa form of LSP1 was modified by SUMO1. 
For a SUMOylated protein, relative abundance of the SUMOylated fraction is usually quite low 
although the opposite result is also available [83]. This relative abundance may also vary 
depending on the cell lysis procedure and the type of lysis buffer being used [83]. Bioinformatic 
screening using SUMOplot™, as described previously [88, 89, 236], followed by site-directed 
mutation and immunoblotting, we successfully identified lysine 270 and 318 to be the primary 
SUMOylation sites for murine endothelial cell-expressed LSP1. 
SUMOylation is reported to affect a number of functions of the modified proteins; most 
notable of them are protein stability, nuclear-cytosolic transport, and the regulation of 
transcriptional activity [237-239]. We observed that deSUMOylation of LSP1 either by mutation 
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of SUMOylation sites or by the action of SENP1 resulted in reduced steady-state levels of LSP1 
even though mRNA level was identical in WT LSP1- or mutant LSP1K270A-transfected HEK 293T 
cells. Since reduced steady-state levels of LSP1 can be due to reduced protein synthesis or protein 
degradation [240], we next explored degradation kinetics of WT LSP1 and mutant LSP1K270A using 
cycloheximide chase assay. This assay clearly showed that the degradation of LSP1K270A mutant 
was much faster (half-life = 4.3 h) than its WT counterpart (half-life = 9.6 h) and can be inhibited 
by proteasome inhibitor MG132. Because ubiquitination is well known for directing the modified 
proteins to proteasomal degradation, we explored whether LSP1 is modified by ubiquitin in the 
presence or absence of proteasome inhibitor. At the earlier stages of expression, deSUMOylated 
LSP1 shows high level of ubiquitination which was increased greatly at later stages but visible 
only in the presence of MG132. This observation is in agreement with some previous reports 
demonstrating that the attachment of SUMO1 to proteins protects them from ubiquitination and 
subsequent proteasomal degradation either by blocking the ubiquitination site [241] or by making 
the ubiquitin binding site inaccessible to the ubiquitin machinery [240, 242]. For LSP1, the latter 
is more appropriate since SUMO and ubiquitin do not compete for the same lysine residue. Taken 
together, these results indicate that SUMOylation protects LSP1 from ubiquitination-directed 
proteasomal degradation, a dynamic process that was observed for various proteins in a number of 
previous reports [81, 197, 240] and stability of LSP1 is regulated by the interplay between its 
SUMOylation and ubiquitination. 
To address whether specialized subcellular distribution and translocation of endothelial 
LSP1 is related to SUMOylation, we performed subcellular fractionation analysis of LSP1-
overexpressed EE2 cells after TNF-α treatment. Without TNF-α treatment, we were able to detect 
SUMOylated LSP1 in all four subcellular fractions we analyzed, however; the expression of 
LSP1K270A was almost exclusively in the nucleus. TNF-α treatment was reported to result in a 
remarkable decrease in nuclear LSP1 with concomitant increase of LSP1 in other fractions 
predominantly in cytoskeleton of endothelial cells [37]. Using EE2 cells overexpressing WT LSP1, 
we observed similar translocation. Interestingly, this translocation was much lower in EE2 cells 
co-expressing LSP1 and SENP1 whereas in the mutant LSP1K270A-overexpressed cells, there was 
no apparent LSP1 translocation. These observations clearly indicate the involvement of 
SUMOylation in nuclear export of LSP1 and are in agreement with many other reports showing 
SUMOylation to be a major player in nuclear export for a number of proteins [243, 256, 257]. 
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In summary, our data provide strong evidence of SUMOylation of endothelial LSP1 which 
help maintain LSP1 stability and functions by protecting LSP1 from ubiquitination-mediated 
proteasomal degradation. SUMOylation also helps translocate LSP1 to the extranuclear 
compartments.  
7.5 Conclusion 
 Activation of either neutrophil or endothelial cell is sufficient to support neutrophil 
adhesion. 
 ICAM-1-mediated neutrophil adhesion is necessary for the phosphorylation of endothelial 
cell-expressed LSP1. 
 Phosphorylation of endothelial cell-expressed LSP1 is mediated by p38 MAPK pathway. 
 LSP1 is an important regulator of many endothelial cell functions, such as endothelial 
permeability, endothelial cell motility, neutrophil adhesion onto endothelial cell and 
neutrophil transendothelial migration.  
 ICAM-1 cross-linking mimics neutrophil adhesion and increases TNF--mediated 
endothelial permeability. 
 ICAM-1 cross-linking-mediated endothelial hypermeability is dependent upon LSP1-
moesin interaction and subsequent endothelial cell contraction whereas neutrophil-
mediated direct endothelial injury is more important in neutrophil adhesion or 
transmigration-mediated endothelial hypermeability. 
 LSP1 regulates many endothelial functions, e.g., endothelial cell motility and neutrophil 
adhesion/transmigration-mediated endothelial hypermeability by modulating GATA-2-
dependent selective expression of PECAM-1 in endothelial cells and subsequently, the 
expression of 61 integrins on the transmigratory neutrophils.  
 LSP1 is post-translationally modified by SUMO1. SUMOylation help maintain LSP1 
functions by preventing rapid proteasomal degradation of LSP1 and by helping nucleus-
to-extranuclear transport of endothelial cell-expressed LSP1. 
7.6 Clinical relevance 
 LSP1 plays important role in mammalian immunity in general and inflammation in 
particular. Overexpression of LSP1 leads to the formation of pseudopod-like projections and 
reduces motility of the LSP1 overexpressed cells. Overexpression of LSP1 in neutrophils reduces 
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their motility and causes neutrophil actin dysfunction (NAD 47/89) disease. Neutrophils from 
NAD 47/89 patients are susceptible to recurrent infections due to reduced motility of their LSP1-
overexpressing neutrophils. On the other hand, normal level of LSP1 is necessary for leukocyte 
functions such as transmigration and chemotaxis. In endothelial cells, LSP1 is localized primarily 
in the nucleus and translocate into cytoskeleton upon inflammatory stimulus. Endothelial cell-
expressed LSP1 is crucial for neutrophil transendothelial migration and extravascular chemotaxis. 
Both endothelial cell- and leukocyte-expressed LSP1 get activated by the p38 MAPK pathway, 
although by two different stimuli. Pharmacological inhibition of p38 MAPK pathway by using 
selecting inhibitors is an ongoing approach of discovering novel anti-inflammatory drugs. 
However, contrary to the manufacturer’s claim, these inhibitors often inhibit other kinases at a 
relatively higher dose. Additionally, involvement of p38 MAPK pathway in many cellular 
processes such as cellular growth, differentiation and apoptosis making it less suitable as a drug 
target.  
 Since LSP1 is a downstream signalling molecule in the p38 MAPK pathway and silencing 
of LSP1 in endothelial cells in vitro reduces inflammatory phenotype in these cells, LSP1 may 
provide a more specific potential target for inflammatory diseases. However, the presence of LSP1 
in many cell types pose a valid challenge in the process of LSP1 targeting potential drugs. In this 
regard, gene therapy utilizing Cre-Lox/P system can be very useful since it can precisely insert, 
delete or mutate LSP1 DNA sequences in specific target cell populations minimizing the effects 
of non-selective inhibition of LSP1 functions.  
7.7 Future directions 
7.7.1 Getting to the tissue and cell-specific role of LSP1 in inflammation  
LSP1 certainly play an important role in inflammation in general and leukocyte recruitment 
in particular. Number of recruited leukocytes in the peritoneum [148] and knee joint [147] was 
found to be higher in the LSP1-deficient mice compared their wild-type counterpart. These studies 
were based on data from simple knock out and wild-type mice. Therefore, these reports do not 
provide any cell-specific role of LSP1. On the other hand, using bone marrow transplanted 
chimeric mice, it was specifically shown that endothelial cell-expressed LSP1 but not the 
neutrophil expressed LSP1 is important for neutrophil transendothelial migration and 
extravascular tissue chemotaxis in cremaster muscle [136, 258]. It is yet to be investigated whether 
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this discrepancy in the role of LSP1 in different models of leukocyte recruitment is due to 
differences in the role of cell-specific LSP1 or simply due to differences in the architecture of 
different tissues. Instead of using bone marrow transplanted chimeric mice, Cre-Lox 
recombination-mediated cell-specific deletion or insertion of LSP1 in specific cell types would 
clearly establish the cell-specific role of LSP1 in vivo in different models of inflammation in 
different tissues. Moreover, to rule out or in the involvement of tissue architecture in the reported 
differences, leukocyte recruitment studies are required to be carried out in tissues having blood 
vessels especially venules of different tissues such as mesenteric venules or pial venules.  
7.7.2 Targeting LSP1 as a potential therapy 
It is already known that overexpression of LSP1 impairs motile functions in leukocytes 
which is a major problem in NAD47/89 patients.  However, the basal level of LSP1 expression is 
necessary for proper functioning of endothelial cells and leukocytes. So, generalized targeting of 
LSP1 will result in numerous unwanted effects. Instead,   Cre-Lox recombination-mediated cell-
specific targeting of LSP1 will dramatically reduce the untoward effects of generalized LSP1 
knock-out. Gene therapy utilizing Cre-Lox/P system is being tested routinely in vivo and in vitro 
[259, 260]. Since Cre-Lox/P system can deliver the necessary DNA inserts for knocking out a gene 
in a specific cell type, it can easily be used to knock out LSP1 in the cell type(s) of interest. This 
kind of LSP1 targeting can provide a good option for the treatment of LSP1-related genetic disease, 
e.g., NAD47/89. 
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